XENOBIOTIC TRANSPORTERS IN LACTATING MAMMARY EPITHELIAL CELLS: PREDICTIONS FOR DRUG ACCUMULATION IN BREAST MILK by Empey, Philip Earle
University of Kentucky 
UKnowledge 
Theses and Dissertations--Pharmacy College of Pharmacy 
2007 
XENOBIOTIC TRANSPORTERS IN LACTATING MAMMARY 
EPITHELIAL CELLS: PREDICTIONS FOR DRUG ACCUMULATION IN 
BREAST MILK 
Philip Earle Empey 
University of Kentucky, pempey@pitt.edu 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Empey, Philip Earle, "XENOBIOTIC TRANSPORTERS IN LACTATING MAMMARY EPITHELIAL CELLS: 
PREDICTIONS FOR DRUG ACCUMULATION IN BREAST MILK" (2007). Theses and Dissertations--
Pharmacy. 30. 
https://uknowledge.uky.edu/pharmacy_etds/30 
This Doctoral Dissertation is brought to you for free and open access by the College of Pharmacy at UKnowledge. It 
has been accepted for inclusion in Theses and Dissertations--Pharmacy by an authorized administrator of 
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
STUDENT AGREEMENT: 
I represent that my thesis or dissertation and abstract are my original work. Proper attribution 
has been given to all outside sources. I understand that I am solely responsible for obtaining 
any needed copyright permissions. I have obtained needed written permission statement(s) 
from the owner(s) of each third-party copyrighted matter to be included in my work, allowing 
electronic distribution (if such use is not permitted by the fair use doctrine) which will be 
submitted to UKnowledge as Additional File. 
I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and 
royalty-free license to archive and make accessible my work in whole or in part in all forms of 
media, now or hereafter known. I agree that the document mentioned above may be made 
available immediately for worldwide access unless an embargo applies. 
I retain all other ownership rights to the copyright of my work. I also retain the right to use in 
future works (such as articles or books) all or part of my work. I understand that I am free to 
register the copyright to my work. 
REVIEW, APPROVAL AND ACCEPTANCE 
The document mentioned above has been reviewed and accepted by the student’s advisor, on 
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of 
the program; we verify that this is the final, approved version of the student’s thesis including all 
changes required by the advisory committee. The undersigned agree to abide by the statements 
above. 
Philip Earle Empey, Student 
Dr. Patrick J. McNamara, Major Professor 
Dr. Janice Buss, Director of Graduate Studies 
ABSTRACT OF DISSERTATION 
 
 
Philip Earle Empey 
 
 
 
 
 
 
 
The Graduate School 
 
University of Kentucky 
 
2007 
XENOBIOTIC TRANSPORTERS IN LACTATING MAMMARY EPITHELIAL CELLS:   
PREDICTIONS FOR DRUG ACCUMULATION IN BREAST MILK 
 
 
 
ABSTRACT OF DISSERTATION 
 
A dissertation submitted in partial fulfillment of the 
 requirements for the degree of Doctor of Philosophy in the 
College of Pharmacy at the University of Kentucky 
 
 
By 
Philip Earle Empey  
Lexington, Kentucky 
 
Director: Patrick J. McNamara, Ph.D., Professor of Pharmaceutical Sciences 
Lexington, Kentucky 
2007 
 
 
Copyright © Philip Earle Empey 2007 
ABSTRACT OF DISSERTATION 
 
 
 
 
XENOBIOTIC TRANSPORTERS IN LACTATING MAMMARY EPITHELIAL CELLS:   
PREDICTIONS FOR DRUG ACCUMULATION IN BREAST MILK 
 
Recent literature has established that breast cancer resistance protein (ABCG2) 
is upregulated during lactation and is responsible for the greater than predicted 
accumulation of many drugs in breast milk.  The objectives of this project were (1) to 
investigate the role of this transporter in the reported apically-directed nitrofurantoin flux 
in the CIT3 cell culture model of lactation, (2) to develop a mathematical model for drug 
transfer into breast milk to relate initial flux rates, steady-state concentrations, efflux 
ratios, and in vivo milk to serum ratios (M/S) and (3) to identify xenobiotic transporters 
that are highly expressed, and therefore potentially important for drug accumulation 
during lactation in mice and humans. 
Expression, localization, and functional assays confirmed that Abcg2 is the 
molecular mechanism for the apically-directed nitrofurantoin flux in CIT3 cells despite an 
unchanged expression level following lactogenic hormone stimulation in this model. 
A simple three compartment model for drug transfer into breast milk incorporating 
the permeability-surface area products for passive diffusion (PSD), paracellular flux 
(PSPC), endogenous transporters (PSB,U, PSA,E, PSB,E, and PSA,U), and ABCG2 
(PSA,E(ABCG2)) transfection was developed.  A stably transfected ABCG2 overexpressing 
MDCKII cell line was successfully created and used to explore the theoretical 
relationships of this new model.  Derivations and correlations presented herein show the 
relationships between the calculated efflux ratios, PSA,E(ABCG2), and M/S attributed to 
ABCG2.   
Six xenobiotic transporters (Abcg2, Slc22a1, Slc15a2, Slc29a1, Slc16a1, and 
Abcc5) were identified as upregulated during lactation in murine developmental datasets 
analyzed by microarray expression profiling.  As existing methods were inadequate to 
obtain pure populations of luminal epithelial cells in sufficient numbers from human 
breast milk or reduction mammoplasty samples for microarray analysis, a new 
fluorescence activated cell sorting method was developed and validated.  ABCG2, 
SLC15A2, SLC22A12, SLC6A14, and SLCO4C1 were significantly upregulated 164-, 
70-, 41-, 8-, and 2-fold during lactation, respectively.  ABCC10, SLC10A1, SLC16A1, 
SLC22A4, SLC22A5, SLC22A9, SLC28A3, SLC29A1, SLC29A2, and SLCO4A1 had an 
expression level similar to, or greater than, levels in the kidney or liver.  The significant 
upregulation of SLCO4C1 with ABCG2 is a novel finding that suggests a coordinated 
vectorial pathway for substrate movement into breast milk. 
KEYWORDS:  ABCG2, transporter, lactation, mathematical modeling, M/S prediction 
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CHAPTER 1: Background 
A. Breastfeeding and the clinical problem of postpartum drug use 
Breast milk is the most complete infant nutrition and breastfeeding is widely 
advocated as the best choice for most infants, their mothers, and society [1-3].  
Breastfed infants have a decreased risk of infectious diseases such as diarrhea [4-7], 
lower respiratory tract disease [6,8-10], otitis media [7,11], bacterial meningitis [12,13], 
and urinary tract infections [10,14,15].  Studies suggest lower rates of sudden infant 
death syndrome in the first year of life [16-18] and a lower incidence of type 1 and 2 
diabetes [19,20], some cancers [21,22], asthma [23,24], and obesity [25,26] in adults 
who were breastfed.  Breastfeeding even offers potential advantages in terms of an 
infant’s cognitive development, as a slightly enhanced performance on IQ tests has been 
documented [27-30].  Maternal benefits include a more rapid postpartum recovery [31], 
increased child spacing [32], a decreased risk of osteoporosis [33], a lower incidence of 
both breast cancer and ovarian cancer [34,35], an earlier return to pre-pregnancy weight 
[36], and emotional benefits such as empowerment and mother-infant bonding.  
Literature also suggests economic, family, and environmental benefits to society such as 
the potential for a decreased annual health care cost of $3.6 billion in the United States 
(estimated in 2001 dollars) and decreased parental employee absenteeism and 
associated loss of family income [37,38].  Few contraindications exist, but notably 
include infant galactosemia, maternal HIV or tuberculosis, and the use of illicit drugs.  
Mothers with exposure to radioactive materials and a short list of other medications such 
as antimetabolites and some cytotoxic drugs should also refrain from breastfeeding until 
these agents are no longer present in the milk [1].   
Current policy statements by the American Academy of Pediatrics recommend 
that infants be exclusively breastfed for at least the first six months of life with the 
addition of complimentary foods to continued breastfeeding through at least 12 months 
of age [1].  Breastfeeding rates have steadily increased in the United States since the 
1970s with 2003 data indicating that 66% of women initiating breastfeeding and 32.8% 
continuing to breastfeed their infants to 6 months (Figure 1-1) [39,40].  However, despite 
efforts of professional organizations and government agencies through aggressive public 
awareness campaigns, breastfeeding rates continue to fall short of the Healthy People 
2010 Initiative goals of 75% of mothers choosing to breastfeed in the early postpartum 
period, 50% at six months, and 25% at one year.  Additional goals specifically for 
2 
exclusive breastfeeding were recently added to the Healthy People 2010 Initiative in 
2007.  These new objectives are to increase the proportion of mothers who breastfeed 
exclusively through 3 months to 60%, and through 6 months to 25%.  Many obstacles to 
achieving these metrics exist.  Data indicate medication use in the postpartum period is 
highly prevalent with greater than 90% of women taking at least one medication 
postpartum [41].  Furthermore, Ito et al. document that 22% of lactating women who 
require antibiotics either stopped breastfeeding or did not start the prescribed medication 
despite the fact that the drugs were considered safe during breastfeeding.  Schirm et al. 
reported that 82.1% of the patients surveyed in the Netherlands breastfed their baby at 
some time during the first 6 months postpartum and that 65.9% of these women had 
administered medications while breastfeeding [42].  These authors found that “drugs 
play an important role in women’s decision to start or continue breastfeeding: women 
frequently hesitated to use drugs during breastfeeding, stopped either breastfeeding or 
drug use to avoid combining the two, took a measure to minimize exposure to the child, 
did not use any drug because of breastfeeding, or did not breastfeed because of drug 
use.” 
 
Figure 1-1: Breastfeeding trends in the United States. 
Data compiled from the Mothers Survey conducted by the Ross Products Division of 
Abbott Laboratories [40].    
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Complicating matters is the lack of data available to lactating mothers and health 
care professionals when making decisions involving medication initiation or continuation 
postpartum.  A 2003 FDA analysis of the prescribing information of the 1625 drugs in the 
Physicians Desk Reference (PDR) underscores the problem (Figure 1-2) [43].  Only 34% 
of drugs had any information on their potential transfer into human milk and when the 
search was expanded to include animal data, over half still had no information to offer.  
The problem is also not confined to older drugs, as less than 10% of the new molecular 
entities approved between 1995 and 2002 gave any information on human milk transfer 
in their regulatory filings [43].  The FDA has since released a draft guidance for the 
industry to try to fill this gap in knowledge; requiring clinical studies in lactating women to 
be performed whenever (1) a new drug is expected to be used in women of reproductive 
age, (2) after approval, use in lactating women is evident, (3) a new indication is being 
sought for an approved drug and there is evidence of use or anticipated use of the drug 
by lactating women, or (4) marketed medications that are commonly used by women of 
reproductive age [44].  The comment period has passed, but it is unclear at this time 
when the final guidance will be released and what official recommendations will be made 
to the pharmaceutical industry.   
 
Figure 1-2: 2003 FDA Analysis of prescription drug labeling for information regarding 
drug transfer into milk. 
Prescribing information either provided no statement, a statement indicating drug 
transfer into breast milk is unknown, a specific recommendation to not use the drug 
during lactation, contained human data or provided information from animal studies, but 
not human data.  Panel A includes labeling information from all drugs in the PDR at the 
time of the study. Panel B excerpts data from new molecular entities approved from 
1995-2002.  Created from data in reference [43]. 
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The overwhelming documented benefits of breastfeeding and paucity of data in 
the literature regarding milk transfer puts patients and health care professions in the 
precarious position of weighing maternal benefit and potential risks to the suckling infant.  
However, as stated in the draft guidance “the applicability and predictability of nonclinical 
models (e.g., predictions of drug transfer or milk/plasma (M/P) ratios using 
physicochemical properties of the drug) are still under consideration, but these models 
[currently] do not help in deciding whether to conduct a study in lactating women.”  A 
better understanding of the mechanisms of drug transfer into breast milk and further 
investigations of in vitro and mathematical models is clearly needed to provide the 
desperately needed data to support evidenced-based therapeutic decisions. 
    
B. Mechanisms of drug transfer into breast milk 
Comprehensive reviews of mammary gland anatomy and physiology are 
presented by Lawrence and Lawrence [45], Hennighausen and Robinson [46], Hale [47], 
and Neville et al.  [48].  The mammary gland is comprised of epithelium and stroma 
(mammary fat pad).  The epithelium forms the milk production functional unit, grape-like 
clusters called alveoli, and the ducts that connect them to the nipple (Figure 1-3).  Two 
types of epithelial cells are present.  The majority are luminal secretory cells which 
produce breast milk and secrete it into a central lumen.  These cells form the barrier 
between the breast milk and the maternal circulation.  Basal myoepithelial cells create 
the contractile framework surrounding the luminal secretory cells and are responsible for 
milk ejection following physiological stimuli.  The stroma is connective tissue containing 
adipocytes, capillaries, lymphatics, sensory neurons, and fibroblasts, which the ductal 
alveolar systems grow into during mammogenesis.  During pregnancy, the size and 
number of alveoli grows significantly and develops under hormonal stimulation 
(estrogen, progesterone, placental lactogen, prolactin, and oxytocin), but lactogenesis 
does not begin until after delivery when estrogen and progesterone levels rapidly 
decline.  Initially, colostrum, a fluid rich in maternal lymphocytes, macrophages, 
lactoferrin, immunoglobulins, and other proteins is secreted.  At this point, in the first few 
days postpartum, intercellular gaps exist between luminal epithelial cells allowing the 
relatively easy passage of large substances via the paracellular route.  Milk secretion 
begins around day two as alveolar cells progressively enlargen and intercellular gaps 
close.  By day five postpartum, mature milk secretion begins and transcellular diffusion 
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becomes the major path of drug transfer from maternal circulation into breast milk as 
tight junctions between cells exist. 
 
Figure 1-3: Mammary gland anatomy 
Panel A. Cross section of breast.  Image obtained from NIH website (mammary.nih.gov).  
Panel B. Diagram of alveolar anatomy modified with permission from reference [45]. 
 
The majority of xenobiotics enter breast milk by passive or facilitated diffusion 
following a concentration gradient, although active transport processes have also been 
observed [49-53].  The overall rate and extent of accumulation in the milk compartment 
and subsequent exposure is controlled by maternal factors, infant factors, and drug 
physiochemical properties.  Maternal factors include the stage of lactation and maternal 
dosing and pharmacokinetics.  The stage of lactation is important for the existence of 
tight junctions (discussed above) and has implications for milk composition.  Protein 
content declines and fat content increases with the transition of colostrum to mature milk 
[54,55].  Changes in breast milk pH are more minor with the colostrum, milk three 
months post-partum, and milk ten months post-partum averaging 7.45, 7.0-7.1, and 7.4 
respectively [56].  Maternal drug pharmacokinetics is perhaps the most important 
variable affecting rate and extent of accumulation as the maternal plasma concentration 
creates the driving force in equilibrium processes.  Higher clearance, shorter half-life, 
less bioavailable, higher protein bound drugs would produce lower maternal free 
concentrations.  Lower dosing rates or nonparenteral administration routes would be 
expected to yield lower exposure risks [47].  Infant factors affecting exposure include 
suckling pattern (volume of milk consumed, frequency, and timing relative to maternal 
plasma concentrations) and drug oral bioavailability in the neonate.  For short half-life 
drugs, although it is difficult to achieve in practice, altering the drug administration or 
6 
suckling pattern to dosing after feeding would be expected to decrease exposure [57].  
The final factor influencing overall rate and extent of xenobiotic accumulation in breast 
milk are its physiochemical properties; molecular weight, degree of ionization (pKa), 
water and lipid solubility, and protein binding.   Small molecular weight molecules such 
as urea and ethanol pass transcellularly by passive diffusion, whereas larger molecules 
in excess of 1000 daltons cannot pass capillary membranes and pass into the milk only 
in trace amounts [47,58,59].  Degree of ionization is also important as ionized or 
electrically charged xenobiotics cannot diffuse through biological membranes.  The pKa 
determines ionization at a given pH and as milk pH averages 7.2, less than that of 
plasma, a phenomenon called “ion trapping” can occur as non-ionized weakly basic 
drugs become ionized in the more acidic conditions of the breast milk [60,61].  
Lipophilicity also plays a role as water soluble compounds have difficulty crossing the 
biological membranes and nonpolar compounds can traverse the lipid bilayer easily.  
The relatively high lipid content of breast milk (3-5%) relative to plasma further favors the 
concentration of lipophilic drugs in milk fat [59].  Protein binding in either the maternal 
serum or breast milk would shift the balance of equilibrium processes as only free drug 
is available to pass through the mammary epithelial cell.  Breast milk protein composition 
is lower than serum at approximately 0.9 g/dL and consists mostly of caseins and whey 
rather than albumin, as found in the serum [62].  Further, α-lactalbumin (the major whey 
protein found in milk) has a lower drug binding capacity relative to albumin, suggesting 
that drugs with greater protein binding are more likely to remain in the serum [63,64].  A 
detailed discussion of role of active processes is presented in Sections D and E.   
 
C. Risk Assessment: The milk to serum ratio (M/S) 
There are many factors contributing to the rate and extent of xenobiotic 
accumulation in breast milk making it difficult to estimate infant exposure risk.  
Pharmacokinetically, concentrations achieved in the infant serum (Cinfant,serum) are 
determined by infant systemic clearance (Clinfant), infant bioavailability (Finfant) and by the 
dose received through breastfeeding as described in Eq. 1-1: 
 
Cinfant, serum= 
Finfant·Dose
Clinfant
 Eq. 1-1
Neonatal bioavailability and systemic clearance are not well-categorized for most drugs 
as conducting pharmacokinetic studies in this population is often difficult due to ethical 
concerns.  Exposure risk is therefore often expressed in terms of the infant dosing rate.  
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Dose is the product of the milk consumption rate (volume per time, Vmilk/ ), maternal 
serum concentrations (Cmaternal), and the proportion of the maternal serum concentration 
in the breast milk (milk to serum ratio, M/S) as shown in Eq. 1-2:  
 
Dose = Cmaternal, serum
M
S
Vmilk
τ
 Eq. 1-2
As maternal serum concentrations can be measured and milk consumption rate 
estimated, M/S ratio is the variable that is focused upon and used to determine the 
extent to which a xenobiotic is transferred into milk.  Quantified appropriately, the M/S is 
either determined from the relative steady state concentrations or by the time-integrated 
drug concentrations (area under the concentration-time curve, AUC) as shown in Eq. 1-3 
[58,60,61]. 
 M
S
=
 Css, milk
 Css, maternal, serum
=
 AUCmilk
 AUCmaternal, serum
 Eq. 1-3
Unfortunately, in the literature it is often calculated from single paired milk and serum 
measurements.  This milk to serum point ratio (M/Spoint) can be inaccurate as it assumes 
milk and serum concentrations parallel one another, which is not always the case as 
concentrations in milk may peak later than observed in plasma [65].  This time lag would 
cause an underestimation of the time-averaged M/S ratio if determined during the 
maternal peak concentration or overestimate it if calculated when the peak in the breast 
milk occurs [58].  To emphasize this possibility and appropriate methologies for studying 
drugs in human milk, Begg et al, reviewed drug situations (sumatriptan, sertraline, 
paroxetine and bupriopion) when a 2-3 fold variability in the calculated M/Spoint of each 
drug (dependent upon time of measurement) was observed [60].  Beyond suboptimal 
study designs, other factors that limit the amount and quality of published data is the 
difficulty in recruiting breastfeeding subjects and the overall lack of interest in conducting 
these experiments [66].   
 Several methods to predict the M/S ratio in vitro have been published in efforts to 
circumvent the difficulties associated with conducting clinical studies [50,67,68].   
Fleishaker et al. developed a passive diffusion model that incorporates ionization, 
protein-binding in the serum and milk, and lipid partitioning into a M/S prediction as 
shown in Eq. 1-4:  
 M
Spredicted
=
fs
un fs W
fm
un fm Sk
 Eq. 1-4
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where fs
un and fm
un are the calculated fraction of the drug unionized in the serum and milk, 
respectively;  fs and fm are the experimentally-determined fractions protein bound in the 
serum and milk, respectively; and W and Sk are the experimentally-determined fat 
partitioning into whole and skim milk, respectively [68].  This passive diffusion model 
relies upon the assumption that only unbound, unionized drugs can cross the mammary 
epithelial barrier and performs well for several drugs tested in rabbits, rats, and humans.  
Figure 1-4 illustrates that for ten drugs (propranolol, phenobarbital, phenytoin, diazepam, 
acetaminophen, antipyrine, salicylic acid, caffeine, paraxanthine and cimetidine) studied 
in rabbits, the M/S observed in vivo was similar to that predicted by the model [69-72].  
The majority of drugs studied in rats and human also fell upon the line of unity.  The 
model, however, is inadequate to explain the accumulation of some drugs such as 
nitrofurantoin and cimetidine in the rat and human where active processes seem to be 
involved [51,73-77].     
 
Figure 1-4: M/S predicted and observed in rabbit, rat, and human.  
The majority of drugs fall on the line of identity between M/S predicted and observed in 
vivo with some exceptions (NF, nitrofurantoin; CM, cimetidine; RN, ranitidine; ACV, 
acyclovir; CP, ciprofloxacin). 
 
 
D. Evidence of drug accumulation by active transport 
Although the transfer of most drugs into milk can be explained by passive 
diffusion, there are several drugs where the measured M/S ratio exceeds that of the 
value predicted by passive diffusion, suggesting the contribution of active processes.  
The involvement of active transport phenomena in xenobiotic milk accumulation has 
been observed in multiple species including humans, rats, mice, goats and cows and 
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has been proven through clinical and animal studies, knock-out and inhibition 
experiments, and in cell culture based transfection systems.   
The most striking human data comes from a clinical study conducted by Gerk et 
al. in which four healthy lactating women received a single oral 100 mg dose of 
nitrofurantoin [51].  The M/Sin vivo determined by a ratio of the nitrofurantoin AUC in the 
milk and serum was 6.21 ± 2.71, over 22 times that predicted by passive diffusion (0.28 
± 0.05).  Oo et al. published similar observations in twelve healthy lactating women who 
were administered 100 mg, 600 mg, or 1200 mg cimetidine in a randomized crossover 
study design [77].  The M/Sin vivo was similar at all dosing levels and was greater than 5.5 
times that predicted (5.77 ± 1.24 vs. 1.05 ± 0.08, respectively).  Studies suggest that 
active processes may exist for other drugs as well; ranitidine, acyclovir, and zidovudine 
all achieve high concentrations in human milk [78-80].  In vitro experiments with 
MCF12A cells, a human cell line derived from non-cancerous mammary gland epithelia, 
also showed the presence of a carrier-mediated uptake process.  Kwok et al. 
demonstrated that carnitine and tetraethylammonium uptake in this cell line could be 
inhibited by other cationic compounds such as cimetidine, verapamil, or carbamazepime 
[81].  These in vivo and in vitro human data definitively demonstrate the presence of 
active transport systems for drug transfer into human milk. 
Rat studies with nitrofurantoin and cimetidine yield similar results [73,74,82-85].  
Oo et al. showed that an infusion of 0.5 mg/h nitrofurantoin resulted in a M/Sin vivo that 
was nearly 100 times greater than the diffusion prediction (31.1 ± 4.0 vs. 0.3 ± 0.1, 
respectively) [85].  Kari et al. replicated this finding with a single orally administered 50 
mg/kg dose of nitrofurantoin (M/Pin vivo of 23.1; nearly 75-fold the M/Spredicted of 0.31), but 
interestingly only observed a 2.5 fold difference (M/Pin vivo 3.49 vs. M/Spredicted 1.4) with the 
nitrofurantoin congener furazolidone [84].  Further, in the same study, another 
nitrofurantoin congener furaltadone exhibited a M/Pin vivo equivalent to that predicted by 
passive diffusion.  Cimetidine further provided specific evidence of an active transport 
process as the M/Sin vivo was saturable, falling from 31.9 ± 9.0 to 26.5 ± 9.5 to 24.6 ± 6.4 
with increasing infusion rate.  Steady-state M/Sin vivo values were also 6-fold higher than 
the M/Spredicted of 4.19 [73].  In the same rat study, although the M/Sin vivo achieved by a 
0.4 mg/h cimetidine infusion was relatively unchanged by coadministration of ranitidine 
(30 mg/h), the converse did provide evidence for the inhibition of an active transport 
process.  A 30 mg/h cimetidine infusion significantly decreased M/Sin vivo resulting from a 
0.4 mg/h ranitidine infusion from 16.1 ± 2.0 to 10.5 ± 2.0 [74]. 
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Knock-out mice and murine-derived cells have primarily been used in efforts to 
identify the specific transport pathway or pathways responsible for the aforementioned 
observations.  The murine CIT3 cell culture model developed by Dr. Margaret Neville 
has been used as an in vitro model of lactation that is suitable for flux experiments [86-
88].  CIT3 cells are a subline of the Comma 1D normal mouse mammary epithelial cell 
that is a coculture of mammary epithelial cells and fibroblasts derived from pregnant 
BALB/c mouse mammary glands [89,90].  When grown on polycarbonate membranes 
and stimulated with lactogenic hormones (prolactin, hydrocortisone, and insulin), they 
form tight junctions with a high transepithelial electrical resistance (TEER) and 
synthesize the milk protein beta-casein.  Toddywalla et al. first demonstrated the 
applicability of this in vitro cell culture system in transwell experiments with the same 
drug shown to accumulate in vivo, nitrofurantoin [86].  The radiolabelled nitrofurantoin 
flux rate was 50% higher in the basolateral to apical than in the apical to basolateral 
direction and was equalized (inhibited) in the presence of 500 µM unlabelled 
nitrofurantoin [86].  Gerk et al. further showed that the CIT3 nitrofurantoin active 
transport system was sodium-dependent, inhibited by dipyridamole, adenosine, and 
guanine, and was likely expressed on the basolateral surface, but these investigators 
were not able to identify the specific transporter [87,88].  It was not until Alfred Schinkel’s 
lab investigated the role of breast cancer resistance protein, Abcg2, in the transport of 
xenobiotics into breast milk that an important molecular mechanism was elucidated.  
Using an Abcg2 knock-out mouse model his lab elegantly showed that the oral 
administration of 10 mg/kg nitrofurantoin produced a milk vs. plasma AUC ratio 76-fold 
higher in wild-type animals than was seen in the Abcg2 knock-outs (45.7 ± 16.2 vs. 0.6 ± 
0.1) [53].  These investigators further extended their work to show that Abcg2 was 
responsible for the active secretion of cimetidine, topotecan, riboflavin, acyclovir, 
ciprofloxacin, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), 2-amino-3-
methylimidazo[4,5-f]quinoline (IQ), and 3-amino-1,4-dimethyl-5H-pyrido[4,3-b]indole 
(Trp-P-1) into mouse milk [53,91-93].  Their observations are summarized in Table 1-1 
and clearly demonstrate the important role that Abcg2 plays in drug transfer into breast 
milk. 
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Table 1-1: Milk to plasma ratios for certain drugs in wild-type and Abcg2 (Bcrp1-/-) 
knock-out mice. 
Wild-type Bcrp1-/- Ratio Reference 
Nitrofurantoin 45.7 0.6 76.2 [53] 
Riboflavin 25.0 0.4 67.6 [91] 
PhIP 12.8 0.5 28.1 [92] 
Topotecan 6.7 0.7 10.1 [92] 
Cimetidine 13.7 2.3 6.0 [92] 
Aflatoxin B1 0.7 0.2 3.8 [92] 
IQ 0.9 0.3 3.4 [92] 
Acylcovir 1.3 0.4 3.3 [92] 
Trp-P-1 1.1 0.4 2.6 [92] 
Ciprofloxacin 3.1 1.6 1.9 [93] 
 
 Earlier investigations with other drugs in goats and cows have also suggested 
the presence of active transport systems.  Rasmussen et al. documented ultrafiltrate 
M/S values of n-acetylated p-aminohippurate and sulfanilamide that were 10-fold higher 
than the value predicted by passive diffusion alone [94,95].  Schadewinkel-Scherkl et al. 
showed that benzylpenicillin accumulated in goat breast milk via an active process and 
this process was significantly decreased when probenecid was given concominantly 
[96].  Estrogen sulfate is also concentrated in goat milk with a milk to plasma ratio of 7.4 
[97].  Finally, the coadministration of a known Abcg2 substrate albendazole, produced a 
decreased enrofloxacin M/S ratio in lactating goats  providing evidence that enrofloxacin 
enters breast milk by an active process [98].    
 Taken together, these data provide strong functional evidence for the 
involvement of active transport processes in the transfer of xenobiotics into breast milk in 
humans and several other species.  Pathways seem to exist for both organic cations (eg. 
cimetidine, ranitidine) and anionic compounds (eg. nitrofurantoin, benzylpenicillin).  The 
significant role of one transporter, Abcg2, has been documented thus far; Section E will 
explore the molecular evidence for this transporter and the many others that may be 
involved in drug transfer into breast milk during lactation.  
 
E. Drug transporters in lactating mammary epithelia 
Identification of the xenobiotic transporters in lactating luminal mammary 
epithelial cells (LMECs) is necessary to improve M/S predictive models and to determine 
the drugs for which an active transport mechanism governs transfer into breast milk.  
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During lactation, the mammary gland becomes a specialized secretory tissue 
responsible for delivering essential nutrients to the infant.  Some of these substances 
have physiochemical properties that limit their ability to efficiently cross the LMEC to 
enter the breast milk or accumulate at concentrations that could not be achieved by 
passive diffusion alone.  As in other secretory tissues, such as the liver and the kidney, 
transporter systems have presumably evolved to meet these demands.  There currently 
exist 420 genes in 53 transporter gene families that have been identified in the human 
genome [99].  These membrane proteins may be expressed in the basolateral (serum 
facing) or apical (milk facing) cell membranes and are driven by ATP, electrochemical 
potentials, or the cotransport of another compound.  Transporters may have an unknown 
function or be involved in the transport of nutrients such as glucose, ions, vitamins, fatty 
acids, or amino acids and have no documented role in xenobiotic transport.  A number of 
transporters such as SLC5A1 (SGLT1; a sodium/glucose transporter) [100], SLC12A2 
(NKCC1, a sodium/potassium/chloride transporter) [101], and SLC5A5 (sodium iodide 
symporter) [102], have been identified in mammary tissue of various species, but few 
studies have focused on transporters known to be important for drug transfer.  It is 
difficult to perform these experiments in humans to obtain an accurate representation of 
expression in LMECs specifically; however, screening studies as well as investigations 
focused on single transporters or transporter families have been published.  The 
difficulties in conducting these experiments and the associated implications for 
interpretation are reviewed along with examples from the literature in the following 
sections.  Molecular evidence for the presence of members of the solute carrier and 
ATP-binding cassette transporter superfamilies is also presented. 
1. Experimental considerations 
Several experimental techniques have been used to identify transporters in the 
mammary gland that may be relevant to drug transport into milk.  Most commonly, whole 
tissue homogenates are prepared for RNA or protein expression level quantification by 
microarray analysis, northern blotting, PCR, or western blotting.  This approach can 
complicate interpretation as the quantified level is a composite of the relevant expression 
in the luminal mammary epithelial cells that secrete milk and form the functional barrier 
and the less important supporting cells such as myoepithelial cells, fibroblasts, 
lymphatics, and stroma.  Some investigators have solved this problem in animal studies 
by localizing the tissue expression by immunohistochemistry or confocal microscopy.  In 
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humans, ethical issues make it difficult to obtain lactating mammary tissue from healthy 
human subjects.  Gross tissue samples from patients undergoing reduction 
mammoplasty procedures can be analyzed, but these would be of undifferentiated cells 
not stimulated by lactogenic hormones; they would not necessarily be representative of 
the expression levels during lactation.  Biopsies of apparently normal tissue adjacent to 
cancerous tissue is potentially available from lactating breast cancer patients, but would 
also be of questionable value as expression of transporters in these cells may be 
affected by growth-factor enriched microenvironments [103].   
A recent study by Bleasby et al. illustrates the difficulties in evaluating what little 
human published data exists [104].  In a comprehensive microarray study designed to be 
a resource for investigations into drug disposition, the expression profile of 50 xenobiotic 
transporter genes was evaluated in 40 tissues from humans and compared to the 
corresponding expression levels in monkeys, dogs, rats, and mice.  The RNA sources 
cited were the following: human, purchased from an external vendor, pooled from 
multiple subjects of both sexes; monkey, two male and two female matched for age; 
dogs, five male and five non-oestrus females; rats, sixteen male and sixteen female, 75 
days old; mice, males and females, females were nulliparous and non-pregnant.  No 
further information is provided and thus, all tissues are presumed to be whole tissue 
homogenates and nonlactating.  Although species comparisons were made across 22 
tissues, the mammary gland was not included in this part of the analysis.  In contrast, in 
a screening study focused on LMECs, Alcorn et al. circumvented both the obstacle of 
finding a source of normal human lactating epithelial cells and that of measuring the 
transporter expression level in LMECs rather than in a whole tissue homogenate [49].  
These investigators used immunomagnetic separation to isolate enough LMECs from 
the heterogeneous cell populations in breast milk to determine the RNA expression level 
of 30 transporter genes by quantitative PCR (qPCR).  Nonlactating luminal mammary 
epithelial cells (MECs) were isolated from reduction mammoplasty tissue specimens to 
serve as a nonlactating control.  The isolation procedure produced pure populations of 
luminal mammary epithelial cells, but unfortunately required the pooling of the six breast 
milk samples and four reduction mammoplasty specimens to assure adequate RNA for 
the single (n=1 in each group) comparison by qPCR and was not able to examine the 
expression level of all transporter genes of interest (eg. did not study ABCG2).   
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2. Solute carrier transporters 
There are currently 46 known transporter gene families within the solute carrier 
(SLC) superfamily [99].  Not all have been fully characterized.  However, several have 
individual members with a known role in xenobiotic transport and have been identified in 
mammary tissue.  
The solute carrier transporter family 22 (SLC22) includes organic anion 
transporters (OCTs), zwitterion/cation transporters (OCTNs), and organic anion 
transporters (OATs) and its members have been associated with xenobiotic transport in 
other tissues.  SLC22A1-3 (OCTs) are uniporters that mediate facilitated diffusion and 
are electrogenic, sodium-independent, and reversible in regards to direction [105].  
SLC22A4 (OCTN1) is a proton/organic cation antiporter (SLC22A4) [106,107], whereas 
SLC22A5 (OCTN2) may function as a sodium-independent organic cation transporter or 
a sodium/carnitine cotransporter [108,109].  SLC22A6-8 (OAT1-3) are believed to be 
organic anion exchangers [105].  Several members of the SLC22 family have been 
detected in the mammary gland.  Gerk et al. identified RNA transcripts for Slc22a1 
(Oct1) and Slc22a3 (Oct3), but not Slc22a2 (Oct2) in lactating rat mammary tissue [110].  
Kwok et al. replicated this finding in the human mammary gland derived MCF12A cell 
line and nonlactating human tissue and further detected SLC22A4 and SLC22A5 protein 
expression by western blotting [81].  SLC22A5 expression was specifically localized to 
the ductal-lobular-alveolar structures by immunohistochemistry.  Alcorn et al. showed a 
similar finding in LMECs, documenting the presence SLC22A1, SLC22A3, SLC22A4, 
and SLC22A5 RNA, but not transcripts for SLC22A2 [49].  Interestingly, the RNA 
expression level of SLC22A1 was markedly increased in LMECs relative to the MEC 
comparators.  No molecular evidence of any of the organic anion transporters in this 
family (SLC22A6-8) was found in rat mammary glands or LMECs [49,110]. 
The solute carrier organic anion transporter family (SLCO) is another major gene 
family that can transport organic anions and xenobiotics.  The members of SLCO family, 
recently reclassified from the SLC21 designation, encode for the organic anion 
transporting polypeptides (OATPs) that seem to exchange a wide range of amphipathic 
compounds by a bidirectional, sodium-independent, pH-dependent, electroneutral 
mechanism [111].  There are currently six human subfamilies (SCLO1-6), containing 11 
genes (SLCO1A2, SLCO1B1, SLCO1B3, SLCO1C1, SLCO2A1, SCLO2B1, SLCO3A1, 
SLCO4A1, SLCO4C1, SLCO5A1, SLCO6A1) with gene specific patterns of tissue 
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distribution and substrate specificities [99,103].  Pizzagalli et al. reported that SLCO2B1 
(OATP-B) appeared to be the most abundantly expressed organic anion polypeptide 
expressed in the mammary gland, but also detected SLCO3A1 (OATP-D) and SLCO4A1 
(OATP-E) in nonlactating human mammary gland total RNA by PCR and northern 
blotting [112].  When immunohistochemistry of the mammary tissue was performed, 
however, OATP-B was localized to the supporting myoepithelial cells rather than the 
luminal MECs that would eventually form the barrier between serum and milk.  
Transcripts for SLCO1A2 (OATP-A), SLCO1B1 (OATP-C), SLCO1B3 (OATP-8), and 
SLCO2A1 (PGT) had very low expression or were not detected in the whole tissue total 
RNA.  In the study by Alcorn et al, SLCO1A2, SLCO2B1, SLCO3A1, and SLCO4A1 
were detected in LMECs and MECs [49].  Relative to MEC pooled sample, the 
expression of SLCO1A2 and SLCO2B1 was higher in the LMEC pooled sample, 
whereas SLCO3A1 and SLCO4A1 were lower.  The expression of SLCO3A1 was higher 
in both luminal mammary epithelial cell samples relative to the liver, kidney, and 
placenta comparators.      
Amino acid or peptide transporters that are expressed in mammary tissue and 
that have been shown capable of transporting xenobiotics include members of the solute 
carrier transporter families 6 and 15.  SLC6A14 (ATB(0+)) is sodium-dependent 
cotransporter with a broad affinity for neutral and cationic amino acids [113].  SLC15A1 
(PEPT1) and SLC15A2 (PEPT2) are electrogenic proton/oligopeptide cotransporters 
[114].  SLC15A1 appears to be low-affinity/high-capacity and SLC15A2 the high-
affinity/low-capacity variant, although both proteins essentially transport the same 
substrates into the cell.  Sloan and Mager discovered SLC6A14 and documented that it 
was expressed in the mammary gland as well as other human tissues [115].  Kwok et al. 
further confirmed SLC6A14 RNA expression in nonlactating human mammary tissue and 
MCF12A cells by PCR [81].  This transporter was not one of the genes studied in the 
LMEC transporter gene expression study by Alcorn et al, however, both SLC15A1 and 
SLC15A2 were studied and were detected [49].  SLC15A1 expression was low in LMEC 
relative to comparator tissues, but SLC15A2 was higher.  Groneberg, et al. focused their 
work on SLC15A2 in the mammary gland and documented RNA expression in both the 
rat mammary gland and in LMECs within expressed human milk [116].  Pept2 protein 
was further localized specifically to the ductal epithelium in the rat. 
Finally, the nucleoside and nucleobase transporters are members of the solute 
carrier superfamily and have been identified in mammary tissue of various species. 
16 
Nucleoside transporters are classified into solute carrier transporter families 28 and 29 
and include the three concentrative nucleoside transporters, SLC28A1-3 (CNT1-3) and 
the four equilibrative nucleoside transporters, SLC29A1-4 (ENT1-4).  Nucleobase 
transporters include the two ascorbic acid transporting solute carrier transporter family 
23 members, SLC23A1-2 (SVCT1-2).  SLC28A1-3 are sodium-dependent, nucleoside 
cotransporters that have differing substrate specificities: SLC28A1 is pyrimidine-
nucleoside preferring, SLC28A2 is purine-nucleoside preferring, and SLC28A3 
transports both pyrimidine and purine nucleosides [117].  SLC29A1-4 are believed to be 
bidirectional transport systems that mediate facilitated diffusion [118].  SLC23A1-2 are 
sodium-dependent, high-affinity L-ascorbic acid cotransporters [119].  In the original 
paper describing SLC28A3, Ritzel et al. demonstrated RNA expression of this 
nucleoside transporter in human mammary gland total RNA [111].  Alcorn et al, reported 
that this transporter was also expressed in LMEC cells, as was SLC28A1, SLC29A1, 
SLC29A3, and SLC23A1 [49].  All but SLC29A1 were expressed at a markedly higher 
level in the single pooled LMEC sample relative to the MEC pooled sample.  SLC28A3 
expression level was also much higher than the liver, kidney, and placenta total RNA 
comparators.  SLC28A2, SLC29A2, and SLC23A2 were not detected in LMECs whereas 
the SLC29A4 expression was not studied.   
3. ATP-binding cassette transporters 
The ATP-binding cassette (ABC) transporter superfamily consists of seven 
subfamilies; three (ABCB, ABCC, ABCG) contain members with roles in xenobiotic 
transport.  ABC transporters use the energy derived from ATP hydrolysis to efflux a wide 
variety of substrates including sugars, amino acids, metal ions, peptides, proteins, and a 
large number of hydrophobic compounds out of the cell [120].  ABCB1 (MDR) encodes 
for P-glycoprotein and is perhaps most studied.  It is found in the epithelia of many 
tissues including the intestine, liver, kidney, blood-brain barrier, testis, placenta, and 
lung, transporting mostly positively charged, hydrophobic compounds [121].  The ABCC 
family currently contains 13 known genes [99].  ABCC 1-6 (MRP1-6), ABCC10 (MRP7), 
ABCC11 (MRP8), and ABCC12 (MRP9) are transporters whereas the remainder are ion 
channels (CFTR/ABCC7) or sulfonylurea receptors ABCC8 (SUR1) and ABCC9 (SUR2) 
[121].  The MRPs transport mainly amphipathic anionic compounds and conjugates 
[103].  There exist 5 known members of the ABCG family, with breast cancer resistance 
protein, ABCG2 (BCRP), being the most relevant for xenobiotic transport.  ABCG2 
17 
transports electroneutral amphipathic drugs and is expressed in several secretory 
tissues [121]. 
Several of the ABC transporters have been identified in mammary tissue.  P-
glycoprotein was identified in the normal human mammary gland by 
immunohistochemistry over 15 years ago [122,123].  ABCB1 RNA and its protein 
product, P-glycoprotein, were also detectable in human MCF12A cells but functional 
activity was not observed [103].  Interestingly, Jonker et al. showed a decrease in P-
glycoprotein expression level in murine mammary gland whole tissue homogenates at 2-
weeks lactating relative to virgin animals [124].  Alcorn et al. also documented that 
lactation appeared to substantially down-regulate ABCB1 in LMEC cells specifically, 
showing a 50-fold lower level in the LMEC vs. MEC sample [49].  This group also 
detected ABCC1, ABCC2, and ABCC5 in the LMEC and MEC samples.  ABCC1 was 
lower and ABCC5 was higher in the LMEC sample relative to the MEC sample.  ABCC3 
and ABCC4 were not detected. The remainder of the transporter encoding genes of the 
ABCC subfamily was not evaluated in this study.  Transcripts for ABCC8 and ABCC9 
were however, detected by Bera et al. in normal mammary gland tissue by PCR 
[125,126].  Several recent studies by the research group of Alfred Schinkel have 
demonstrated that ABCG2 plays a significant role in xenobiotic accumulation in breast 
milk [91,124,127-129].  ABCG2 is expressed in cow, murine, and human lactating 
mammary tissues and appears to be developmentally regulated in mice, achieving the 
highest protein expression level during lactation [124].  ABCG2 was 
immunohistochemically localized to a few cells in the virgin mammary gland of cows and 
mice and to the alveolar epithelial cells in the lactating tissue [92,124,130].  As murine 
Abcg2 is associated with the stem cell phenotype, it is possible that the cells observed in 
the virgin tissues are the mammary epithelial stem cells that undergo proliferation during 
lactogenic hormone stimulation [130].  ABCG2 was not studied in the LMEC vs. MEC 
study by Alcorn et al., so it is currently not known if the increased expression level in 
whole mammary epithelial glands during lactation is a result of increased expression 
within MECs/LMECs or simply due to an increased proportion of these cells within the 
entire mammary gland following differentiation to the lactation stage.  The role of ABCG2 
in xenobiotic transport is discussed in greater detail in the next section. 
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F. ABCG2 
The considerable recent interest in the structure and function of Breast Cancer 
Resistance Protein has resulted in the publication of several good review papers 
[92,131-134].  ABCG2 was first cloned by Doyle et al. from a multidrug resistant breast 
cancer cell line (MCF-7/AdrVp) and given the name Breast Cancer Resistance Protein 
based on this derivation, despite the fact it is not highly expressed in breast cancer 
[135].  The gene is comprised of 16 exons and encodes for a 655 amino acid protein that 
contains a single N-terminal ATP binding cassette followed by six pututative 
transmembrane spanning regions [92].  The protein is much smaller than P-glycoprotein, 
only 70 kDA, but is termed a “half-transporter” as it is believed to function as a 
homodimer, although higher form oligomers have been reported [136].  Nonsynonymous 
single nucleotide polymorphisms have been reported; notably, the C421A (Q41K) is 
prevalent in the Japanese population (~35%), resulting in reduced protein expression 
levels and potential clinical significance [137-139].  The promoter is predicted to be 
TATAless and studies have begun to functionally evaluate some of the regulatory 
elements.  Recent evidence suggests that hypoxia [140], aryl hydrocarbon receptor 
(AhR) agonists [141], and peroxisome proliferator activator receptor alpha (PPARα) 
agonists [142] increase the expression of ABCG2.  Progesterone upregulated ABCG2 
expression, but controversy exists regarding the regulatory effects of estradiol 
[133,143,144]. 
RNA and protein expression of ABCG2 are greatest in the placenta, although 
high expression is also found in the liver, intestine, and breast [145].  It is also expressed 
in stem cells, endothelial cells of the blood-brain barrier, lung, ovary and testis [131].  
Species differences are evident as Abcg2 is highly expressed in the murine kidney (RNA 
not detected in human kidney samples) and only moderately expressed in the murine 
placenta [132].  Tissue-specific sex differences also exist with Bcrp1 expression and 
function in the male murine liver exceeding that of the female [146].  Localization is 
apical and the protein functions to efflux its substrates from the cell. 
ABCG2 is capable of transporting a diverse array of substrates; however, the 
spectrum is not as structurally diverse as for P-glycoprotein or MRP1 [147].  A recent 
listing compiled by Krishnamurthy and Scheutz includes drug classes such as anticancer 
drugs (eg. anthracyclines, camptothecans, methotrexate, tyrosine kinase inhibitors, but 
not vinca alkaloids), HIV nucleoside reverse transcriptase inhibitors, natural compounds 
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(eg. flavonoids, dietary carcinogens such as PhIP, porphyrins), and fluorescent dyes (eg. 
Hoechst 33342, Rhodamine 123) [132].  More recent studies have added nitrofurantoin 
[53], cimetidine [127], dipyridamole [148], several HMG-CoA reductase inhibitors 
[149,150], fluoroquinolones [93,151], and benzimidazoles such as the antithemintics and 
pantoprazole [152,153] to the rapidly growing list.  ABCG2 appears to have a preference 
for sulfate conjugates of steroids and xenobiotics rather than glucuronide conjugates and 
is not dependent on intracellular glutathione to transport drugs [147].  Potent inhibitors 
such as fumitremorgan C (FTC) and its derivative Ko143, GF120918, novobiocin, and 
imatinib have been discovered and are used experimentally.  GF120918 is a mixed 
inhibitor, with a potent activity versus P-glycoprotein as well as ABCG2.  Ko143, in 
contrast, is highly specific for ABCG2 with almost 300-fold more inhibitory potency vs. 
ABCG2 compared to P-glycoprotein [133].  In vitro screening systems have identified 
many other drugs with the capability to inhibit ABCG2-mediated transport [154,155]. 
Conclusive evidence for the physiological role of breast cancer resistance protein 
and its endogenous substrate(s) has been elusive.  Investigators initially looked to the 
expression in hematopoetic stem cells for the answer.  The ability of these cells to export 
Hoechst 33342 had previously been used to identify the subpopulation of stem cells in 
murine bone marrow [156].  Abcg2 has recently been shown to be responsible for this 
phenotype [130].  Further, high expression in pluripotent stem cells and little to no 
expression in more differentiated lineages suggests Abcg2 may have a specific 
importance for pluripotent stem cell biology [92].  Interestingly, a high concentration of 
the toxic heme precursor protoporphyrin IX accumulates in Abcg2-/- progenitor cells 
under hypoxic conditions [140,157].   These knock-out animals also exhibited high 
erythrocyte levels of the phototoxic chlorophyll-breakdown product pheophorbide a, 
leading to lethal diet-induced lesions suggesting the physiological role of Abcg2 may 
involve protection against natural dietary toxins [158].   
The high expression in the placental syncytiotrophoblast at the chorionic villus 
suggests a protective role for the fetus by effluxing substances that enter the placenta 
back into maternal circulation [131,159].  Jonker et al. demonstrated that the fetal 
topotecan plasma levels in Abcb1-deficient mice administered GF120918 were twice 
that of controls [160].  Staud et al. further showed that cimetidine is transported towards 
the maternal circulation, against its concentration gradient, in a placental perfusion 
model [161].  Interestingly, a recent study by Grube et al. suggested ABCG2, together 
with OATP2B1, may form a vectorial transport system for the efficient transfer of 
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common substrates across the placental barrier [162].  Their data indicated a correlation 
between ABCG2 and OATP2B1 RNA expression levels, that ABCG2 is expressed in the 
apical and OATP2B1 in the basolateral membrane, and that they both transport the 
steroid sulfates estrone 3 sulfate and dehydroepiandrosterone. 
ABCG2 also seems to take a protective role in the small intestine and liver.  In 
the same study presented above by Jonker et al. using Abcb1-deficient mice, GF120918 
increased the topotecan AUC by decreasing hepatobiliary excretion and increasing 
intestinal reuptake [160].  The increase in topotecan bioavailability with GF120918 
coadministration was replicated in humans in a clinical study by Kruijtzer et al. [163].  
The development of the Abcg2 knock-out mouse has been a truly powerful tool in 
uncovering the importance of Acbg2 in limiting systemic xenobiotic exposure.  A series 
of studies show that the AUC of nitrofurantoin, the dietary carcinogen PhIP, and 
ciprofloxacin is nearly 4-fold, 3-fold, and over 2-fold higher in Abcg2 deficient mice 
compared to wild type, respectively [53,93,128].   
The high apical expression of ABCG2 in the mammary gland however seems 
illogical if its physiological role is that of xenotoxin elimination.  It is likely that it functions 
in the breast to secrete nutrients into milk, a hypothesis supported by van Herwaarden  
and colleagues’ recent observation that riboflavin is an ABCG2 substrate and that the 
milk secretion of riboflavin is reduced over 60-fold in Abcg2 knock-out relative to wild-
type animals [91,92].  Specific evidence for its role in the transfer of xenobiotics into 
breast milk is provided in a preceding section (Section E).  It is interesting to note that 
the majority of the drugs for which the passive diffusion prediction fails (detailed in 
Section D), nitrofurantoin, cimetidine, acyclovir, ciprofloxacin, have since been shown to 
be ABCG2 substrates.  This suggests that a transport pathway involving Abcg2 may be 
an important route of drug transfer into breast milk and that knowledge of a drug’s ability 
to interact with ABCG2 may improve our ability to predict accumulation into breast milk.   
 
G. Summary 
Despite the documented benefits of breastfeeding and major governmental 
advocacy efforts, a paucity of data exists regarding the transfer of most drugs into breast 
milk.  For most of the drugs that have been studied, passive diffusion governs the extent 
of accumulation and the exposure risk can be predicted using mathematical models.   
However, examples of xenobiotic accumulation into breast milk well above that predicted 
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by passive diffusion have been documented and attributed to active transport processes.  
ABCG2 clearly transports many drugs known to accumulate in breast milk.  Despite 
some inconsistencies with the properties of nitrofurantoin flux in the CIT3 cell culture 
model, ABCG2 was found to be responsible for nitrofurantoin accumulation in breast 
milk in vivo.  The large body of ABCG2 data suggests that knowledge of a xenobiotic’s 
potential interaction with this transporter may help improve in vitro M/S predictions.  The 
expression of several other members of the SLC and ABC transporter superfamilies has 
also been reported in a variety of species but interpretation is complicated by the fact 
that expression data is often from nonlactating tissues and/or whole tissue homogenates 
rather than LMECs.  No study has comprehensively studied the expression of all known 
xenobiotic transporters in nonpooled human LMEC samples.   
This dissertation work will address many of these unanswered questions to drive 
future predictive models and enhance our understanding of the mechanisms of drug 
transfer into breast milk.  It aims: (1) to clarify the existing CIT3 nitrofurantoin flux 
observations through an evaluation of the potential role of Abcg2 in this model system; 
(2) to extend the in vitro paradigm for M/S prediction by determining if an ABCG2-
transfection model system can estimate the extent of in vivo xenobiotic breast milk 
accumulation; and (3) to provide a comprehensive analysis of the expression level of all 
known xenobiotic transporters in lactating LMECs obtained from individual patients. 
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CHAPTER 2: Plan of Work 
A. Hypothesis 1:  Breast cancer resistance protein (Abcg2) is responsible for the 
basolateral to apical transport of nitrofurantoin in CIT3 cells. 
• Specific Aim 1:  To determine if Abcg2 is detectable in CIT3 cells with and 
without lactogenic hormone stimulation. 
• Specific Aim 2: To determine if nitrofurantoin is transported in unstimulated CIT3 
cells. 
• Specific Aim 3: To evaluate if established Abcg2 inhibitors decrease the transport 
of nitrofurantoin and if known Abcg2 substrates are transported in CIT3 cells.  
Significant past efforts of our lab have focused on nitrofurantoin transfer into 
human milk and the identification of the transport system in stimulated CIT3 cells.  
Recent data demonstrate the role of Abcg2 in transporting nitrofurantoin in the mouse 
and substantial upregulation of this transporter during lactation [53,124].  Data from Gerk 
et al. suggest the system is sodium-dependent, inhibited by dipyridamole, and is likely 
expressed on the basolateral surface of CIT3 cells when stimulated with lactogenic 
hormones [87,88].  Specific Aim 1 will determine Abcg2 RNA (qPCR) and protein 
(western blotting and confocal microscopy) expression levels in unstimulated and 
stimulated CIT3 cells.  Specific Aim 2 will employ transwell flux assays to determine if 
the preferential basolateral to apical nitrofurantoin flux is also observed in unstimulated 
CIT3 (not stimulated with lactogenic hormones).  Specific Aim 3 will determine if Abcg2 
plays a role in nitrofurantoin transport in the CIT3 cell culture system through the use of 
specific inhibitors.  Well-characterized Abcg2 substrates will also be tested to confirm 
any role Abcg2 plays in this model system. 
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B. Hypothesis 2:  Flux experiments in an ABCG2-transfection model system can 
estimate the extent of in vivo xenobiotic accumulation (M/S ratio) in breast milk.  
• Specific Aim 4:  To create a stable ABCG2-transfected cell line that has 
appropriate characteristics for flux experiments. 
• Specific Aim 5:  To validate the model system with known ABCG2 substrates 
(PhIP, nitrofurantoin, cimetidine, methotrexate) and ABCG2 inhibitors (GF120918 
and fumitremorgin C). 
• Specific Aim 6:  To establish a mathematical model for xenobiotic transport in an 
ABCG2-overexpressed cell culture system and to compare measurements of 
efflux activity. 
• Specific Aim 7:  To define the relationship between in vitro efflux ratios and the in 
vivo M/S ratio. 
A large number of xenobiotics known to significantly accumulate in breast milk 
have recently been shown to be substrates of the apical efflux transporter ABCG2 
[53,93,127].  The objective of this series of experiments is to determine if a flux-based 
ABCG2-transfected cell system could be utilized to predict the extent of drug 
accumulation in vivo.  Specific Aim 4 will use molecular biology techniques to establish a 
stably transfected ABCG2 overexpressing cell line derived from a single clone that can 
be used for monolayer flux studies.  The model system will be validated in Specific Aim 5 
with a series of expression and functional assays with known ABCG2 substrates and 
inhibitors.  Specific Aim 6 will then create a mathematical model to define the 
relationships between permeability-surface area product specifically attributed to apical 
efflux (PSa,efflux) and the commonly used experimental measurements efflux activity (ERA, 
ERα).  This model will be used to explain experimental data (Aim 5) and literature-
derived efflux ratios from other ABCG2 overexpressed cell lines to gain insight into the 
best measure of efflux activity for future work.  Finally, Specific Aim 7 will model the 
relationship between in vitro efflux ratios and in vivo M/S to understand the utility and 
limitations of the developed cell culture model. 
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C. Hypothesis 3a:  The determination of xenobiotic transporter genes with increased 
expression in lactating mammary epithelial cells relative to the nonlactating cells and 
other secretory tissues will identify transporters responsible for drug accumulation in 
breast milk. 
 
D. Hypothesis 3b:  The increased Abcg2 expression in mammary tissue observed during 
lactation is a due to increased expression of Abcg2 within luminal mammary epithelial 
cells rather than an expansion of this cell type relative to others within the mammary 
gland.    
• Specific Aim 8: To identify xenobiotic transporters highly expressed in mice 
during lactation (in vivo). 
• Specific Aim 9: To develop a robust methodology to isolate a pure population of 
epithelial cells from human breast milk and reduction mammoplasty clinical 
samples.   
• Specific Aim 10: To identify xenobiotic transporters highly expressed in human 
lactating mammary epithelial cells relative to nonlactating mammary epithelial 
cells and other secretory tissues. 
 
 Several investigators have undertaken screening approaches to quantify the 
expression level of various transporters in tissue homogenates and often include the 
mammary gland in these studies.  These efforts only provide limited information as: (1) 
the expression level represents an average from all cell types in the tissue, not just the 
cells forming the barrier for flux;  (2) the tissue condition chosen for analysis is often the 
nonlactating mammary gland; (3) this approach also does not provide information as to 
the potential regulation of transporter genes during lactation; (3) nor are they complete 
enough to evaluate the potential for the involvement of multiple transport systems.  
Previous efforts in our lab utilized qPCR to determine the β-actin normalized expression 
level of 30 transporters in a single pooled sample of human luminal mammary epithelial 
cells from breast milk and from the same cell type in nonlactating reduction 
mammoplasty tissue.  This dissertation work will use microarray to build upon, and 
address the limitations of, existing knowledge.  Specific Aim 8 will explore xenobiotic 
transporter expression during lactation relative to other stages of development by mining 
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existing murine development datasets.  Specific Aim 9 will develop and validate a new 
methodology necessary to obtain a pure population of human luminal mammary 
epithelial cells in sufficient numbers from clinical samples for microarray.  Specific Aim 
10 will identify transporters with high expression in lactating mammary epithelial cells 
relative to similar nonlactating cells and other secretory tissues (liver and kidney).    
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CHAPTER 3: Materials and Methods 
A. Materials 
CIT3 cells (passage 9) were generously provided by Dr. Margaret Neville at the 
University of Colorado.  Other cell lines were purchased from the established vendors: 
LLC-PK1 cells (an epithelial cell line comprised of porcine kidney proximal tubule cells 
originally deposited by Eli Lilly and Company) from American Type Culture Collection 
(ATCC, Manassas, VA), and MDCKI and MDCKII cells (sub-types I and II cell lines 
originally isolated from a canine kidney by H. Madin and N. B. Darby) from European 
Collection of Cell Cultures (ECACC, Salisbury, Wiltshire, UK).   All cell culture plates, 
#3412 and #3414 transwells, and #3407 snapwells were obtained from Corning Costar 
(Cambridge, MA).  All cell culture media, enzymes, and reagents including human 
epidermal growth factor were purchased from Invitrogen (Carlsbad, California).  Human 
insulin, hydrocortisone, 10x Tris-borate EDTA (TBE) buffer, Trizma® base, Trizma® 
HCL, magnesium chloride, EDTA, mannitol, sucrose, bovine serum albumin (BSA), 
sodium azide, methanol, nitrofurantoin, cimetidine, hyaluronidase, collagenase, dimethyl 
sulfoxide (DMSO), and the monoclonal mouse anti-β-actin antibody were obtained from 
Sigma-Aldrich (St. Louis, MO).  Ciprofloxacin was obtained from ICN Biomedical 
(Aurora, OH).  GF120918 was a generous gift from GlaxoSmithKline (Research Triangle, 
NC).  Fumitremorgin C (FTC) was purchased from Alexis Biochemicals (San Diego, CA).  
DB-67 was a generous gift from Dr. Markos Leggas.  Ovine prolactin was purchased 
from the National Hormone and Pituitary Program (Torrance, CA).   
RNeasy® Micro Kit and Qiashredder columns were obtained from Qiagen 
(Valencia, CA).  Phosphate-buffered saline (PBS), Hanks balanced salt solution (HBSS), 
the SuperScriptTM First-Strand Synthesis System for RT-PCR kit, NuPAGE® 4-12% Bis-
tris gels, NuPAGE®  MOPS SDS buffers,  NuPAGE® reducing agent and antioxidant, 
PVDF sandwich membrane and filter paper, Magic MarkTM XP protein ladder, genecitin, 
Alexa Fluor® 488 goat anti-mouse IgG (H+L) secondary antibody, Alexa Fluor® 568 
goat anti-rabbit IgG (H+L) secondary antibody, Prolong® Gold antifade reagent 
containing DAPI, and Hoechst 33342 were purchased from Invitrogen (Carlsbad, 
California).  The SYBR® Green PCR Core Reagents kit was obtained from Applied 
Biosystems (Foster City, CA). Fluorescein calibration dye was purchased from Bio-Rad 
(Hercules, CA).  All primers were purchased from Integrated DNA Technologies 
(Coralville, IA).  Sea-Kem LE agarose was obtained from Cambrex (Rockland, ME).  
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Ethidium bromide, Tween-20, sodium hydroxide, and Triton®-X-100 were purchased 
from Fisher Scientific (Hampton, NH).  The BCA Protein Assay kit, goat anti-mouse HRP 
conjugate secondary antibody, and Supersignal® West Pico chemiluminescent kit were 
obtained from Pierce (Rockford, IL).  PNGase F was purchased from New England 
Biolabs (Ipswich, MA).  Complete Mini EDTA-free protease inhibitor tablets, FuGENE 6® 
transfection reagent, and DNAse I was obtained from Roche Diagnostics (Indianapolis, 
IN).  
Goat serum was purchased from Vector Laboratories (Burlingame, CA).  The 
BXP-21 mouse anti-human ABCG2 monoclonal antibody and the BXP-53 rat anti-mouse 
Abcg2 monoclonal antibody was obtained from Kamiya Biomedical (Thousand Oaks, 
CA).  The anti-ZO-1 (n-terminus) rabbit polyclonal primary antibody was obtained from 
Zymed (San Francisco, CA).  The phycoerythrin (PE) labeled mouse anti-human ABCG2 
(clone 5d3) and mouse IgG2b isotype control were purchased from eBioscience (San 
Diego, CA).  The fluorescein isothiocyanate (FITC) conjugated mouse anti-human 
ABCG2 (clone 5d3) was obtained from Chemicon International (Temecula, CA).  The 
monoclonal rat anti-human epithelial basement membrane antigen (MUC1) IgG2a 
subtype antibody (MFGM/5/11[ICR.2]) was obtained from Immunologicals Direct/AbD 
Serotec (Raleigh, NC).  Rat IgG2a isotype control (clone R35-95), FITC-conjugated 
mouse IgG1 isotype control antibody and the FITC-conjugated mouse anti-rat IgG2a 
(clone RG7/1.30) secondary antibody were purchased from BD Biosciences/Pharmingen 
(San Jose, CA).  The EasySep® human MUC1 selection kit, "The Big Easy" EasySep® 
magnet, anti-human MUC1 mouse IgG1 subtype (clone 214D4) antibody, and mouse 
monoclonal FITC-conjugated anti-dextran antibody (clone DX1) were obtained from 
StemCell Technologies (Vancouver, Canada).  The Vectastain ABC kit and the 
monoclonal mouse anti-human (IgG1) cytokeratin cocktail CK22 (40-68 kDa) antibody 
was obtained by the UK Cytology department from Vector Laboratories (Burlingame, 
CA) and Biomeda Corp (Foster City, CA), respectively.  Human kidney and liver total 
RNA was purchased from Clonetech (Mountain View, CA).   
The following radiochemicals were purchased: 14C-nitrofurantoin (58 mCi/mmol) 
from Chemsyn Labs (Lexena, KS),  3H-cimetidine (25 Ci/mmol) from Amersham 
(Piscataway, NJ), 14C-PhIP (10mCi/mmol) from Toronto Research Chemicals (Toronto, 
CA),  14C-sucrose (495 mCi/mmol) and 14C-ciprofloxacin (20 mCi/mmol) from Moravek 
(Brea, CA),  3H-mannitol (27 Ci/mmol) from MP Biomedicals (Solon, OH).  Bio-safe® II 
28 
scintillation cocktail was obtained from Research Products International (Mount 
Prospect, IL). 
 
B. Expression and functional role of Abcg2 in CIT3 cells 
1. Cell culture 
CIT3 cells were cultured following established protocols [87].  Briefly, 1 x 106 cells 
(passages 15-19) were seeded on 0.4 μm 4.66 cm2  polycarbonate #3412 transwells 
and grown in “growth media” (DMEM/12 medium with 2% inactivated fetal bovine serum, 
2.38 g/L HEPES, 1.2 g/L sodium bicarbonate, 5 ng/mL epidermal growth factor, 10 
μg/mL insulin, 100 U/mL penicillin, and 100 μg/mL streptomycin).  TEER was measured 
every other day with a Millicell ohmmeter and a Millicell-ERS probe (Millipore, Bedford, 
MA)  for 10-18 days until > 800 Ω•cm2 was achieved.  Cells were then differentiated for 4 
days in “secretion media” which was identical to the growth media except that the 
epidermal growth factor was replaced with 3 μg/mL ovine prolactin and 3 μg/mL 
hydrocortisone. 
2. RNA isolation and quantitative PCR 
Cells were grown on #3412 transwells in growth media to a TEER > 800 Ω•cm2, 
then in either growth media or secretion media for an additional 4 days.   Following a 
wash with ice-cold PBS, cells were scraped off the transwells, and pelleted by 
centrifugation at 300 g for 5 min.  Isolation of total RNA from pelleted cells was 
performed using the RNeasy® Micro Kit per manufacturer protocol with sample 
disruption using Qiashredder® and on-column DNAse treatment.  Mammary gland tissue 
from a lactating CD1 mouse 7 days post-partum served as a positive control.  Total RNA 
isolation from this fibrous tissue was performed in parallel to the CIT3 cells following an 
additional tissue pulverization step using liquid nitrogen with a mortar and pestle.  The 
resulting total RNA concentration was determined by the measurement of optical density 
at 260 nm with a small volume UV-Vis Spectrophotometer (ND-1000, NanoDrop, 
Wilmingon, DE). Total RNA integrity was verified by an OD260/OD280 absorption ratio 
greater than 1.9.  Reverse-transcription of 1.5 μg RNA to cDNA was performed with the 
SuperScriptTM First-Strand Synthesis System for RT-PCR kit following manufacturer’s 
protocol using oligo(dT) to prime the reaction preferentially for mRNA.  All samples to be 
compared were run together using master mixes to limit potential sources of variation. 
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Quantification of the expression level of Abcg2, milk proteins β-casein (Csn2) 
and α-lactalbumin (lalba), and the house-keeping gene β-actin (Actb) was performed 
using the quantitative polymerase chain reaction (qPCR) on the iCycler Multicolor Real-
Time PCR Detection System (Bio-Rad, Hercules, CA).  Gene-specific primer sequences 
were either designed (Csn2 and Lalba) or obtained from published literature (Actb and 
Abcg2).  Primers were designed using reference sequences deposited in NCBI’s Entrez 
Gene with the software assistance of Primer3 (Whitehead Institute for Biomedical 
Research, Cambridge, MA) and Oligo Tool Kit (Operon, Huntsville, AL) [164].  All 
primers utilized were confirmed to generate unique products using NCBI’s BLAST.  
Reference accession numbers, primer sequences, and product sizes are provided in 
Table 3-1.  qPCR reaction master mixes (50 µL) were made using the SYBR® Green 
PCR Core Reagents kit and contained 200 nM of each primer, 1.25 mM dNTPs, 1x 
SYBR Green buffer, 0.025 U/μL Taq polymerase, optimized concentrations of 
magnesium chloride for each primer pair, 20 nM fluorescein, and 0.15 μg of sample 
cDNA.  The amplification protocol included a “hot-start” (95ºC for 5 min) followed by 50 
cycles of a denaturation step (95ºC for 45 sec), an annealing step (optimized annealing 
temperature for each primer pair for 1 min) and an extension step (72ºC for 1 min).  
SYBR Green fluorescence was quantified during each cycle at the end of the extension 
step.  Following amplification, a melting curve program was run to aid in determining the 
specificity of the reaction.  Each reaction mixture was heated to 95ºC and then cooled 
1ºC/min while monitoring the rate of change in fluorescence.  When plotted against 
temperature, this allows for the discrimination of specific amplification products from one 
another [165].  Finally, to confirm the generation of a single product of appropriate size, 
all amplification products were separated by 3% agarose gel electrophoresis in 1 x TBE 
running buffer for 50 min at 150 mV, visualized by staining with ethidium bromide, and 
imaged on an Image Station 2000 MM (Eastman Kodak, New Haven, CT).  Optimization 
of the best conditions for each primer pair (annealing temperature and magnesium) was 
performed using high and low dilutions of the positive control and water only reactions.  
Conditions producing fluorescence above a threshold level in the fewest number of 
cycles while generating a single product of the appropriate size via melt curve analysis 
and gel electrophoresis were accepted. 
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Table 3-1: Murine primers and conditions for qPCR. 
Gene Reference 
Sequence 
Forward Primer (5’→3’) Prod. 
Size  
(bp) 
Mg 
Conc 
(mM) 
Anneal
Temp
(ºC) 
Ref.
Reverse Primer (5’→3’) 
Actb NM_007393 TGTTACCAACTGGGACGACA 165 3.5 62 [166]
GGGGTGTTGAAGGTCTCAAA 
Csn2 NM_009972 TGTGCTCCAGGCTAAAGTTC 103 3.5 62 - 
GATGTTTTGTGGGACGGGAT 
Lalba NM_010679 GACAACGGCAGCACAGAGTA 133 3.5 62 - 
CATCATCCAACTCGTCATCC 
Abcg2 NM_011920 GAACTCCAGAGCCGTTAGGAC 166 3.5 62 [167]
CAGAATAGCATTAAGGCCAGGTT
 
Data analysis was performed using the iCycler IQ Optical System software 
version 3.1 (Bio-Rad, Hercules, CA) according to the relative quantification with an 
external standard method [168].  Briefly, a standard curve consisting of a serial dilution 
for each gene was made from the lactating mammary gland positive control sample in 
triplicate and run simultaneously with the samples in the same plate.  SYBR Green 
fluorescence captured during each cycle of the run was plotted vs. the cycle number in 
real-time.  An arbitrary fluorescence level was then set in the exponential phase of the 
amplification such that it was above any background fluorescence level.  The cycle at 
which each standard’s amplification curve crosses this threshold level (threshold cycle) 
was plotted vs. relative copy number and a best fit line was generated by linear 
regression.  Relative copy number of each gene in the samples was then determined in 
triplicate and normalized to relative copy number of the housekeeping gene β-actin 
within each sample. Negative controls from the reverse transcription and the PCR 
reactions were incorporated into all runs.  
3. Western blot 
CIT3 cells were grown to confluence in growth media and then an additional 4 
days in either growth media or secretion media to determine if Abcg2 protein was 
detectable in the cell line with and without lactogenic hormone stimulation.  Following a 
wash with ice-cold PBS, cells were scraped and pelleted by centrifugation at 300 g for 5 
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min.  Mammary gland tissue from a lactating CD1 mouse 7 days post-partum previously 
pulverized for RNA isolation served as a positive control.  To isolate crude membrane 
fractions from these samples, 1 mL “Dounce Buffer” (Tris buffer pH 7.6 at 4ºC, 0.5 mM 
magnesium chloride) with protease inhibitors (Complete Mini EDTA-free tablets) was 
first added to allow the cells to swell.  Membrane disruption was achieved with brief 
pulses of sonication using a probe ultrasonic processor (Fisher Scientific, Hampton, NH) 
and the tonicity restored to 150 mM with sodium chloride.  Following another 
centrifugation at 300 g for 5 min, the supernatant was removed and EDTA was added to 
a final concentration of 5 mM.  The sample was then centrifuged further at 100,000 g for 
1 hour at 4ºC to pellet the crude membrane fractions.  Pellets were resuspended in 
“resuspension buffer” (0.2 M mannitol, 0.07 M sucrose, 50 μM Tris HCl, 1 μM EDTA) 
and protein concentrations were measured using the BCA Protein Assay kit. 
Western blot analysis was then performed on these samples with or without a 
deglycosylation step using PNGase F according to the manufacturer’s protocol.  Gel 
electrophoresis was completed using NuPAGE® 4-12% Bis-tris gels and NuPAGE®  
MOPS SDS buffers in the X-Cell SureLock™ Mini-Cell system (Invitrogen, Carlsbad, 
CA).  NuPAGE® reducing agent was added to all samples prior to heating to 70ºC for 10 
min.  Samples and the Magic Mark XP protein ladder were run for 200 V for 1 h and then 
transferred to a PVDF membrane using 30 V for 1.25 h at room temperature.  The 
membrane was blocked for 1 h with 3% BSA in TBST (10 mM Tris buffer pH 7.4, 150 
mM sodium chloride, 0.05% Tween-20) prior to overnight incubation with either 1:50 
BXP-53 (for Abcg2) or 1:2000 anti-β-actin in TBST and then washed for 10 min X 3 with 
TBST.  Labeling was accomplished with 1:10,000 goat anti-mouse HRP conjugate in 3% 
BSA in TBST for 1 h.  Following 3 more 10 min TBST washes, Abcg2 protein on the 
membrane was visualized using the Supersignal® West Pico chemiluminescent kit and 
the Image Station 2000 MM (Eastman Kodak, New Haven, CT).  Quantification was 
achieved with band densitometry within the Molecular Imaging Software version 4.04 
(Eastman Kodak, New Haven, CT). 
4. Confocal microscopy 
Expression level and cellular localization of Abcg2 in CIT3 with and without 
lactogenic hormone stimulation were determined by confocal microscopy.  As with 
previous experiments, cells were grown in growth media on polycarbonate filter 
membranes to a TEER > 800 Ω•cm2 to allow for polarization, then in either growth media 
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or secretion media for an additional 4 days.  As the membranes were to be eventually 
repositioned to glass slides, 0.4 μm 1 cm2 #3407 snapwells were used.  Membranes 
were initially washed with ice-cold PBS, cut, and transferred to a 24-well plate for easier 
processing and staining.  Cells were fixed with -20ºC methanol for 10 min, rehydrated 
with room temperature PBS for 5 min, and permeabilized with room temperature 0.2% 
Triton®-X-100 in PBS for 15 min.  Membranes were then blocked through the addition of 
10% goat serum to the permeabilization solution for 30 min at room temperature.  Abcg2 
and the tight-junction protein ZO-1 were then labeled with 1:20 BXP-53 and 1:100 anti-
ZO-1 in the same blocking solution for 1 h at room temperature respectively.  Three 5 
min washes with permeabilization buffer then removed residual primary antibody prior to 
a 1 h incubation with 1:500 Alexa Fluor® 488 anti-mouse and 1:500 Alexa Fluor® 568 
anti-rabbit secondary antibodies in blocking solution.  Finally membranes were again 
washed with permeabilization solution three times, rinsed with PBS, mounted on glass 
slides with Prolong Gold® containing DAPI to visualize nuclei, sealed under a cover slip, 
and allowed to cure overnight.  Fluorescence emission was captured using the 100x oil-
immersion objective at 3 distinct wavelengths with an inverted laser-scanning confocal 
microscope (Leica, Germany) equipped with He-Ne and argon lasers at the UK Imaging 
Facility.  Appropriate negative controls (without the Abcg2 primary antibody) were run to 
set background fluorescence.   
5. Flux assay procedures 
Two different flux systems were utilized.  Early radiolabelled nitrofurantoin 
experiments (Specific Aim 2) were performed following published protocols using 0.4 μm 
1 cm2 #3407 snapwells and vertical diffusion chambers (Navicyte, Sparks, NY) and 
manifold (Harvard Apparatus, Holliston, MA) [87,88].  When the supply of radiolabelled 
nitrofurantoin was exhausted, all subsequent experiments (Specific Aim 3) were 
performed using the larger surface area 0.4 μm 4.66 cm2 #3412 transwell filters in the 
horizontal orientation to allow for greater mass transfer to increase the sensitivity of the 
system.  For the snapwell experiment, approximately 0.5 x 106 cells were seeded 
whereas 1 x 106 cells were seeded to transwells for all subsequent experiments.  
Regardless of approach used, cells were grown for similar lengths of time (10-18 days 
initially, then 4 days in either growth or secretion media) to achieve TEER > 800 Ω•cm2.  
On the day of the experiment, cells were preincubated with 37ºC DMEM/F12 containing 
only 2.38 g/L HEPES and 1.2 g/L sodium bicarbonate (free of serum, proteins, 
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hormones, and antibiotics) and any inhibitors or vehicle only controls to be tested in 
specific wells on that day.  Experiments were initiated by replacing the preincubation 
solutions with fresh solution and adding the “loading solution” containing the substrate to 
be tested and either 0.01 μM 3H-mannitol or 0.2 μM 14C-sucrose as a marker of 
paracellular flux to either the basolateral (B) or apical (A) chamber.  Vertical chambers 
were maintained at 37ºC by perfusing the manifold with solution from a recirculating 
waterbath and constantly mixed by bubbling 95% oxygen/5% carbon dioxide into the 
chambers.  Horizontal chambers were kept at 37ºC in a 5% carbon dioxide incubator 
and constantly mixed with a 10º 3-D Rotator (Barnstead International, Dubuque, Iowa).   
B and A chambers were sampled at specific times and samples were frozen for 
subsequent HPLC analysis (nitrofurantoin) or mixed with 3.5 mL Bio-safe IITM liquid 
scintillation cocktail for later counting on the Tri-Carb 2200CA (PerkinElmer, Waltham, 
MA).  Permeability in the basolateral to apical (B→A) and apical to basolateral (A→B) 
directions were determined as described in the Flux assay data analysis section on page 
34.  Experiments involving nitrofurantoin were performed in a darkened room due to this 
drug’s sensitivity to light.  
6. Flux assay study designs 
The initial experiment to determine if there was a directionality to nitrofurantoin 
flux in unstimulated CIT3 cells as was previously demonstrated for CIT3 cells following 
lactogenic hormone stimulation was performed by loading 0.2 μCi/well (approx 1.5 μM) 
14C-nitrofurantoin (greater than 97% pure) to either the B or A snapwell chamber (n=3 of 
each).  One hundred microliter samples were obtained at 1, 20, 40, 60, 80, 100, and 120 
min from both chambers and immediately mixed with liquid scintillation cocktail for 
counting.  TEER and nitrofurantoin permeability of unstimulated cells vs. those 
stimulated with lactogenic hormones for 4 days were then compared. 
The ability to inhibit the predominantly B→A directed flux of 10 μM nitrofurantoin 
in unstimulated and stimulated CIT3 cells with Abcg2 inhibitors was determined using 
the Abcg2 inhibitor FTC at 10 μM.  The inhibitor was added to all preincubation buffers 
and both B and A chambers of the #3412 transwells.  The experiment was initiated by 
adding nitrofurantoin and 3H-mannitol to final concentration of 10 μM and 0.01 μM, 
respecitively, to the B or A chamber (n=3 of each).  One hundred fifty microliters was 
sampled from both chambers at 0.5, 1, and 2 h for determination of pmol nitrofurantoin 
transferred at each timepoint by HPLC and 50 μL was collected at 1 and 2 h for similar 
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mannitol mass quantification by liquid scintillation counting.  Permeability of 
nitrofurantoin in both directions was then compared with and without inhibitors in either 
unstimulated or stimulated conditions. 
Finally to further demonstrate the potential role of Abcg2 in unstimulated CIT3 
cells, two known Abcg2 substrates were tested using similar experimental procedures.  2 
μM 14C-PhIP and 0.01 μM 3H-mannitol and the same inhibitor were used in the first 
experiment and 5 μM cimetidine (traced with 500 µCi/µmol 3H-cimetidine) and 0.2 mM 
14C-sucrose was used in the second.  In the PhIP experiment, 200 μL was sampled from 
both sides of each chamber at 0.5, 1, and 2 h, whereas 150 μL was sampled from both 
sides of each chamber at 0.5, 1, 2, and 4 h in the cimetidine experiment.  All samples 
were immediately added to liquid scintillation cocktail.  Permeability of each drug in both 
directions was then compared with and without inhibitors.  Chemical structures of all 
agents used in the transport studies can be found in Appendix 2. 
7. Nitrofurantoin HPLC analysis in cell culture media 
The amount of nitrofurantoin transferred at each timepoint was calculated by 
HPLC analysis using a published assay with minor modifications [53].  Briefly, 50 μL of 
the sample from each timepoint in cell culture was injected onto the Shimadzu HPLC 6A 
series HPLC system (Kyoto, Japan) without extraction.  Samples were only vortexed and 
briefly centrifuged to pellet any debris.  The mobile phase was modified from 75:25 to 
80:20 acetonitrile:3.5 mM potassium phosphate pH 3.0 at 1 mL/min to shorten the run 
time to 5 min.  The retention time of nitrofurantoin was 3.5 min on the Lichrosorb 5 RP-
18 125 x 4 mm column (Phenonemex, Torrance, CA) with good peak separation.  UV 
absorbance was measured at 366 nm.  Sample and standard injection order was 
randomized.  Peak heights were used for interpolation on the standard curve.   
8. Flux assay data analysis                           
The apparent permeability (Papp, (μL/h)/cm2) of each drug or paracellular marker 
was determined by calculating its flux (J, pmol/h) across the cell layer and dividing by the 
surface area (A, cm2) of the transwell or snapwell and the initial concentration (C0, 
pmol/mL) in the donor chamber as shown in Eq. 3-1.   
 
Papp = 
J
A · C0
 Eq. 3-1
35 
 Cumulative amount of drug moving to the recipient chamber was assumed to be 
negligible relative to donor concentration such that initial donor concentrations were 
maintained (sink conditions).  Flux of each drug was determined by best fit line through 
the linear region of the graph of the cumulative pmol transferred vs. time.  Linear 
regression was performed using GraphPad Prism 5.0 (San Diego, CA).  Regression 
lines were forced through the origin for PhIP as less than 3 points were available in the 
linear range of the curve.  Consistent with similar flux assays in the published literature, 
leakage of the paracellular marker used in each experiment was tolerated up to an 
apparent permeability of 1%/h (4.3 (μL/h)/cm2) [127].   
9. Statistical Analysis 
Normalized relative RNA expression of β-casein, α-lactalbumin, and Abcg2 in 
CIT3 cells with and without lactogenic hormone stimulation were compared with an 
unpaired t-test.  Sucrose permeabilities in unstimulated CIT3 cells were also compared 
with an unpaired t-test.   All other directionality and inhibition studies were compared 
using one-way ANOVA with Bonferroni’s multiple comparisons as above except that only 
select comparisons were considered in post-hoc testing.  In the stimulated vs. 
unstimulated nitrofurantoin directionality experiment, the following comparisons were 
made: unstimulated B→A vs. A→B, stimulated B→A vs. A→B, unstimulated B→A vs. 
stimulated B→A, and unstimulated A→B vs. stimulated A→B.  In all inhibition 
experiments, the comparisons selected were B→A vs. A→B, B→A vs. B→A inhibited, 
A→B vs. A→B inhibited, and B→A inhibited vs. A→B inhibited.  All statistical analyses 
were performed using GraphPad Prism 5.0 (San Diego, CA) with a p-value < 0.05 
considered significant.   
 
C. Creation of an ABCG2 stably transfected model system 
1. Selection of a cell line 
Several cell lines (LLC-PK1, MDCKI and MDCKII) were evaluated prior to 
transfection to identify the candidate with the best properties for subsequent 
experiments: ease of maintenance in culture, an ability to form a monolayer on 
transwells exhibiting high TEER and low flux of a paracellular flux marker (mannitol), no 
background expression of Abcg2, limited expression of other xenobiotic transporters, 
and ease of selection post-transfection.  Each was purchased from an established 
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source and was grown in the media specified by that vendor.  To compare TEER and 
mannitol flux, cells were grown on #3414 transwells until a maximal TEER was achieved 
and mannitol flux experiments were performed as described with CIT3 cells in the  Flux 
assay procedures section on page 32.  Background expression of Abcg2 and other 
xenobiotic transporters was evaluated by reviewing of published literature.  The 
concentration of genecitin necessary for selection of transfected cells was estimated by 
visually inspecting growth following exposure of the parent cell line to a range of 
concentrations (100-1000 μg/mL) of this agent. 
2. Transfection 
The pcDNA3 plasmid construct alone (empty vector) and the pcDNA3 plasmid 
containing wild-type ABCG2 were generously provided by Dr. Markos Leggas (Figure 
3-1).  MDCKII cell transfection was performed at 50% confluence with the lipid-based 
FuGENE 6® transfection reagent at a 3:1 ratio per manufacturer’s protocol.  Success of 
transfection was initially evaluated at 48 h by western blot analysis of cell lysates for 
ABCG2 following procedures described in the Western blot on page 37.  Transfected 
cells were then selected through the addition of 800 μg/mL genecitin to the parent cell 
line media (MEM containing glutamax, 5% FBS, 100 U/mL penicillin, and 100 μg/mL 
streptomycin). 
 
Figure 3-1: pcDNA3/ABCG2 plasmid construct. 
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3. Western blot 
Procedures for western blot analysis of ABCG2 expression in crude membrane 
fractions were the same as those described for CIT3 cells on page 30 with different 
antibodies.  The ABCG2 primary antibody used was 1:500 BXP-21 and the secondary 
antibody was therefore 1:10,000 goat anti-mouse HRP conjugate.  When protein from 
cell lysates rather than crude membrane fractions was desired, it was prepared by 
scraping the cells, washing with ice-cold PBS, pelleting by centrifugation at 300 g for 5 
min, and adding “lysis solution” (50 mM HEPES, 1 mM EDTA, protease inhibitors (from 
Complete Mini EDTA-free tablets)) to the pellet.  Protein isolated from ABCG2-
transfected Saos-2 cells (Saos-2-ABCG2) served as a positive control [169,170]. 
4. Flow cytometry and fluorescence-activated cell sorting (FACS) 
Relative quantification of ABCG2 surface expression was performed by flow 
cytometry using a PE-conjugated primary antibody raised against an external epitope of 
ABCG2.  Cells were trypsinized, pelleted by centrifugation at 300 g for 5 min, 
resuspended in ice-cold HBSS (without calcium/magnesium) containing 1 mM EDTA 
and counted on a hemocytometer.  Five hundred thousand cells were added to a 12 x 75 
mm polystyrene tube, again pelleted by centrifugation, and labeled with 0.5 μg of the 
Anti-ABCG2(clone 5d3)-PE or IgG2b-PE isotype control antibody for 30 min at 4ºC in 50 
μL of HBSS (without calcium/magnesium) containing 2% FBS, 1 mM EDTA, and 0.1% 
sodium azide.  Following labeling, cells were washed with the same labeling solution to 
remove residual antibody, centrifuged at 300 g for 5 min, resuspended, and brought to 
the UK Flow Cytometry Core Facility on ice for immediate analysis.  Cell clumps or 
debris were gated out using forward and side scatter and following excitation at 488 nm 
the PE fluorescence of 3 x 104 events per tube were captured at 575 nm on the 
FACSCalibur cytofluorimeter (BD Biosciences, San Jose, CA).  Relative expression level 
was quantified by subtracting the geometric mean fluorescence intensity (MFI) of the PE 
histogram of the isotype control from that of the anti-ABCG2 antibody.  Antibody 
titrations were performed for all new batches of the anti-ABCG2-PE antibody using 
Saos-2-ABCG2 cells and mouse IgG2b isotype-control antibody.   
Sorting of individual live cells with high surface expression of ABCG2 for clonal 
selection was achieved using FACS and the same antibody, this time conjugated to 
FITC.  Transfected cells selected in 800 μg/mL genecitin for 2 weeks were trypsinized, 
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pelleted by centrifugation at 300 g for 5 min and counted on a hemocytometer.  Cells (5 
x 105) were added to a 12 x 75 mm polypropylene tube and blocked with 10% goat 
serum in HBSS for 5 min at room temperature.  Cells were then washed, centrifuged, 
and the pellets were labeled with 10 μL of the Anti-ABCG2(clone 5d3)-FITC antibody for 
30 min at room temperature in HBSS + 2% FBS.  Residual antibody was removed 
following centrifugation and cells were resuspended in HBSS with 2% FBS containing 2 
μg/mL propidium iodide (PI).  At the UK Flow Cytometry Core Facility, cell clumps or 
debris were removed from the analysis using forward and side scatter and following 
excitation at 488 nm cells with low PI fluorescence at 575 nm (presumed viable) and with 
high FITC fluorescence at 525 nm were sorted into individual wells of a 96-well plate 
using the MoFloTM High-Performance Cell Sorter (DakoCytomation, Fort Collins, 
Colorado).  Gates were set based on fluorescence of single color controls.   
5. Hoechst 33342 efflux 
ABCG2 functional activity was assessed by efflux of the fluorescent ABCG2 
substrate Hoechst 33342 by flow cytometry.  Following clonal expansion of single cells 
plated via FACS, 1 x 105 were seeded in 12-well plates and grown to confluence.  On 
the day of the experiment, these MDCKII-ABCG2 cells were first washed with PBS and 
preincubated with OptiMEM with or without 1 μM GF120918 for 15 min.  Hoechst 33342 
(10 μM) was then added and allowed to accumulate for 45 min at 37ºC while mixing in 
an incubator containing 5% carbon dioxide.  Cells were next washed with PBS, 
OptiMEM with or without the inhibitor replaced, and efflux was allowed for 10 min.  Efflux 
was stopped by placing the wells on ice and washing with ice-cold PBS (without calcium 
or magnesium).  Three hundred microliters of 10X trypsin/EDTA containing no phenol 
red was subsequently added to loosen the cells from the plate.  The resulting cell 
suspension was centrifuged at 300 g for 5 min at 4ºC and resuspended in PBS (without 
calcium or magnesium) containing 2.5% FBS and 2 μg/mL PI and brought to the UK 
Flow Cytometry Core Facility for analysis on the MoFloTM High-Performance Cell Sorter 
(DakoCytomation, Fort Collins, Colorado).  Cell clumps, debris, and presumed nonviable 
cells were removed from analysis using forward/side scatter and PI fluorescence.  
Hoechst 33342 fluorescence of each cell was analyzed by excitation at 325 nm and a 
measurement of the emission at 440 nm.  A gate set at the beginning of the Hoechst 
33342 histogram of the GF120918-treated samples of each clone was used to assess 
ABCG2 functional activity of each sample.  Specifically, the number of cells with 
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fluorescence intensity less than this level (dim population) was quantified and expressed 
as a percentage of total cells in the sample.  All gates were set based on fluorescence of 
unstained and single color controls.  Empty vector-transfected cells were used as a 
negative control.  Hoechst 33342 accumulation and efflux times were optimized using 
Saos-2-ABCG2 cells prior to experiments with MDCKII-ABCG2 clones.   
6. DB-67 accumulation 
The accumulation of the camptothecin analog DB-67 was assessed in several of 
the clones by similar procedures.  Four hundred thousand MDCKII-ABCG2 cells 
expanded from single clones were plated in 6-well plates (n=3 of each condition), grown 
to confluence, and preincubated with or without 1 μM GF120918 in OptiMEM for 15 min.  
One micromolar DB-67 was then added and allowed to accumulate for 20 min at 37ºC 
while mixing in an incubator containing 5% carbon dioxide.  Substrate accumulation was 
stopped by placing the plate on ice and washing three times with ice-cold HBSS 
containing 10% FBS.  Cells were lysed with 0.5 N sodium hydroxide and an aliquot was 
used to determine protein concentrations using the BCA Protein Assay kit.  The 
remaining sample was analyzed by HPLC with fluorescence detection for total DB-67 
(lactone and carboxylate forms) following previously published methods [171].  Data was 
expressed as total DB-67 accumulation normalized to protein content and compared 
with and without the inhibitor in each cell line by t-tests. 
7. Confocal microscopy 
Procedures for the determination of expression level and cellular localization of 
ABCG2 in MDCKII-ABCG2 cells were the same as those described for CIT3 cells on 
page 31 except that the anti-ABCG2 primary antibody used was 1:40 BXP-21.  Empty 
vector-transfected cells were used as a negative control. 
8. Flux assays 
Evaluation of the MDCKII-ABCG2 model system with known ABCG2 substrates 
and inhibitors was performed using procedures detailed in the Flux assay procedures 
and Flux assay data analysis sections on pages 32 and 35.  All experiments were 
performed with 1 x 106 cells grown for 3-4 days on #3414 transwells in the horizontal 
orientation.  Directionality experiments were performed in OptiMEM with 10 μM 
nitrofurantoin, 2 μM 14C-PhIP, 5 μM cimetidine (traced with 2 mCi/µmol 3H-cimetidine), 5 
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nM 3H-methotrexate, or 10 μM ciprofloxacin (traced with 8 µCi/µmol 14C-ciprofloxacin) 
added to the donor chamber.  Inhibition experiments were also performed in OptiMEM 
with either 1 μM GF120918, 10 μM FTC, or vehicle-only control with all of these 
substrates except for methotrexate and ciprofloxacin.  Sampling was performed as 
detailed: nitrofurantoin, 130 μL at 0.5 h, 1 h, 2 h, 3 h (directionality), 120 μL at 0.5 h, 1 h, 
2 h, 3 h; PhIP, 50 μL at 0.5 h, 1 h, 2 h, 3 h, 4 h (directionality), 300 μL at 0.5 h, 1 h 
(inhibition); cimetidine, 200 μL at 0.5 h, 1 h, 2 h; methotrexate, 200 μL at 0.5 h, 1 h, 2 h; 
and ciprofloxacin, 50 μL at 0.5 h, 1 h, 2 h, 4 h.  All substrates except nitrofurantoin were 
assayed by liquid scintillation counting.  Nitrofurantoin was assayed by HPLC as 
described on page 34.  A paracellular marker (14C-sucrose or 3H-mannitol) was used in 
all experiments and leakage was tolerated up to an apparent permeability of 1%/h (4.3 
(μL/h)/cm2).   Permeabilities were calculated for each drug and statistical tests were 
performed as described on page 35 except that comparisons were made between the 
empty vector and the MDCKII-ABCG2 clone 40 for directionality experiments and 
between control and the various inhibitor treated samples within each cell type in the 
inhibition assays.  The percentage inhibition of the component of the B→A permeability 
attributed to ABCG2 was also calculated as shown in Eq. 3-2.   The difference in the 
ABCG2-transfected B→A permeability and the empty vector-transfected B→A 
permeability with the inhibitor (PappABCG2, I - PappEmpty, I) is subtracted from that of wells 
without the inhibitor (PappABCG2 - PappEmpty) and dividing by the same difference in the 
uninhibited condition.   
 % Inhibition = 
(PappABCG2 - PappEmpty) - (PappABCG2, I - PappEmpty, I)
(PappABCG2 - PappEmpty)
 X 100 Eq. 3-2
 
D. Mathematical modeling and derivation of commonly used measurements of efflux 
activity. 
1. Development of a model for drug transfer into milk 
A simple mathematical model, built upon the recently published work of Kalvass 
and Pollack, was developed to describe drug transfer into breast milk (Figure 3-2) [172].  
This three compartment system incorporates the permeability-surface area product 
attributed to: paracellular flux between the cells (PSPC), passive diffusion across the 
LMEC basolateral and apical membranes (PSD), basolateral uptake (PSB,U), apical efflux 
(PSA,E), basolateral efflux (PSB,E) and apical uptake (PSA,U).   
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Figure 3-2: Simple kinetic model for flux across a LMEC monolayer 
 
Assuming passive diffusion is equal for the basolateral and apical membranes 
and ignoring any potential protein binding, ionization, or fat partitioning phenomena, the 
kinetic model can be described by the following set of equations: 
 dXB
dt
 = CC PSD+PSB,E - CB PSD+PSB,U + CA-CB PSPC Eq. 3-3
 dXC
dt
 = CA PSD+PSA,U  + CB PSD+PSB,U - CC 2PSD+PSA,E+PSB,E  Eq. 3-4
 dXA
dt
 = CC PSD+PSA,E - CA PSD+PSA,U + CB-CA PSPC Eq. 3-5
where dXA/dt, dXB/dt, and dXC/dt represent the substrate flux into and out of the apical 
(A, milk), basolateral (B, serum), and cellular compartments (C, LMEC), respectively; 
and  CA, CB, and CC, represent the substrate concentrations in each compartment.  The 
complete derivations of all equations discussed in this and subsequent sections can be 
found in Appendix 3. 
2. Initial rate: B→A 
Assuming initial unidirectional flux into the apical compartment (CA = 0), and rapid 
equilibration between the B and C compartments such that dXC/dt = 0, B→A flux can be 
described by: 
 dXA,B→A
dt
 = CB
0 PSD+PSB,U PSD+PSA,E
2PSD+PSA,E+PSB,E
+PSPC  Eq. 3-6
Basolateral Cellular Apical 
PSD 
PSB,U 
PSD
PSA,E 
PSA,UPSB,E 
PSPC
Serum LMEC Milk 
B C A 
Tight 
Junction
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In the complete absence of substrate active uptake into or efflux out of the cell (PSB,U, 
PSA,E, PSB,E, and PSA,U = 0), for example in a parent cell line with no endogenous 
transporter expression, the relationship collapses to: 
 dXA,B→A
dt parent
 = CB 
0 PSD
2
+PSPC  Eq. 3-7
Subsequently, transfection of a single apical efflux transporter into the parent cell line 
(eg. The MDCKII-ABCG2 cells created in section C), yields the following:  
 dXA,B→A
dt ABCG2
 = CB 
0 PSD PSD+PSA,E(ABCG2)
2PSD+PSA,E(ABCG2)
+PSPC  Eq. 3-8
PSA,E(ABCG2) represents the permeability-surface area product attributed to the transfected 
transporter ABCG2. 
3. Initial rate: A→B  
Assuming initial unidirectional flux into the apical compartment (CB = 0), and rapid 
equilibration between the A and C compartment such that dXC/dt = 0, A→B flux can be 
described by: 
 dXB, A→B
dt
 = CA
0 PSD+PSA,U PSD+PSB,E
2PSD+PSA,E+PSB,E
+PSPC  Eq. 3-9
In the complete absence of substrate active uptake into or efflux out of the cell (PSB,U, 
PSA,E, PSB,E, and PSA,U = 0), for example in a parent cell line with no background 
transporter expression, the relationship collapses to: 
 dXB, A→B
dt parent
 = CA 
0 PSD
2
+PSPC  Eq. 3-10
Subsequently, transfection of a single apical efflux transporter into the parent cell line 
(eg. The MDCKII-ABCG2 cells created in section C), yields the following:  
 dXB, A→B
dt ABCG2
 = CA 
0 PSD 2
2PSD+PSA,E(ABCG2)
+PSPC  Eq. 3-11
 
4. Apical efflux ratio: ERA 
The apical efflux ratio, ERA, is defined as the ratio of the initial rate of B→A flux 
when all active transport processes are not inhibited divided by the initial rate of B→A 
flux when all active transport processes are inhibited completely: 
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ERA=
dXA,B→A
dt
dXA,B→A
dt inhibited
 = 
CB
0 PSD+PSB,U PSD+PSA,E
2PSD+PSA,E+PSB,E
+PSPC
CB 
0 PSD
2 +PSPC
 Eq. 3-12
If we assume permeability-surface area product for passive diffusion is much greater 
than that for paracellular flux between cells (PSD >> PSPC) or that paracellular flux 
between cells is negligible (PSPC→0), the equation for ERA can be rearranged to: 
 
ERA=
dXA,B→A
dt
dXA,B→A
dt inhibited
 = 
2 PSD+PSB,U PSD+PSA,E
PSD 2PSD+PSA,E+PSB,E
 Eq. 3-13
If the same assumption is made when determining ERA for transfection of the single 
apical efflux transporter ABCG2 into the parent cell line with no background endogenous 
transporter expression (Eq. 3-8 divided by Eq. 3-7), the following relationship results: 
 
ERA= 
2 PSD+PSA,E(ABCG2)
2PSD+PSA,E(ABCG2)
 Eq. 3-14
5. Asymmetry efflux ratio: ERα 
The asymmetry efflux ratio, ERα, is defined as the ratio of the initial rate of B→A 
flux (Eq. 3-6) divided by the initial rate of A→B (Eq. 3-9): 
 
ERα
dXA,B→A
dt ABCG2
dXB,A→B
dt ABCG2
CB 
0 PSD+PSB,U PSD+PSA,E
2PSD+PSA,E+PSB,E
+PSPC
CA 
0 PSD+PSA,U PSD+PSB,E
2PSD+PSA,E+PSB,E
+PSPC
 Eq. 3-15
If we assume the initial donor concentrations in the basolateral and apical compartments 
are equal experimentally (CB 
0 CA
0 ), and that PSPC is negligible (PSPC→0), the equation 
can be simplified to: 
 
ERα=
PSD+PSA,E PSD+PSB,U
PSD+PSA,U PSD+PSB,E
 Eq. 3-16
Finally, if the same assumption is made when determining ERα for transfection of the 
single apical efflux transporter ABCG2 into the parent cell line with no background 
endogenous transporter expression (Eq. 3-8 divided by Eq. 3-11), the following 
relationship results: 
 
ERα=
PSD+PSA,E(ABCG2)
PSD
 Eq. 3-17
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6. Steady-state concentrations in compartments A, B, and C 
The steady-state substrate concentrations in compartments A, B, and C (dXA/dt, 
dXB/dt, and dXC/dt = 0) can be determined by rearranging the differential equations Eq. 
3-3, Eq. 3-4, and Eq. 3-5 to produce: 
 
CB,SS=
CA,SSPSPC+CC,SS PSD+PSB,E
PSD+PSB,U+PSPC
 Eq. 3-18
 
CC,SS=
CA,SS PSD+PSA,U +CB,SS PSD+PSB,U
2PSD+PSA,E+PSB,E
 Eq. 3-19
 
CA,SS=
CB,SSPSPC+CC,SS PSD+PSA,E
PSD+PSA,U+PSPC
 Eq. 3-20
If we assume PSPC is negligible relative to the other processes (PSPC→0), equations Eq. 
3-18 and Eq. 3-20 for the steady state concentrations in the basolateral and apical 
compartments can be reduced to Eq. 3-21 and Eq. 3-22, respectively: 
 
CB,SS=
CC,SS PSD+PSB,E
PSD+PSB,U
 Eq. 3-21
 
CA,SS=
CC,SS PSD+PSA,E
PSD+PSA,U
 Eq. 3-22
Recalling that concentrations in this model are unbound drug, the steady-state ratio of a 
drug in the apical vs. the basolateral compartment can be determined by dividing CA,SS 
by CB,SS (Eq. 3-22 by Eq. 3-21).  This results in the same asymmetry efflux ratio (ERα) 
presented earlier:  
 CA,SS,unbound
CB,SS,unbound
=
PSD+PSA,E PSD+PSB,U
PSD+PSA,U PSD+PSB,E
ERα Eq. 3-23
7. Relationships to M/S ratio 
To extend the model to the in vivo situation, we assume the clearance terms that 
define the in vivo unbound ratio of the drug at steady state in the milk and serum are 
comparable to the in vitro permeability-surface area product terms that define the similar 
ratio in the model (Eq. 3-23), such that: 
 Cmilk,unbound
Cserum,unbound
=
ClD+ClA,E ClD+ClB,U
ClD+ClA,U ClD+ClB,E
 Eq. 3-24
45 
The Passive Diffusion model for drug transfer into breast milk is based on total drug 
concentrations and provides the following prediction for the M/S ratio: 
 M
Sin vivo
M
Sdiffusion
=
fs
un fs W
fm
un fm Sk
 Eq. 3-25
where fs
un and fm
un are the fraction of the drug unionized in the serum and milk, 
respectively;  fs and fm are the fraction protein bound in the serum and milk, respectively; 
and W and Sk are the fat partitioning into whole and skim milk, respectively [68].  It 
assumes that the ratio of unbound concentrations in the milk and serum are equal 
(Cmilk,unbound = Cserum,unbound) and suggests that M/S ratio observed in vivo is governed 
by protein binding and ionization in the milk, and serum and partitioning into milk fat.  If 
active processes exist, Cmilk,unbound would not equal Cserum,unbound and another component 
would need to be added to the prediction to account for differences in these unbound 
concentrations.   
 M
Sin vivo
=
Cmilk,unbound
Cserum,unbound
fs
un fs W
fm
un fm Sk
 Eq. 3-26
Replacing the unbound ratio in the milk and serum at steady state with the clearance 
terms that govern that ratio (Eq. 3-24) allows the incorporation of active processes to put 
forth a new in vivo conceptual model:   
 M
Sin vivo
=
ClD+ClA,E ClD+ClB,U
ClD+ClA,U ClD+ClB,E
fs
un fs W
fm
un fm Sk
 Eq. 3-27
It also suggests that it may be possible to predict the in vivo M/S ratio using in vitro ERα  
determinations and simple in vitro measurements of protein binding, ionization potential, 
and skim to whole milk partitioning: 
 ClD+ClA,E ClD+ClB,U
ClD+ClA,U ClD+ClB,E
≈
PSD+PSA,E PSD+PSB,U
PSD+PSA,U PSD+PSB,E
 Eq. 3-28
 M
Sin vivo
=
PSD+PSA,E PSD+PSB,U
PSD+PSA,U PSD+PSB,E
fs
un fs W
fm
un fm Sk
 Eq. 3-29
 M
Sin vivo
=ERα
fs
un fs W
fm
un fm Sk
Eq. 3-30
8. Application of the model 
The theoretical limits of the initial B→A and A→B rates and efflux ratios with 
increasing PSA,E(ABCG2) and PSD were simulated to gain a greater understanding of the 
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model.   Apparent permeability data from the published literature as well as generated 
through this dissertation work were analyzed to examine the applicability of this kinetic 
model to experimental data. Graphed flux data from all publications using two different 
cell lines (MDCKII transfected with either Abcg2 or ABCG2) created by the lab of Dr. 
Alfred Schinkel was gathered for calculation of the apical efflux ratio (ERA) and the 
asymmetry efflux ratio (ERα) in an external data set [53,91,93,127-129,152,153,173].  
The flux of each drug per unit time, expressed as a percentage of initial donor mass, 
was extracted from each graph and linear regression was used to determine a flux rate 
using methods previously described.  Efflux ratios were then generated from the external 
data sets and are presented as a single value as only mean permeabilities were 
available in the literature. The ERA and the ERα for nitrofurantoin, PhIP, cimetidine, 
ciprofloxacin, and methotrexate in the MDCKII-ABCG2 model system created in Section 
C (Specific Aim 5) were also determined.  As each condition in each experiment was 
performed in triplicate and the resulting individual permeabilities used in the calculations 
of the efflux ratios were unmatched, the mean and standard deviation of these ratios 
were calculated by determining all efflux ratios possible from the experimental data (eg. 
n=3 ABCG2 B→A and n=3 Empty B→A ABCG2 observations yields nine possible ERA 
values).   The simulations and efflux ratios were then used to provide some guidance as 
to which efflux ratio (eg. ERA, ERα) is a better experimental measurement of apical efflux 
attributed to ABCG2 (PSA,E(ABDG2)) in flux assays. 
Experimental constraints for the model were then considered.  The assumption 
that there exists no other active flux processes in the parent cell line and that the 
permeability-surface area product for diffusion is much greater than that of paracellular 
flux (PSD >> PSPC) were challenged.   
Finally, correlations were conducted to gain a greater understanding of the 
relationships between in vitro efflux ratios and in vivo M/S ratios.  Pearson’s Correlations 
between various efflux ratios (measurements of the ABCG2/Abcg2-mediated efflux in 
the in vitro model system) and the ratio of the M/S in a wild-type mouse vs. that of the 
Abcg2 knockout animal (an in vivo estimation of the M/S attributed to Abcg2) were also 
performed and the correlation coefficients (r) reported (GraphPad Prism 5.0, San Diego, 
CA).  To illustrate any possible relationship between the variables graphically, 
orthogonal (Deming) regression (GraphPad Prism 5.0, San Diego, CA) was also 
performed to generate the best-fit line as both variables are independent.   Despite the 
use of all possible combinations of the unmatched permeabilities to generate an 
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estimate of the “true” mean and standard deviation of each efflux ratio, it would not be 
appropriate to use all these datapoints in the correlation as the experiment was truly only 
performed in triplicate.  Therefore, correlations were performed using these estimates of 
the mean and standard deviation with a sample size of three for each experiment. 
 
E. Microarray expression profiling of transporter gene expression in murine 
developmental datasets 
1. Developmental datasets  
Microarray analysis was used to identify murine xenobiotic transporters that were 
differentially expressed during lactation.  The published literature and NCBI Gene 
Expression Omnibus (http://www.ncbi.nlm.nih.gov/projects/geo/) were searched and 
three existing datasets found.  The work by Stein el al, Clarkson et al, and  Medrano et 
al. captured gene expression in the mammary gland at various time points during 
development, but none specifically focused on xenobiotic transporters and lactation 
[174-176].  Stein et al. provided the most robust set of data with one Balb/C mouse used 
per chip and 3 chips (biological replicates) per time point.  The murine developmental 
time points available from this study included virgin weeks 10 and 12; pregnancy day 1, 
2, 3, 8.5, 12.5, 14.5, and 17.5; lactation day 1, 3, and 7; and involution day 1, 2, 3, 4, and 
10.  Clarkson et al. included 3 C57/Bl/6 mice per chip and 2 chips (biological replicates) 
per time point.  The 12 stages of adult mammary gland development included virgin 
week 8; gestation day 5, 10, and 15; lactation day 0, 5, and 10; and 12, 24, 48, 72, and 
96 hours after forced weaning.  Medrano included one C57 mouse per chip and variable 
number of chips at each time point: 3 virgin at 6 weeks, 2 at pregnancy day 14, 2 at 
lactation day 10, and 2 at involution day 4.  Stein et al. and Clarkson et al. specifically 
noted removing the lymph nodes from the whole mammary gland during excision.  
2. Data and statistical analysis 
Data from all 17 time points of the Stein et al. dataset were obtained in the form 
of a tab-delineated file containing detection calls, normalized MAS5 signal data, gene 
symbols, and annotations from all 12488 probesets of the GeneChip® Mu74v2A Array 
(Affymetrix, Santa Clara, CA).  The Clarkson et al. and Medrano et al. data was obtained 
as raw .cel files and were analyzed by the Expression Console 1.1 (Affymetrix, Santa 
Clara, CA)  software using the MAS5 algorithm normalizing to a target intensity of 100.  
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This analysis scheme was chosen to replicate that used by Stein et al. for comparison 
purposes.  Stein et al. data from virgin mice at weeks 10 and 12 (6 chips), Clarkson et al. 
data from virgin mice at 8 weeks (2 chips), and Medrano et al. data from virgin mice at 6 
weeks (3 chips) were grouped into a “nonlactating” group.  Similarly, Stein et al. data 
from lactation day 1, 3, and 7 (9 chips), Clarkson et al. data from lactation day 5 and 10 
(4 chips) and Medrano data from lactation day 10 (2 chips) were grouped into a 
“lactating” group.   
In order to decrease the number of comparisons made several filtering 
approaches were used.  In the detection call, a one-sided Wilcoxon Signed Rank test 
performed within MicroArray Suite 5.0 (Affymetrix, Santa Clara, CA) during original 
analysis, the hybridization signal from each probe set was designated as being Present, 
Marginal or Absent.  Signal intensity data for probesets identified as Absent in all 15 
arrays in the lactating group were removed from the analysis.  To further decrease the 
likelihood of false positives from multiple comparisons, two approaches to filter for 
probesets representing only xenobiotic transporters were explored.  In the first, gene 
symbols of the transporter families Abc(A-G), Slc(1-43), and Slco were retrieved from 
Entrez Gene (search date: 1/9/07).  The 395 hits were then submitted to Affymetrix 
NetAffyxTM Analysis Center (http://www.affymetrix.com/analysis/) to determine which 
could be detected by the Mu74v2 GeneChip® array set.  Two hundred probeset IDs 
were returned by the query, with the majority detecting transcripts that had no known 
role in xenobiotic transport.  The second filtering approach (the method eventually 
chosen) used the published literature to establish a list of genes with a proposed role in 
xenobiotic transport.  This list of genes of interest was built by first combining the human 
gene symbols analyzed in three comprehensive surveys of transporter gene expression 
in various tissues by Alcorn et al, Calcagno et al, and Bleasby et al. [49,104,177].  
Mouse homologs of these genes were then identified using NCBI Entrez Gene 
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene) and NCBI Homologene 
(http://www.ncbi.nlm.nih.gov/sites/entrez/query.fcgi?db=homologene). These fifty-two 
genes from the ABCA, ABCB, ABCC, ABCG, SLC6, SLC10, SLC15, SLC16, SLC17, 
SLC22, SLC23, SLC 28, SLC29, SLC6, and SLCO families with potential relevance for 
xenobiotic transport were finally submitted to NetAffyxTM, resulting in only 32 probeset 
hits (Table 3-2). Unfortunately, even though many of the genes of interest could be 
detected by the entire array set, few were on chip A, the only chip run by these three 
research groups [174-176].  
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Table 3-2: Human and mouse transporter genes of interest and number of probesets 
available for each on the U133 plus 2.0 and Mu74v2A GeneChips®. 
Human Mouse 
Common 
Name 
Gene 
Symbol 
Number of 
probesets on 
U133 plus 2.0 
Gene 
Symbol 
Number of 
probesets on 
Mu74v2A 
ABC2 ABCA2 3 Abca2 1 
ABC-C ABCA3 1 Abca3 0 
MDR1 ABCB1 2 Abcb1a 1 
MDR3 ABCB4 3 Abcb4 1 
BSEP ABCB11 2 Abcb11 0 
MRP1 ABCC1 2 Abcc1 1 
MRP2 ABCC2 1 Abcc2 1 
MRP3 ABCC3 6 Abcc3 1 
MRP4 ABCC4 5 Abcc4 0 
MRP5 ABCC5 3 Abcc5 1 
MRP6 ABCC6 2 Abcc6 1 
MRP7 ABCC10 2 Abcc10 0 
MRP8 ABCC11 2 --   
MRP9 ABCC12 2 Abcc12 0 
BCRP ABCG2 1 Abcg2 1 
OSTalpha OSTalpha 1 Osta 1 
NTCP SLC10A1 1 Slc10a1 3 
ASBT SLC10A2 1 Slc10a2 1 
PEPT1 SLC15A1 2 Slc15a1 0 
PEPT2 SLC15A2 3 Slc15a2 1 
MCT1 SLC16A1 5 Slc16a1 1 
MCT2 SLC16A7 3 Slc16a7 1 
NaPil SLC17A1 5 Slc17a1 2 
OCT1 SLC22A1 1 Slc22a1 1 
OCT2 SLC22A2 1 Slc22a2 1 
OCT3 SLC22A3 3 Slc22a3 0 
OCTN1 SLC22A4 2 Slc22a4 1 
OCTN2 SLC22A5 1 Slc22a5 1 
OAT1 SLC22A6 3 Slc22a6 1 
OAT2 SLC22A7 5 Slc22a7 0 
OAT3 SLC22A8 2 Slc22a8 0 
UST3 SLC22A9 2 Slc22a19 0 
OAT4 SLC22A11 1 --   
URAT1 SLC22A12 1 Slc22a12 1 
SVCT1 SLC23A1 1 Slc23a1 1 
SVCT2 SLC23A2 4 Slc23a2 1 
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Table 3-2 cont. 
Human Mouse 
Common 
Name 
Gene 
Symbol 
Number of 
probesets on 
U133 plus 2.0 
Gene 
Symbol 
Number of 
probesets on 
Mu74v2A 
CNT1 SLC28A1 4 Slc28a1 0 
CNT2 SLC28A2 2 Slc28a2 0 
CNT3 SLC28A3 1 Slc28a3 0 
ENT1 SLC29A1 2 Slc29a1 2 
ENT2 SLC29A2 5 Slc29a2 1 
ENT3 SLC29A3 1 Slc29a3 0 
ENT4 SLC29A4 1 Slc29a4 0 
ATB(0+) SLC6A14 1 Slc6a14 0 
OATP-A SLCO1A2 3 Slco1a4 0 
OATP-C SLCO1B1 1 --   
OATP-8 SLCO1B3 1 Slco1b2 0 
OATP-F SLCO1C1 1 Slco1c1 0 
PGT SLCO2A1 1 Slco2a1 0 
OATP-B SLCO2B1 3 Slco2b1 0 
OATP-D SLCO3A1 3 Slco3a1 1 
OATP-E SLCO4A1 3 Slco4a1 0 
OATP-H SLCO4C1 1 Slco4c1 0 
OATP-J SLCO5A1 1 Slco5a1 1 
OATP-I SLCO6A1 1 Slco6b1 0 
 
The first analysis performed was a test of the signal concordance within and 
between chips of each group to gauge overall variability of the samples as they 
originated from different mouse strains in experiments performed by three separate 
research groups.  It was evaluated using Pearson’s correlations to compare the signal 
values generated by the MAS5 algorithm.  
Next, to determine which genes in the filtered list were differentially expressed, 
individual t-tests were performed on the 32 probesets to compare signal intensity in 
lactating versus nonlactating arrays; a p-value < 0.05 considered significant.  The 
calculated fold change, the ratio of the mean signal intensity from a given probeset on 
the lactating arrays (n=15) to the signal intensity of the nonlactating arrays (n=11), was 
reported. 
As multiple testing is performed in microarray analysis, false positives are of 
concern.  Although there are several different methods available to adjust the p-value 
downwards to some arbitrary level in attempts to protect against this problem, it is 
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unclear how strict one needs to be.  To maintain the greatest sensitivity and not “miss” 
potential transporters of interest, the alpha was maintained at 0.05; it was understood 
that this approach may lead to a higher rate of false positives. 
 
F. Identification of xenobiotic transporters highly expressed in human LMEC and MEC 
clinical samples  
1. Tissue sources and subject selection 
Patient surgical reduction mammoplasty specimens served as the source of 
MECs.  UK Surgical Pathology and the UK Tissue Procurement Service provided three 
anonymized mammary tissue samples under a local Institutional Review Board (IRB) 
approved protocol.  Each specimen was comprised of resected mammary tissue from 
the left and right breasts that was declared histologically normal per Attending 
Pathologist reports.  Samples were immediately stored in RPMI 1640 media containing 
5% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin at 4ºC for later processing. 
Human breast milk served as the source of LMECs and was obtained fresh from 
three healthy lactating volunteers utilizing the UK General Clinical Research Center 
facilities under an IRB-approved protocol.  Exclusion criteria included: clinically 
significant cardiovascular, gastrointestinal, renal, hepatic, pulmonary, or hematological 
disease; a history of cerebral trauma; tobacco use within two years; consumption of 
caffeine or alcohol within 48 h; or any medication usage (other than prenatal vitamins, 
analgesics, or antihistamines) within 7 days of a study visit.  Subjects were specifically 
asked if they were taking any oral contraceptives.   Volunteers provided up to eight 
ounces of breast milk each visit (up to 16 visits) using the provided breast pump 
(Lactina® Select, Medela, McHenry, IL) and a sterile collection apparatus.  Each sample 
was immediately put on ice and was processed through RNA isolation individually.  RNA 
samples from the same patient were eventually pooled for microarray expression 
profiling. 
2. Heterogeneous single cell suspensions from reduction mammoplasty tissue 
All histologically normal reduction mammoplasty specimens were processed 
fresh (within 6 hours of procedure), processed to breast organoids, and frozen at -80°C 
until all samples had been collected according to published methods [49,178].  Briefly, 
skin and fat was excised from each specimen using two opposing scalpel blades and 
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resulting tissue was minced into < 0.5 cm cubed pieces (Figure 3-3).  The minced tissue 
was transferred to 50 mL conical vials and “digestion media” (RPMI 1640 containing 5% 
FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, 1 mg/mL hyaluronidase, 1 mg/mL 
collagenase) was added leaving 5 mL of air in the tube for mixing purposes.  Following 
an overnight incubation at 37ºC on a rotating mixer (Dynal, New Hyde Park, NY), 
organoids were pelleted by centrifugation at 300 g for 5 min at 4ºC and the entire 
supernatant (containing the fat layer) was discarded.  Organoids were then washed 
three times with RPMI 1640 containing 5% FBS, 100 U/mL penicillin, and 100 μg/mL 
streptomycin at 37ºC.  To remove red blood cells, organoids were allowed to sediment 
from the 30 mL of the same media for 30 minutes.  The supernatant was carefully 
removed and the procedure was repeated two more times.  Finally, “cell preservation 
media” (RPMI 1640 containing 15% FBS and 10% DMSO) was added and organoids 
were aliquoted and frozen at -80ºC (by cooling at -1ºC/min in a Mr. Frosty®, Nalgene, 
Rochester, NY) until all subject recruitment had been completed. 
 
Figure 3-3: Photo of reduction mammoplasty specimen with fat excised. 
 
To achieve heterogeneous single-cell populations, thawed samples were washed 
once with cold RPMI containing 1% FBS, once with cold HBBS (containing no calcium or 
magnesium), and then digested by gentle pipetting in 10 mL 0.25% trypsin/EDTA 
containing 0.4 mg/mL DNAse 1 at 37°C for 5-15 minutes until no clumps were observed.  
The digestion was stopped by the addition of 5 mL cold RPMI containing 5% FBS and 
the mixture was further diluted with 10 mL cold HBSS (containing no calcium or 
magnesium), 2% FBS, and 1 mM EDTA.  Overall cell yield was increased significantly 
with the addition of a second 10 min incubation with 5 mL HBSS containing 0.4 mg/mL 
DNAse to decrease cell clumping.  This second digestion step was stopped by the 
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addition of cold HBSS (containing no calcium or magnesium) containing 2% FBS and 1 
mM EDTA.  Finally, a heterogeneous single cell suspension was achieved by filtering 
through a 40-µm cell strainer and was counted on a hemocytometer.  A small volume of 
this cell suspension was saved for immunocytostaining.  
3. Heterogeneous single cell suspensions from breast milk 
Milk samples were centrifuged in 50 mL conical polypropylene vials at 600 g for 
15 min. The fat layer was removed with a spatula and the remaining milk layer was 
aspirated with a pipette.  The resulting cell pellets were washed twice with 30 mL cold 
HBSS (containing no calcium or magnesium), 2% FBS, and 1 mM EDTA, pooled, and 
filtered through a 40-µm cell strainer to yield a single cell suspension.  The resulting 
heterogeneous population of cells was counted on a hemocytometer and a small volume 
was saved for immunocytostaining. 
4. Luminal MEC isolation by immunomagnetic separation 
 Immunomagnetic separation was evaluated as a methodology to isolate a pure 
population of luminal MECs from the heterogeneous single cells suspension in sufficient 
numbers for subsequent microarray analysis.  The method previously developed by 
Alcorn et al. used magnetic Dynabeads® coated with a primary antibody for epithelial 
basement membrane antigen (MUC1) (clone MFGM/5/11[ICR.2]), a surface marker 
specific to MECs, to isolate cells for qPCR [49].  This technique, although specific, was 
not robust enough to provide the quantity of cells needed for microarray analysis and 
another system had to be developed.   
The EasySep® human MUC1 selection kit was tested with breast milk samples.  
The system consists of magnetic iron dextran nanoparticles conjugated to a different 
MUC1 antibody (clone 214D4) via a novel tetrameric antibody complex (Figure 3-4).  
Single cell suspensions derived from breast milk were blocked with cold 2% human 
serum in HBSS containing 2% FBS for 15 min.  Cells were then pelleted by 
centrifugation, resuspended in HBSS containing 2% FBS at a concentration of 1 x 108 
per milliliter and processed according to manufacturer protocol.  Isolated populations 
were counted on a hemocytometer and purity was assessed by flow cytometry through 
quantification of the nanoparticle-MEC complexes with 5 μg/mL FITC-conjugated anti-
dextran antibody vs. isotype control. A small volume was also saved for cytospin 
preparations and immunocytostaining. 
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Figure 3-4: Schematic drawing of EasySep® magnetic labeling of human cells [179]. 
The anti-cell antibody used was a murine anti-MUC1 (clone 214D4).  Purity of the 
resulting populations was quantified by detection of the nanoparticle-cell complexes with 
an antibody directed against the nanoparticle (not shown in diagram). 
 
5. Luminal MEC isolation by FACS 
FACS was also evaluated as a technique to isolate luminal MECs in sufficient 
numbers from the heterogeneous single cell suspension.  Again, the MEC-specific 
surface expression of EMA/MUC1 was probed, but this time using the original 
EMA/MUC1 antibody (MFGM/5/11[ICR.2]) and protocols modified from the literature 
[49,178,180-182].  Single cell suspensions derived from breast milk and reduction 
mammoplasty specimens were blocked with cold 2% human serum in HBSS containing 
2% FBS and 1 mM EDTA for 15 min.  Cell pellets were then stained with a monoclonal 
rat anti-human epithelial basement membrane antigen IgG2a antibody or isotype control 
for 20 min on ice.  Followed a wash with HBSS containing 2% FBS and 1 mM EDTA, 
luminal mammary epithelial cells were visualized using a secondary FITC-conjugated 
mouse anti-rat IgG2a.  MUC1 positive and negative populations were identified utilizing 
the isotype control antibody and were sorted into HBSS containing 10% FBS.  Due to 
the large numbers of dead cells in the previously frozen reduction mammoplasty 
samples, the addition of propidium iodide before FACS was found useful to exclude 
presumed nonviable cells from the analysis (as described on page 37).  Isolated 
populations were counted with a hemocytometer and a small volume was saved for 
cytospin preparations and immunocytostaining. 
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6. Immunocytostaining 
Cytospins of each cell population (approximately 1 x 105 cells) were made using 
the Shandon Cytospin 3 cytocentrifuge (IMEB, San Marcos, CA).  Preparations were 
then air dried and fixed with alcohol. Slides were stained at the UK Cytology Department 
using the Vectastain ABC kit and a monoclonal mouse anti-human (IgG1) cytokeratin 
cocktail CK22 (40-68 kDa) specific for simple epithelial cells to verify purity of the sorted 
populations. 
7. RNA isolation 
RNA was immediately isolated from purified luminal mammary epithelial cells 
following FACS using the RNeasy Micro kit per manufacturer’s protocol including sample 
homogenization and on-column DNA digestion and quantified as described on page 28.  
Resulting RNA quality was further tested using the Bioanalyzer 2100 (Agilent, Santa 
Clara, CA) at the UK Microarray Core Facility.  RNA from breast milk samples obtained 
from the same patient was pooled to achieve the 2.5 μg necessary for microarray 
analysis (~1.5 μg) and qPCR validation (~1 μg).  Although final elution from the RNeasy 
columns was performed with only 14 μL of water, pooled samples were still too dilute for 
microarray analysis and qPCR and were evaporated in a vacuum centrifuge to a 
concentration of least 100 ng/mL prior to subsequent procedures. 
8. Microarray expression profiling and statistical analysis 
Isolated total RNA (1 - 1.5 μg) from the three MEC samples and three LMEC 
samples were used for probe generation and hybridization to Human Genome U133 
Plus 2.0 Arrays (Affymetrix, Santa Clara, CA) at the UK Microarray Core Facility.  Each 
GeneChip® array contains probesets for about 47,000 transcripts and variants 
representing 38,500 well-characterized genes and expressed sequence tags (ESTs) in 
the human genome.  For comparison of transporter gene expression in LMEC versus 
other secretory tissues, an external dataset needed to be identified.  The microarray 
data repositories EMBL-EBI ArrayExpress (http://www.ebi.ac.uk/arrayexpress), NCBI 
Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/projects/geo/), and the 
published literature were searched for experiments containing healthy human liver and 
kidney data from the same U133 Plus 2.0 arrays.  Suitable raw chip data was obtained 
from the ArrayExpress repository experiment E-AFMX-11 (http://www.ebi.ac.uk/ 
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arrayexpress/experiments/E-AFMX-11) in which six mixed male and female healthy liver 
and kidney samples were analyzed [183].   
Following hybridization of the LMEC and MEC samples, expression level was 
determined with MicroArray Suite 5.0 (Affymetrix, Santa Clara, CA).  The microarray 
data from all 18 arrays were analyzed in unison and scaled to the same threshold to 
normalize for variances in chip intensity.  As described in the mouse microarray 
expression profiling section on page 47, the first analysis performed was a test of the 
signal concordance within and between chips of each group to gauge overall variability 
of the samples.  Next, signal intensity data for probesets identified as Absent across all 
LMEC arrays were removed from the analysis.  As before, to decrease the likelihood of 
false positives, two approaches to filter for probesets representing xenobiotic 
transporters were explored.  In the first, gene symbols of the transporter families ABC(A-
G), SLC(1-43), and SLCO were retrieved from Entrez Gene (search date: 1/9/07).  The 
417 hits were then submitted to Affymetrix NetAffyxTM Analysis Center 
(http://www.affymetrix.com/analysis/) to determine which could be detected by the U133 
Plus 2.0 GeneChip® array.  Eight hundred and ninety probeset IDs (often more than 1 
for a transcript) were identified with the majority again detecting transcripts that had no 
known role in xenobiotic transport.  In the second filtering approach (the method 
eventually chosen), the fifty-five genes with potential relevance for xenobiotic transport 
identified from the literature (as described on page 47) were submitted and resulted in 
122 probesets that spanned every gene of interest (Table 3-2).   
In order to determine transporters of potential importance for xenobiotic transport 
in LMEC, a two step screening paradigm was designed (Figure 3-5).  In the first, 
individual t-tests were performed on the 122 probesets to compare signal intensity in 
LMEC versus MEC arrays; a p-value < 0.05 was considered significant. Those 
transporter genes whose expression was significantly upregulated during lactation were 
of interest whereas those significantly downregulated were not.  The transporter 
probeset comparisons that did not achieve significance were not discarded as similar 
gene expression in LMEC and MEC cells could still be of importance if that expression 
level was high.  To determine that relative expression level, it was compared to the 
expression level in two other secretory tissues, the kidney and liver.  T-tests were again 
performed and probesets with a signal intensity equivalent to, or significantly higher than 
each comparator were identified. 
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9. qPCR 
Reverse-transcription and qPCR analysis of SLCO4C1 and the human milk 
protein β-casein (CSN2) were performed as described with CIT3 cells on page 28.  To 
validate the expression level relative to the liver and kidney performed in the microarray 
analysis, total RNA pooled from 250 subjects that was previously purchased from 
Clonetech (Mountain View, CA) was used.  These kidney and liver RNA comparators 
were exactly the same samples that were measured by Alcorn et al. [49].  One 
microgram of total RNA from each sample was added to the reaction and all samples to 
be compared were run together using master mixes to limit potential sources of 
variation.   
Gene-specific primer sequences for SLCO4C1 and CSN2 were designed, 
optimized, and expression level detected in the samples as described previously.  
Reference accession numbers, primer sequences, and product sizes are provided in 
Table 3-3.  RNA from cells isolated from breast milk samples pooled from several 
subjects was used to generate the standard curves. 
 
Table 3-3: Human primers and conditions. 
Gene Reference 
Sequence 
Forward Primer (5’→3’) Prod. 
Size  
(bp) 
Mg 
Conc 
(mM) 
Anneal
Temp
(ºC) 
Ref.
Reverse Primer (5’→3’) 
CSN2 NM_001891 AAGGGAGACCATAGAAAGCCT 138 3.5 62 - 
GGCTGGAAAGAGGGGTAGATTT
SLCO4C1 
 
NM_180991 GAGAAGCTCCGGTCACTGTC 149 3.5 62 - 
ACTACAATACCTTGCGTGAC 
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CHAPTER 4: Results 
A. Expression and functional role of Abcg2 in CIT3 cells 
1. Specific Aim 1: To determine if Abcg2 is detectable in CIT3 cells with and 
without lactogenic hormone stimulation 
qPCR was performed to determine if transcripts for Abcg2 could be detected in 
CIT3 cells and if expression was increased following lactogenic hormone stimulation.  
The milk proteins β-casein and α-lactalbumin, were used as positive controls and 
mammary gland from a lactating CD1 mouse 7 days post-partum was used as the 
comparator for relative quantification (to generate the standard curves).   Quality of the 
primer pairs used for the quantification of each gene was demonstrated by correlation 
coefficients > 0.99, PCR efficiencies of 95-100%, and single products on the melt curve 
analysis and agarose gel electrophoresis (Figure 4-1, Figure 4-2, Figure 4-3, Figure 4-4).   
Figure 4-5 depicts the β-actin normalized RNA expression level in CIT3 cells with and 
without hormone stimulation run in triplicate.  β-casein and α-lactalbumin were 
significantly upregulated following 4 days of lactogenic hormone stimulation (3 µg/mL 
ovine prolactin and 3 µg/mL hydrocortisone added, epidermal growth factor removed).  
Abcg2 was detected, but the RNA expression was not significantly increased.  The 
expression level in CIT3 cells (unstimulated or stimulated) was lower than that of in vivo 
mouse mammary gland comparator. 
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Figure 4-1: Mouse β-casein amplification curve, melt curve analysis, standard curve, and 
agarose gel electrophoresis generated from standards over a 6-log10 dilution series.   
  
 
 
←103 bp 
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Figure 4-2: Mouse α-lactalbumin amplification curve, melt curve analysis, standard 
curve, and agarose gel electrophoresis generated from standards over a 5-log10 dilution 
series.  
  
 
 
←133 bp 
  
 
62 
Figure 4-3: Mouse Abcg2 amplification curve, melt curve analysis, standard curve, and 
agarose gel electrophoresis generated from standards over a 3-log10 dilution series.     
  
 
 
 
←166 bp 
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Figure 4-4: Mouse β-actin amplification curve, melt curve analysis, standard curve, and 
agarose gel electrophoresis generated from standards over a 2-log10 dilution series.   
 
 
 
←167 bp 
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Figure 4-5: Relative RNA expression of β-casein, α-lactalbumin, and Abcg2 in 
unstimulated CIT3 cells and CIT3 cells following 4 days of lactogenic hormone 
stimulation. 
Murine lactating mammary gland was used for generation of standard curves (Abcg2: 
10-1→10-4, β-casein: 10-1→10-7, α-lactalbumin: 10-1→10-6, and β-actin: 10-1→10-3) and all 
samples were prepared at a 1:10 dilution.  An asterisk denotes p < 0.05 for the 
comparison indicated. 
 
 
Western blot analysis was performed to determine if Abcg2 protein could be 
detected in CIT3 cells and if expression was increased following lactogenic hormone 
stimulation.  Crude membrane fractions were prepared from unstimulated and stimulated 
CIT3 cells in parallel to the cells that underwent qPCR analysis.  Again, mammary gland 
tissue from a lactating CD1 mouse 7 days post-partum was used as a positive control, 
but was loaded on the gel at a much lower amount to be able to visualize it along with 
the CIT3 cells under similar exposure conditions.  Due to variations in protein size that 
were detected by the BXP-53 antibody in initial western blots, paired samples underwent 
a deglycosylation step and were loaded in parallel to the native protein in each sample to 
confirm band identity.  Figure 4-6 shows the expected Abcg2 band at ~70 kDa in the 
positive control.  This band was reduced to ~60 kDa following treatment with PNGase F.  
In CIT3 cells, the native Abcg2 protein was detectable at ~80 kDa and was also reduced 
to ~60 kDa following deglycosylation.  Native Abcg2 protein expression was greater in 
the ovein prolactin and hydrocortisone stimulated CIT3 cells as the β-actin-normalized 
band density of native Abcg2 was 18% greater than in the unstimulated cells. 
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Figure 4-6: Western blot of native and deglycosylated Abcg2 in mouse lactating 
mammary gland (7 days post-partum), unstimulated CIT3 cells, and CIT3 cells following 
4 days of lactogenic hormone stimulation. 
 
Expression level of Abcg2 was also visualized in unstimulated and stimulated 
CIT3 cells by confocal microscopy, with cellular localization in the X-Z plane 
demonstrated in stimulated cells.  Cells exposed to lactogenic hormone stimulation had 
noticeably greater Abcg2-associated fluorescence relative to unstimulated cells when 
imaged with equivalent background FITC exposure (Figure 4-7).  Figure 4-8 
demonstrates that the localization of Abcg2 in stimulated CIT3 cells is in the apical 
membrane. 
 
Figure 4-7: Fluorescent microscopy of Abcg2 in unstimulated and stimulated CIT3 cells.  
Unstimulated Stimulated 
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Figure 4-8: X-Z confocal microscopy of Abcg2 localization in stimulated CIT3 cells. 
Abcg2 (FITC-green) is localized in the apical membrane of stimulated CIT3 cells grown 
on snapwells.  The tight junction protein ZO-1 (PE-red) and cell nuclei (DAPI-blue) were 
stained for orientation.  All antibodies except for BXP-53 were added to stimulated cells 
for a negative control.  Abcg2-associated fluorescence in unstimulated cells was too dim 
to determine cellular localization.   
 
 
2. Specific Aim 2: To determine if nitrofurantoin is transported in unstimulated 
CIT3 cells. 
The purpose of this initial flux experiment was to determine if there is 
directionality to nitrofurantoin flux in unstimulated CIT3 cells as was previously 
demonstrated in CIT3 cells exposed to lactogenic hormones.  Unstimulated CIT3 cells 
did form the tight junctions necessary for flux assays as TEER exceeded 800 Ω•cm2 and 
followed a similar profile as stimulated cells (Figure 4-9).  The nitrofurantoin HPLC assay 
performed well with a limit of quantification of 3.9 ng/mL and the intra-day coefficients of 
variation of < 10% (Figure 4-10).  Figure 4-11 illustrates that nitrofurantoin flux was linear 
over the 2 h experiment and that a greater apically directed permeability was observed 
in both unstimulated (50.7 ± 5.6 μL/h/cm2 B→A vs. 19.2 ± 0.4 μL/h/cm2 A→B) and 
stimulated (68.0 ± 0.2 μL/h/cm2 B→A vs. 20.1 ± 4.3 μL/h/cm2 A→B) conditions.  The 
B→A permeability in stimulated cells (68.0 ± 0.2 μL/h/cm2) was greater than that of the 
unstimulated cells (50.7 ± 5.6 μL/h/cm2), but the A→B permeabilities (20.1 ± 4.3 
μL/h/cm2 vs. 19.2 ± 0.4 μL/h/cm2) were similar. 
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Figure 4-9: TEER of unstimulated and stimulated CIT3 cells grown on snapwells.  
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Figure 4-10: Nitrofurantoin HPLC chromatogram and standard curve in CIT3 cell culture 
media without serum, proteins, hormones or antibiotics. 
      Media only         Media + 125 ng/mL NF 
 
Standard Curve (3.9 ng/mL – 2000 ng/mL) 
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Figure 4-11: Directionality of radiolabelled nitrofurantoin transport in unstimulated and 
stimulated CIT3 cells grown on snapwells. 
Flux in each well was normalized to a donor concentration of 1.5 μM.  An asterisk 
denotes p < 0.05 for the comparison indicated. 
 
3. Specific Aim 3: To evaluate if established Abcg2 inhibitors decrease the 
transport of nitrofurantoin and if known Abcg2 substrates are transported in CIT3 cells. 
The goal of this next series of flux experiments was to determine if Abcg2 is 
responsible for the transport of nitrofurantoin in both stimulated and unstimulated CIT3 
cells through inhibition studies with the Abcg2 inhibitor, FTC. Figure 4-12 shows that the 
B→A permeability significantly decreased with the addition of 10 μM FTC in both 
unstimulated (14.2 ± 0.6 μL/h/cm2 down to 8.96 ± 0.3 μL/h/cm2) and stimulated (16.3 ± 
0.7 μL/h/cm2 down to 10.9 ± 0.1 μL/h/cm2) conditions.  The corresponding A→B 
permeabilities increased, but did not achieve significance.  However, the addition of 10 
μM FTC did cause the B→A and A→B permeabilities to collapse to a common value in 
both unstimulated (8.96 ± 0.3 μL/h/cm2 B→A vs. 8.4 ± 1.9 μL/h/cm2 A→B)  and 
stimulated (10.9 ± 0.1 μL/h/cm2 B→A vs. 10.9 ± 1.0 μL/h/cm2 A→B) conditions.   
Finally, to further demonstrate a potential role of Abcg2 in this model system, the 
flux of two Abcg2 substrates that are known to accumulate in breast milk was tested in 
unstimulated CIT3 cells.  Panel A of Figure 4-13 depicts the directionality and inhibition 
of the transport of 2 μM PhIP.  Only the first two time points (and the origin) were used to 
determine the flux rates as the amount of PhIP in the recipient chamber beyond that time 
appeared to violate the assumption of sink conditions.  The B→A permeability (98.80 ± 
7.4 μL/h/cm2) was significantly greater than the reverse direction (60.0 ± 2.1 μL/h/cm2) 
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and both significantly collapsed to a common value (B→A decreased from 98.80 ± 7.4 
μL/h/cm2 to 68.2 ± 3.0 μL/h/cm2 and A→B increased from 60.0 ± 2.1 to 71.2 ± 1.8 
μL/h/cm2) with the addition of FTC.  Cimetidine permeabilities did not show the expected 
results.  Flux of 5 μM cimetidine was linear over the entire four hours of the experiment 
(Panel B of Figure 4-13).  Although a greater mean B→A permeability (2.0 ± 0.3 
μL/h/cm2) was observed relative to A→B (1.7 ± 0.1 μL/h/cm2), it did not achieve 
significance.  Similarly, the addition of FTC did not significantly alter the permeabilities in 
either direction (B→A was 2.0 ± 0.3 μL/h/cm2 alone vs. 1.7 ± 0.1 μL/h/cm2 with FTC and 
A→B was 1.7 ± 0.1 μL/h/cm2  alone vs. 1.7 ± 0.1 μL/h/cm2 with FTC).  The relative 
magnitude of the permeabilities was much smaller with cimetidine than with 
nitrofurantoin and PhIP.   
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Figure 4-12: Directionality of nitrofurantoin transport and inhibition by the Abcg2 inhibitor, 
fumitremorgin C (FTC), in unstimulated and stimulated CIT3 cells grown on transwells. 
Flux in each well was normalized to a donor concentration of 10 μM.  An asterisk 
denotes p < 0.05 for the comparison indicated. 
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Figure 4-13: Directionality of PhIP and cimetidine transport and inhibition by the Abcg2 
inhibitor, fumitremorgin C (FTC), in CIT3 cells grown on transwells. 
A. Flux of 2 μM PhIP.  Flux rate for permeability calculations based on linear portion of 
curve, 0.5 - 1 h, forced through the origin.  B. Flux of 5 μM cimetidine.    An asterisk 
denotes p < 0.05 for the comparison indicated. 
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B. Creation of an ABCG2 stably transfected model system  
1. Specific Aim 4: To create a stable ABCG2-transfected cell line that has 
appropriate characteristics for flux experiments. 
To select an appropriate cell line for the ABCG2 transfection, LLC-PK1, MDCKI, 
and MDCKII cell lines were compared.  The MDCKI and MDCKII cells are both sub-
clones of a canine cocker spaniel kidney heterogeneous cell line derived in 1958.  
MDCKI cells are lower passage number and reportedly attain much higher TEER values. 
However, this epithelial phenotype is unstable and overgrowth or incomplete 
trypsinization during passaging may select for an altered phenotype (product labeling, 
ECACC).  MDCKII cells are higher passage cells and have reportedly lower TEER 
values, but have been used extensively for transfection and flux assays.  LLC-PK1 cells 
are also kidney-derived and have been extensively used for transfection and flux assays, 
but are porcine.  In terms of background transporter gene expression, RNA transcripts 
for the orthologs of human ABCB1, ABCC1, and ABCC2 have been found in MDCKII 
and LLC-PK1 [184].  SLCO1A2 was detected in the original MDCK cell line, but not in 
either MDCKII or LLC-PK1 cells.  SLCO1B1 was not found.  Most importantly, neither 
MDCKII cells or LLC-PK1 cells had any background Abcg2 activity as measured by 
topotecan flux [160].  Data for MDCKI cells was not found in the literature.  To determine 
ease of selection post-transfection with genecitin, each cell line was exposed to a 
concentration range of 100 – 1000 μg/mL.  The MDCKII cells were most sensitive as all 
cells that were exposed to 800 μg/mL were dead by 4 days.  The LLC-PK1 cells needed 
marginally more genecitin, 1000 μg/mL, for the same result.  MDCKI cells took over a 
week at 1000 μg/mL for a similar effect.  Finally, to confirm each cell lines’ ability to form 
tight junctions, TEER and the flux of 0.01 μM mannitol was measured.  Maximal TEER 
achieved in the LLC-PK1, MDCKI, and MDCKII cells was ~140 Ω•cm2, >6000 Ω•cm2, 
and ~130 Ω•cm2, respectively.  Figure 4-14 shows the mannitol permeabilities of each 
cell line with LLC-PK1 cells greatly exceeding the others.  Based on these comparisons, 
MDCKII cells were selected for development of the model system. 
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Figure 4-14: Paracellular flux of radiolabelled mannitol in candidate parent cell lines 
grown on snapwells. 
Flux in each well was normalized to a donor concentration of 0.01 μM.  Equal numbers 
of snapwells were tested in the B→A and A→B directions and were pooled as there was 
no directionality to the flux.  An asterisk denotes p < 0.05 for the comparison indicated. 
 
 
The pcDNA3-ABCG2 plasmid or empty vector control was successfully 
transfected into MDCKII cells, as demonstrated by western blot and Hoechst 33342 
efflux of the heterogeneous population at 48 hrs (“dim” population, Figure 4-15).  
Following selection, initial attempts at clonal selection using a limiting dilution approach 
produced seven clones that were expanded and once again tested for ABCG2 function 
by Hoechst 33342 efflux.  Only clone 2 had any appreciable GF120918-inhibitable 
ABCG2 function as indicated by the presence and absence of a small dim population 
with and without the inhibitor. Clone 2 was resorted using FACS, where presumed viable 
cells with high ABCG2 expression were identified and sorted individually into a 96-well 
plate (Figure 4-16).  Ten clones were expanded and ABCG2 expression and function 
were determined by western blotting, flow cytometry, Hoechst 33342 efflux, and DB-67 
accumulation.  Results from select MDCKII-ABCG2 clones with varying levels of 
expression are presented in Figure 4-17, Figure 4-18, and Figure 4-19.  Finally, apical 
localization of ABCG2 was confirmed in MDCKII-ABCG2 clone 40, the highest ABCG2 
expressing clone, by confocal microscopy (Figure 4-20).  This clone was selected for 
use in all subsequent experiments based on performance in aforementioned assays. 
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Figure 4-15: Successful transfection of ABCG2 into MDCKII cells as determined by 
western blot and Hoechst 33342 efflux assays at 48 h.   
A. Western blot of ABCG2 in 12 μg of cell lysates.  B. Efflux of Hoechst 33342.  Abcg2-
transfected cells efflux Hoechst 33342, producing a “dim” phenotype.  Empty vector and 
1 μM GF120918 inhibition of this “dim” phenotype were run as negative controls.  Cell 
clumps and debris and presumed nonviable cells (PI-positive) were removed from the 
analysis.   
 
 
Figure 4-16: Fluorescence activated cell sorting (FACS) of individual cells with high 
surface expression of ABCG2 
MDCKII-ABCG2 Clone 2 cells with high ABCG2 expression were identified (black box) 
and sorted individually into a 96-well plate.  Cell clumps and debris and presumed 
nonviable cells (PI-positive) were removed.   
 
A B
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Figure 4-17: Western Blot for ABCG2 in crude membrane fractions of select MDCKII-
ABCG2 clones.   
Western blot of ABCG2 (~72 kDA) and β-actin (~42 kDa) in 10 μg of crude membrane 
fractions.  Saos-ABCG2 and empty vector was loaded as a positive and negative 
control, respectively. 
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Figure 4-18: Flow cytometric analysis of surface ABCG2 expression and Hoechst 33342 
efflux with or without the ABCG2 inhibitor, GF120918, in select MDCKII-ABCG2 clones.   
A. Surface expression of ABCG2.  The MFI difference between the ABCG2 labeled (red 
shaded) and isotype control (black line) in each clone was calculated as a surrogate for 
expression level (mean, n=3). B. Hoechst 33342 efflux.  Percentage of cells in the dim 
gate (blue shaded) relative to each clone’s GF120918-inihibited control (black line) was 
used as a surrogate for ABCG2 activity. 
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Figure 4-19: DB-67 accumulation in select MDCKII-ABCG2 clones with or without the 
ABCG2 inhibitor, GF120918.  
Accumulation of 1 μM DB-67 with or without 1 μM GF120918 preincubation.  An asterisk 
denotes p < 0.05 for the comparison indicated. 
 
 
Figure 4-20: Confocal microscopy of ABCG2 expression and localization in MDCKII-
ABCG2 Clone 40 cells.   
Panel A.  A high expression level of ABCG2 (FITC-green) is visualized in MDCKII-
ABCG2 Clone 40 cells relative to empty vector cells.  Panel B. X-Z section shows that 
ACGB2 is localized in the apical membrane.  Cell nuclei (DAPI-blue) were stained for 
orientation.   
Empty Vector MDCKII-ABCG2  Clone 40 
 
A 
B 
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2. Specific  Aim 5: To validate the model system with known ABCG2 substrates 
(nitrofurantoin, PhIP, cimetidine, methotrexate, ciprofloxacin) and ABCG2 inhibitors 
(GF120918 and FTC). 
The stably transfected ABCG2 overexpressing model system was thoroughly 
validated for monolayer flux assays with a series of directionality and inhibition 
experiments with known ABCG2 substrates and inhibitors.  In directionality experiments, 
the B→A and A→B flux in ABCG2-transfected and empty vector-transfected cells were 
compared.  In inhibition experiments, the ability of 1 μM GF120918 and 10 μM FTC to 
inhibit the B→A flux attributed to ABCG2 was evaluated.  Graphs of results for each 
substrate are presented in a consistent format with linearity of the time points chosen to 
determine flux rate on the left (represented by the plotted regression line) and the 
calculated permeabilities presented on the right. 
The first substrate evaluated was nitrofurantoin. Figure 4-21 panel A illustrates 
the linearity of the flux of 10 μM nitrofurantoin over the 3 h experiment.  Background 
permeability in the empty vector-transfected cells was predominantly directed towards 
the B chamber (5.3 ± 0.3 μL/h/cm2 B→A vs. 9.5 ± 0.3 μL/h/cm2 A→B) and the 
transfection of ABCG2 reversed this phenomenon (32.2 ± 0.3 μL/h/cm2 B→A vs. 2.3 ± 
0.3 μL/h/cm2 A→B).  Panel B shows that both 1 μM GF120918 and 10 μM FTC reversed 
the increase in B→A flux in the ABCG2-transfected cells relative to the empty vector-
transfected cells, decreasing the permeability by 84.5% and 96.3% respectively. 
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Figure 4-21: Directionality of nitrofurantoin transport and inhibition of B→A flux by 
various inhibitors in empty vector and ABCG2-transfected cells grown in transwells. 
Each transwell was normalized to a donor concentration of 10 μM.  An asterisk denotes 
p < 0.05 for the comparison indicated.  
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PhIP flux was only linear up to 1 h so the flux rate was determined by linear 
regression of only the first two time points and was forced through the origin.  Figure 
4-22 Panel A shows there was no difference in the B→A and A→B permeabilities in the 
empty vector-transfected cells (39.1 ± 4.8 μL/h/cm2 B→A vs. 38.9 ± 2.0 μL/h/cm2 A→B).  
However, the addition of ABCG2 to the cell line both significantly increased the flux in 
the B→A direction (39.1 ± 4.8 μL/h/cm2 B→A in the empty vector to 97.3 ± 4.8 μL/h/cm2 
B→A in the ABCG2-transfected) and significantly decreased flux in the A→B direction 
(38.9 ± 2.0 μL/h/cm2 A→B in the empty vector to 4.1 ± 0.3 μL/h/cm2 A→B in the ABCG2-
transfected).  Panel B illustrates that addition of 10 μM FTC completely ablated the 
higher B→A permeability observed in the ABCG2-transfected cells relative to the empty 
vector cells.  The 1 μM addition of GF120918, however, had no effect. 
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Figure 4-22: Directionality of PhIP transport and inhibition of B→A flux by various 
inhibitors in empty vector and ABCG2-transfected cells grown in transwells. 
Each transwell was normalized to a donor concentration of 2 μM.  Flux rate for 
permeability calculations based on linear portion of curve, 0.5 - 1 h, forced through the 
origin.  An asterisk denotes p < 0.05 for the comparison indicated.  
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The magnitude of cimetidine flux was less than the previous two substrates, but 
was linear over the entire time course of the experiment.  Figure 4-23 Panel A shows 
there was no difference in the B→A and A→B permeabilities in the empty vector-
transfected cells (2.3 ± 0.4 μL/h/cm2 B→A vs. 1.6 ± 0.3 μL/h/cm2 A→B).  The ABCG2 
cells both significantly increased the flux in the B→A direction (2.3 ± 0.4 μL/h/cm2 B→A 
in the empty vector to 8.4 ± 0.2 μL/h/cm2 B→A in the ABCG2-transfected) and 
significantly decreased flux in the A→B direction (1.6 ± 0.3 μL/h/cm2 A→B in the empty 
vector to 0.5 ± 0.06 μL/h/cm2 A→B in the ABCG2-transfected).  Panel B shows that both 
1 μM GF120918 and 10 μM FTC completed ablated B→A flux attributed to ABCG2 in 
the ABCG2-transfected cells. 
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Figure 4-23: Directionality of cimetidine transport and inhibition of B→A flux by various 
inhibitors in empty vector and ABCG2-transfected cells grown in transwells. 
Each transwell was normalized to a donor concentration of 5 μM.  An asterisk denotes p 
< 0.05 for the comparison indicated.  
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Although the flux of methotrexate appeared linear over the course of the 
experiment (Figure 4-24 Panel A), the overall magnitude was much lower than 
cimetidine and was nearly equal to that of the paracellular marker sucrose (Figure 4-24 
Panel B).  There was still a predominant B→A directionality in the ABCG2 transfectants 
(0.4 ± 0.08 μL/h/cm2 B→A vs. 0.3 ± 0.04 μL/h/cm2 A→B) that was not seen in the empty 
vector transfected cells (0.8 ± 0.06 μL/h/cm2 B→A vs. 0.9 ± 0.03 μL/h/cm2 A→B), but it is 
difficult to interpret as the B→A flux in the ABCG2-transfected cells were lower than that 
of their empty vector controls (0.4 ± 0.08 μL/h/cm2 vs. 0.8 ± 0.06 μL/h/cm2, respectively).  
Inhibition studies were not performed due to the extremely low permeability of 
methotrexate. 
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Figure 4-24: Directionality of methotrexate and sucrose transport in empty vector and 
ABCG2-transfected cells grown in transwells. 
Panel A. Methotrexate flux and permeability.  Each transwell was normalized to a donor 
concentration of 5 nM.  Panel B. Sucrose flux and permeability.  Each transwell was 
normalized to a donor concentration of 0.2 µM. An asterisk denotes p < 0.05 for the 
comparison indicated.  
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The flux of the final substrate studied, ciprofloxacin, was also linear over the 4 h 
experimental time course and was greater than that of methotrexate and cimetidine, but 
less than nitrofurantoin and PhIP.  Figure 4-25 demonstrates that there was no 
difference in the B→A and A→B permeabilities in the empty vector-transfected cells (3.2 
± 0.1 μL/h/cm2 B→A vs. 4.2 ± 0.4 μL/h/cm2 A→B).  The transfection of ABCG2 into the 
cells both significantly increased the flux in the B→A direction (3.2 ± 0.1 μL/h/cm2 B→A 
in the empty vector to 16.2 ± 1.0 μL/h/cm2 B→A in the ABCG2-transfected) and 
significantly decreased the flux in the A→B direction (4.2 ± 0.4 μL/h/cm2 A→B in the 
empty vector to 2.5 ± 0.5 μL/h/cm2 A→B in the ABCG2-transfected).  Inhibition studies 
were not performed.  
 
Figure 4-25: Directionality of ciprofloxacin transport in empty vector and ABCG2-
transfected cells grown in transwells. 
Each transwell was normalized to a donor concentration of 10 μM.  An asterisk denotes 
p < 0.05 for the comparison indicated.  
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C. Mathematical modeling and derivation of commonly used measurements of efflux 
activity. 
1. Specific Aim 6: To establish a mathematical model for xenobiotic transport in 
an ABCG2-overexpressed cell culture system and to compare measurements of efflux 
activity.  
To explore the utility of the simple three compartment kinetic model presented in 
Figure 3-2, the theoretical limits of the initial rates with increasing PSA,E(ABCG2) were first 
determined.  The initial B→A rate for a single transfected system with an apical efflux 
transporter is described by Eq. 3-8 and is dependent upon CB
0 , PSA,E(ABCG2), PSD, and 
PSPC.  Inherent in this relationship is the observation that as PSA,E(ABCG2) becomes much 
greater than PSD, dXA/dt increases until it achieves a maximal flux for a given initial 
basolateral concentration (Eq. 4-1, depicted in Figure 4-26 below): 
 
lim
PSA,E ∞
dXA,B→A
dt ABCG2
= CB 
0 PSD+PSPC  Eq. 4-1
 
Figure 4-26: Effect of increasing permeability-surface area product attributed to apical 
efflux (PSA,E(ABCG2)) on flux (dXA/dt).   
Flux (dXA/dt) increases as PSA,E(ABCG2) increases to a maximum of CB 
0 PSD+PSPC .  
PSPC, PSD, and CB 
0  were fixed at 0.1, 0.5, and 10 respectively.  As the apparent 
permeability and permeability-surface area product are proportional to flux, substituting 
any of these parameters on the y-axis would yield the same relationship.  
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The initial A→B rate in a single transfected system with an apical efflux 
transporter is described by Eq. 3-11 and is dependent upon CA
0 , PSA,E(ABCG2), PSD, and 
PSPC.  As PSA,E(ABCG2) becomes much greater than PSD, dXB/dt decreases until it 
achieves a minimum flux for a given initial basolateral concentration (Eq. 4-2, illustrated 
below in Figure 4-27): 
 
lim
PSA,E
dXB, A→B
dt ABCG2
 = CA 
0 PSPC  Eq. 4-2
 
Figure 4-27: Effect of increasing permeability-surface area product attributed to apical 
efflux (PSA,E(ABCG2)) on A→B flux (dXB/dt).   
Flux (dXB/dt) decreases as PSA,E increases to a minimum of CA 
0 PSPC .  PSPC, PSD, and 
CA 
0  were fixed at 0.1, 0.5, and 10 respectively.  As the apparent permeability and 
permeability-surface area product are proportional to flux, substituting any of these 
parameters on the y-axis would yield the same relationship.  
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Next, the theoretical limits of ERA in a single apical efflux transporter system were 
explored in a similar manner.  This efflux ratio was derived in Eq. 3-14 for the single 
transfection of an apical efflux transporter when PSPC is assumed to be insignificant.  As 
presented in the work of Kalvass and Pollack, if the permeability-surface area product for 
apical efflux is much greater than that for passive diffusion (PSA,E(ABCG2) >> PSD) an ERA 
upper limit of 2 is reached [172].  Conceptually, an infinitely large PSA,E(ABCG2) serves to 
essentially remove one of the two transcellular diffusion barriers (the apical membrane), 
therefore doubling the B→A permeability and ERA. 
 
lim
PSA,E ∞
ERA,ABCG2
parent
 =  2 Eq. 4-3
A maximal value was not observed for the ERα when PSA,E(ABCG2) is increased 
under the same conditions (single transfection of an apical efflux transporter and 
PSPC→0).  The equation presented in Eq. 3-17 shows that this efflux ratio is expected to 
remain proportional to PSA,E(ABCG2).  Rearrangement of the equation emphasizes this 
proportionality as shown in Eq. 4-4 below.  In contrast, solving for PSA,E(ABCG2) in the 
apical efflux ratio equation given in Eq. 3-14 results in a much more complex relationship 
where no direct proportionality to ERA exists (Eq. 4-5). 
 PSA,E(ABCG2)=PSD ERα-1  Eq. 4-4
 
PSA,E(ABCG2)= 
2PSD (ERA,ABCG2
parent
-1)
2-ERA,ABCG2
parent
Eq. 4-5
To apply these theoretical relationships to actual data and to test the 
assumptions of the model experimentally, two data sets were examined.  The first was 
built from flux data in all publications using two different cell lines (MDCKII transfected 
with either ABCG2 or Abcg2) created by the lab of Dr. Alfred Schinkel.  Table 4-1 
compares the ERA and ERα of several Abcg2/ABCG2 substrates in a murine Abcg2-
transfected (Panel A) or human ABCG2-transfected (Panel B) MDCKII cell lines.  
Substrates that appear to violate the assumption of the single apical efflux transporter 
system (PSB,U, PSA,E, PSB,E, and PSA,U = 0) as evidenced by an ERα Empty ≠ 1 (ratio of 
the B→A  and A→B flux rates in the empty vector-transfected cell line), are identified by 
shading.  Data from the remaining drugs suggest that the calculated ERA did appear 
insensitive to expected variations in PSA,E as different Abcg2 substrates yielded similar 
ERA values that all approximated the maximum theoretical value of two.  The ERα 
91 
however, spanned a much wider range, presumably reflecting the proportionality of the 
efflux ratio with PSA,E.  
 
Table 4-1: Comparison of the ERA and ERα of several Abcg2/ABCG2 substrates in 
murine and human Abcg2/ABCG2-transfected MDCKII cell lines in the literature. 
Apical efflux ratios (ERA), asymmetry efflux ratios (ERα), and the ratio of the asymmetry 
ratios in Abcg2/ABCG2-transfected vs. empty vector-transfected cells (ERα Ratio) in 
Abcg2 (Panel A) or ABCG2 (Panel B) transfected MDCKII cells were calculated using 
flux data compiled from the literature.  Drugs where the mean of ERα Empty was not 
within 20% of unity were identified (shaded rows). 
A ERα 
Empty 
ERA 
Abcg2 
ERα 
Abcg2 
ERα Ratio 
(g2/Empty) Reference
Nitrofurantoin 0.64 2.63 8.70 13.62 [53] 
Ciprofloxacin 0.88 2.52 4.37 4.96 [93] 
Ofloxacin 0.90 2.22 6.17 6.88 [93] 
Norfloxacin 0.91 2.92 3.26 3.58 [93] 
Topotecan 2.23 3.13 14.85 6.66 [153] 
PhIP 1.20 1.27 16.43 13.67 [128] 
Cimetidine 1.26 3.01 7.14 5.67 [127] 
Aflatoxin 1.12 1.58 9.32 8.29 [129] 
IQ 1.09 1.84 16.70 15.30 [129] 
Trp-P-1 1.09 2.89 4.25 3.91 [129] 
Pantoprazole 1.00 1.34 5.05 5.05 [153] 
Imatinib 1.03 2.39 35.27 34.11 [173] 
Riboflavin 0.13 2.33 1.65 12.49 [91] 
Albendazole 1.14 1.70 18.33 16.04 [152] 
Oxfendazole 1.14 2.35 5.70 5.00 [152] 
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Table 4-1 cont. 
B ERα 
Empty 
ERA 
ABCG2 
ERα  
ABCG2 
ERα Ratio 
(G2/Empty) Reference
Nitrofurantoin 0.64 2.66 3.21 5.02 [53] 
Ciprofloxacin 0.88 1.18 2.13 2.42 [93] 
Ofloxacin 0.90 1.29 1.56 1.73 [93] 
Norfloxacin 0.91 1.29 1.32 1.45 [93] 
Topotecan 2.08 1.46 5.79 2.79 [127] 
PhIP 0.60 1.89 12.74 21.29 [127] 
Cimetidine 1.26 2.44 3.11 2.47 [127] 
Estradiol 0.68 0.83 0.66 0.98 [127] 
Aflatoxin 1.12 1.15 1.91 1.70 [129] 
IQ 1.09 1.30 2.47 2.26 [129] 
Trp-P-1 1.09 1.64 1.39 1.28 [129] 
Albendazole 1.14 1.36 2.11 1.84 [152] 
Oxfendazole 1.14 0.87 1.17 1.02 [152] 
 
The second data set that included efflux ratios calculated using the newly 
developed ABCG2-transfected MDCKII cell line created in Aim 5 is presented in Table 
4-2.  Three of five ABCG2 substrates studied exhibited a predominant B→A or A→B flux 
in the empty vector-transfected controls as exhibited by an ERα Empty ≠ 1 and were 
removed from the comparison.  The ERA for PhIP once again approximated the 
maximum model predicted value of two whereas its ERα was much higher.  
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Table 4-2: Comparison of the ERA and ERα of several Abcg2/ABCG2 substrates in the 
newly created ABCG2-transfected MDCKII cell line. 
Apical efflux ratios (ERA), asymmetry efflux ratios (ERα), and the ratio of the asymmetry 
ratios in ABCG2-transfected vs. empty vector-transfected MDCKII cells (ERα Ratio) were 
calculated using flux data presented in Aim 5.  Several experiments were performed with 
PhIP and grouped. Drugs where the ERα Empty was not within 20% of unity were 
identified (shaded rows).  Data is presented as the mean and standard deviation of all 
possible efflux ratios from the unmatched individual experimental permeabilities. 
 ERα 
Empty 
ERA 
ABCG2 
ERα  
ABCG2 
ERα 
Ratio 
 Mean SD Mean SD Mean SD Mean SD 
Nitrofurantoin 0.55 0.03 6.13 0.28 13.93 1.43 25.31 2.78 
Cimetidine 1.46 0.34 3.68 0.62 16.94 2.02 12.18 2.98 
PhIP 0.98 0.08 2.35 0.17 42.55 4.89 43.83 5.86 
1.01 0.12 2.52 0.30 23.86 1.81 24.00 3.23 
Methotrexate 0.94 0.07 0.56 0.09 1.59 0.30 1.69 0.33 
Ciprofloxacin 0.77 0.07 5.04 0.29 6.55 1.27 8.61 1.74 
 
These data sets provide some challenges to the assumptions of the model.  First, 
the existence of other active transport processes in the parent MDCKII cell line has been 
documented in the literature and was observed in the ERα Empty ratios.  However, 
allowing endogenous PSB,U, PSA,E, PSB,E, and PSA,U processes to persist in the model 
complicates efforts to establish relationships between the passive permeability-surface 
area product attributed the transfection of ABCG2 (PSA,E(ABCG2)) and experimentally 
measured efflux ratios as described below.   
The relationships that describe the initial flux rate in the B→A or A→B direction 
(Eq. 3-6 and Eq. 3-9) were updated to reflect the addition of ABCG2 into a parent cell 
line with endogenous active uptake and efflux processes in both the apical and 
basolateral membranes to produce Eq. 4-6 and Eq. 4-7: 
 dXA,B→A
dt
 = CB 
0 PSD+PSB,U PSD+PSA,E+PSA,E(ABCG2
2PSD+PSA,E+PSB,E+PSA,E(ABCG2
+PSPC  Eq. 4-6
 dXB, A→B
dt
 = CA 
0 PSD+PSA,U PSD+PSB,E
2PSD+PSA,E+PSB,E+PSA,E(ABCG2
+PSPC  Eq. 4-7
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If ERA and ERα are redefined using these new rate equations and we again assume 
CB 
0 CA 
0 experimentally and PSPC→0: 
 
ERA= 
PSD+PSA,E+PSA,E(ABCG2)
2PSD+PSA,E+PSB,E+PSA,E(ABCG2)
2PSD+PSA,E
PSD+PSA,E
 Eq. 4-8
 
ERα=
PSD+PSA,E+PSA,E(ABCG2)
PSD+PSA,U
PSD+PSB,U
PSD+PSB,E
 Eq. 4-9
An examination of these efflux ratios demonstrates that ERA is still restricted to values 
between 1 and 2 and that ERα can fall in a much larger range.  ERA is dependent upon 
PSD, PSA,E, PSB,E, and PSA,E(ABCG2), whereas ERα could also be affected by any of the 
endogenous processes.  In an attempt to isolate the apical efflux terms attributed to 
ABCG2 transfection (PSA,E(ABCG2)), the ERα was further divided by ERα of the empty 
vector-transfected cells to produce the ERα Ratio (ERα(ABCG2)/ERα(Empty) :  
 ERα(ABCG2)
ERα(Empty)
=
PSD+PSA,E+PSA,E(ABCG2)
PSD+PSA,E
Eq. 4-10
 
PSA,E(ABCG2)= PSD+PSA,E
ERα(ABCG2)
ERα(Empty)
1  Eq. 4-11
As shown in the rearrangement of Eq. 4-10 to Eq. 4-11, it is not possible to 
remove effects of endogenous apical efflux processes (PSA,E) from the relationship; 
however proportionality between PSA,E(ABCG2) and this ERα Ratio still does exist.  
Experimentally, any variability in the cell line PSA,E(ABCG2) and PSA,E (transporter 
expression levels) or a substrate’s ability to cross the membrane by passive diffusion 
(PSD) or to interact with either transport process (PSA,E(ABCG2) and PSA,E) would be 
expected to affect the ratio.  The effects of changes in PSD, PSA,E, and PSA,E(ABCG2) on 
ERA and the ERα Ratio are illustrated graphically in Figure 4-28.  Increases in PSA,E or a 
higher relative substrate PSD lowers the maximal achievable ERA and blunts the ERα 
Ratio.  The final columns of Table 4-1 and Table 4-2 show that the ERα Ratio does 
appear to “correct” the ERα ABCG2 by accounting for the endogenous processes 
observed in the empty vector transfected cells (eg. nitrofurantoin and ciprofloxacin with 
ERα Empty < 1 in Table 4-2). 
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Figure 4-28: Effect of changes in PSD and PSA,E on the relationship between the 
individual efflux ratios and PSA,E(ABCG2). 
Panel A. Effect of changes in endogenous apical efflux activity (PSA,E) ranging from 0 to 
5 on the relationship between the permeability-surface area product attributed to ABCG2 
(PSA,E(ABCG2)) and the apical efflux ratio (ERA) or ratio of the asymmetry ratio in the 
ABCG2-transfected to that of empty vector cells (ERα Ratio).  Arrows depict the changes 
in efflux ratios with increasing PSA,E. PSB,E and PSD were fixed at 0 and 0.1, respectively.  
Panel B.  Effect of different permeability surface area products attributed to passive 
diffusion (PSD) ranging from 0.2 – 10 on the relationship between the permeability-
surface area product attributed to ABCG2 (PSA,E(ABCG2)) and the apical efflux ratio (ERA) 
or ratio of the asymmetry ratio in the ABCG2-transfected to that of empty vector cells 
(ERα Ratio).  Arrows depict changes in efflux ratios with increasing PSD.  PSA,E and PSB,E 
were fixed at 0. 
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The second challenge to the constraints of the model involves the assumption 
that PSD is much greater than that of PSPC or that PSPC→0.  Table 4-3 again presents 
the five substrates studied in Aim 5, but this time provides the calculated permeability of 
the paracellular marker used each study beside that of each ABCG2 substrate.  For 
methotrexate and ciprofloxacin in general and for virtually every calculated ABCG2 A→B 
permeability, the PSPC was not negligible in comparison to that of the substrate studied.  
To understand the effect of a PSPC that is not zero and that may be variable from 
experiment to experiment the relationship between PSA,E(ABCG2) and the ERA or ERα Ratio 
was graphed in the setting of an increasing PSPC (Figure 4-29).   As with increases in 
PSD and PSA,E, increases in PSPC lowers the maximal achievable ERA and blunts the ERα 
Ratio.  Perhaps even more importantly, the relationship between ERα Ratio and 
PSA,E(ABCG2) was also no longer linear. 
To control for the potential ramifications of variable PSPC in the experimental 
data, the permeability of the paracellular marker was subtracted from that of the drug 
being studied.  This approach has a theoretical basis in the model as demonstrated by 
the rearrangement of Eq. 4-6 and Eq. 4-7 to Eq. 4-12 and Eq. 4-13 below but is 
dependent on one major assumption; that the PSPC of the paracellular marker being 
measured is equal to the PSPC of the drug being studied. 
 dXA,B→A
dt
CB 
0  - PSPC = 
PSD+PSB,U PSD+PSA,E+PSA,E(ABCG2)
2PSD+PSA,E+PSB,E+PSA,E(ABCG2)
 Eq. 4-12
 dXB, A→B
dt
CA 
0  - PSPC = 
PSD+PSA,U PSD+PSB,E
2PSD+PSA,E+PSB,E+PSA,E(ABCG2)
 Eq. 4-13
Table 4-3 provides the ERα and ERα Ratio of the five ABCG2 substrates studied 
in the new model system recalculated using these equations.  Relative to the values 
calculated earlier and presented in Table 4-2, the correction increased both efflux ratios 
for nitrofurantoin and substantially increased both values for ciprofloxacin.  Efflux ratios 
for cimetidine and PhIP were less affected as the ABCG2 A→B permeability difference 
was relatively unchanged from the original ABCG2 A→B permeability (permeability of 
the paracellular marker was not large compared to that of the substrate being studied).  
Methotrexate could not be evaluated as the permeability of the drug was nearly identical 
and sometimes less than that of sucrose resulting in negative permeability differences.  
The PSPC subtraction also led to a very small ABCG2 A→B permeability and 
substantially increased the variability in the ERα and ERα Ratio for ciprofloxacin.
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Table 4-3: The relative permeabilities of the paracellular marker and the drug being 
studied in each flux experiment and corrected efflux ratios. 
ERα and ERα Ratio were calculated accounting for PSPC.  Permeability of the paracellular 
marker mannitol (*) or sucrose (†) was assumed to be equivalent to paracellular 
permeability of the drug being studied in the same transwell and was subtracted from the 
total permeability to yield the transcellular permeability of each drug.  Data is presented 
as the mean and standard deviation of all possible efflux ratios from the unmatched 
individual experimental permeabilities. 
  
Papp 
(drug) 
Papp 
(paracellular)
Papp 
Difference 
ERα 
ABCG2 
ERα 
Ratio 
Mean SD Mean SD Mean SD Mean SD Mean SD 
N
itr
of
ur
an
to
in
* Empty B→A 5.26 0.27 2.19 0.31 3.07 0.23 31.30 4.79 78.05 12.37 
Empty A→B 9.54 0.33 1.92 0.36 7.62 0.18
ABCG2 B→A 32.18 0.27 1.74 0.44 30.45 0.18
ABCG2 A→B 2.33 0.29 1.34 0.40 0.99 0.18
C
im
et
id
in
e†
 Empty B→A 2.33 0.43 0.85 0.47 1.48 0.14 26.53 2.24 17.36 2.27 
Empty A→B 1.64 0.29 0.67 0.20 0.96 0.09
ABCG2 B→A 8.38 0.16 0.76 0.12 7.62 0.10
ABCG2 A→B 0.50 0.06 0.21 0.05 0.29 0.03
P
hI
P
* 
Empty B→A 62.79 5.12 1.27 0.25 61.52 5.27 49.50 6.96 50.76 7.91 
Empty A→B 64.40 3.18 1.61 0.29 62.79 3.17
ABCG2 B→A 147.16 3.85 1.13 0.28 146.03 4.13
ABCG2 A→B 3.50 0.49 0.50 0.06 3.00 0.51
Empty B→A 39.05 4.81 2.23 0.39 36.82 5.19 27.53 1.95 28.07 4.11 
Empty A→B 38.86 1.96 1.83 0.24 37.02 2.08
ABCG2 B→A 97.27 4.77 0.71 0.11 96.56 4.67
ABCG2 A→B 4.09 0.30 0.57 0.08 3.52 0.23
M
et
ho
tre
xa
te
†  Empty B→A 0.82 0.06 0.90 0.04 -0.09 0.06
Empty A→B 0.87 0.02 0.93 0.00 -0.06 0.02
ABCG2 B→A 0.45 0.08 0.29 0.02 0.16 0.08
ABCG2 A→B 0.29 0.04 0.28 0.01 0.01 0.02
C
ip
ro
flo
xa
ci
n*
 Empty B→A 3.22 0.10 1.76 0.27 1.46 0.23 281.1 348.8 467.2 560.4 
Empty A→B 4.22 0.41 1.84 0.24 2.38 0.25
ABCG2 B→A 16.20 0.97 2.14 0.78 14.06 0.29
ABCG2 A→B 2.54 0.50 2.34 0.66 0.21 0.17
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Figure 4-29: Effect of variable PSPC on the relationship between the individual efflux 
ratios and PSA,E(ABCG2). 
Effect of variable PSPC ranging from 0 to 0.5 on the relationship between the 
permeability-surface area product attributed to ABCG2 (PSA,E(ABCG2)) and the apical efflux 
ratio (ERA) or ratio of the asymetry ratio in the ABCG2-transfected to that of empty 
vector cells (ERα Ratio).  Arrows depict the changes in efflux ratios with increasing PSPC.  
PSA,E, PSB,E, and PSD were fixed at 0, 0, and 0.5 respectively.   
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2. Specific Aim 7: To define the relationship between in vitro efflux ratios and the 
in vivo M/S ratio. 
To explore the relationships between flux attributed to ABCG2/Abcg2 in both in 
vitro and in vivo systems, milk to plasma ratios of several Abcg2 substrates in wild-type 
and Abcg2 knock-out mice were gathered from the literature (Table 1-1). Correlations 
between the ratio of the milk to plasma ratios (M/P) in the wild-type and Bcrp1-/- mice 
and the murine and human ERα and ERα Ratio (presented previously in Table 4-1, Table 
4-2, and Table 4-3) were then performed.  Figure 4-30 Panel A shows the correlation for 
murine ERα.  Nitrofurantoin, riboflavin, topotecan, and cimetidine are plotted, but not 
included in the correlation as these drugs showed directional flux in the empty vector-
transfected cells, thereby violating the constraint of the ERα, that no other transport 
processes were present.  Nitrofurantoin and riboflavin also demonstrated a large Abcg2-
attributed effect in vivo that was not observed in vitro.  A correlation coefficient of 0.60 
was achieved with the remaining 5 datapoints.  The disproportionate Abcg2 affect in vivo 
with nitrofurantoin and riboflavin may be as a result of other transporter systems that 
were present in the in vitro system that cannot be controlled for in the ERα calculation.  
Theoretically, the ERα Ratio can control for these endogenous active transport processes 
(all except PSA,E) that may be present in the single transfection cell line (Eq. 4-10), so 
correlations were performed using this term versus the same M/P ratio.  Figure 4-30 
Panel B presents the correlations with and without the drugs excluded in Panel A.  The 
correlation coefficient was 0.52 without these substrates and when they were added, it 
improved to 0.58; a value similar to what was achieved with the murine ERα correlation 
that did not contain these drugs.  Similar comparisons were made in Figure 4-30 Panels 
C and D with the literature-derived human data.  The human ERα, however, achieved a 
highly significant correlation (r = 0.996; p < 0.0003) with the murine M/P ratios once 
nitrofurantoin, topotecan, and cimetidine were removed (riboflavin ERα Ratio was not 
available for analysis) (Panel C).  As seen with the murine in vitro data, the human ERα 
Ratio could not fully account for the much higher Abcg2 effect observed in the in vivo 
M/P ratio (nitrofurantoin in particular).  The ERα Ratio correlation coefficient for the 
analysis containing all the compounds was poor at 0.33, whereas the one for containing 
only the drugs analyzed in Panel C remained significant (r = 0.996; p < 0.0003).  It is 
important to note that human correlations suffered from a sparse representation of data 
points in the middle of the curves.  The collection of low M/P ratio and efflux ratio drugs 
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and the single high M/P and high efflux drug, PhIP, likely contributed to the significant 
correlations and apparently superior ERα human correlation. 
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Figure 4-30: Correlations between the in vivo ratio of murine milk to plasma ratios in the 
wild-type and Abcg2 knock-out (M/P wild-type/Bcrp-/-) to the in vitro human and murine 
asymmetry efflux ratio (ERα) and ratio of ABCG2 to empty vector-transfected asymmetry 
efflux ratios (ERα Ratio).  
Panel A. Murine ERα.  The directional flux of riboflavin, nitrofurantoin, cimetidine, and 
topotecan in the empty vector-transfected cells suggests endogenous transport 
processes were present for these drugs so they were removed from correlation (open 
circles). Panel B. Murine ERα Ratio.  Correlations were performed with (dashed line) and 
without (solid line) the drugs excluded in Panel A.  Panels C. Human ERα.  
Nitrofurantoin, topotecan, and cimetidine were again removed from correlation for 
reasons described above. Panel D. Human ERα Ratio.  The best-fit orthogonal 
regression lines with (dashed line) and without (solid line) the drugs excluded in Panel C 
are displayed.  The Pearson correlation coefficient (r) determined in each scenario is 
also reported.   
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Flux experiments performed in Aim 5 allowed for a more detailed analysis of the 
model than was possible with the literature-derived data.  Accurate measurements of the 
flux of the paracellular marker used in each assay provided the ability to determine if the 
correlations could be improved when the efflux ratios were corrected by subtraction of 
permeability attributed to the paracellular marker (as presented in Eq. 4-12 and Eq. 
4-13).  Figure 4-31 Panels A and B presents the human efflux ratios from Table 4-2 
versus the ratio of the M/P ratios in wild-type and Abcg2 knock-out mice from Table 1-1.  
An evaluation of the ERα using human data could not be performed as three of the four 
drugs (ciprofloxacin, cimetidine, nitrofurantoin) showed a directional flux in the empty 
vector-transfected cells, thereby violating the contraint of this efflux ratio.  The ERα Ratio 
performed fairly well as the rank-order of Abcg2-attributed effect in vivo was observed in 
vitro for three of the four drugs (ciprofloxacin, cimetidine, PhIP).  The nitrofurantoin efflux 
ratio, however, seemed somewhat blunted compared to that observed in vivo.  It should 
also be noted that some variability was observed with PhIP in the two experiments that 
were performed.  Figure 4-31 Panels C and D present the corrected ERα and ERα Ratio 
following subtraction of the paracellular marker permeability from that of the substrate 
measured concurrently (data presented in Table 4-3).  Ciprofloxacin was affected the 
greatest by this correction as the permeability of the paracellular maker was very similar 
to the A→B flux of ciprofloxacin (2.54 ± 0.5 for ciprofloxacin vs. 2.34 ± 0.7 for mannitol).  
When all possible combinations of the unmatched permeabilities were evaluated, the 
variability of the ciprofloxacin efflux ratios following subtraction were much larger than 
observed without it.  The standard deviations surrounding these both the ERα and the 
ERα Ratio was greater than 100% of the mean and was much larger than observed with 
the other substrates.  The ERα Ratio with the substraction performed better than ERα 
Ratio without it as the correlation of the in vivo Abcg2-attributed effect and in vitro ERα 
Ratio for nitrofurantoin and its overall rank order was improved.  The Pearson correlation 
coefficient was 0.94 and trended towards significance with a p-value of 0.06 with 
ciprofloxacin excluded from the analysis. 
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Figure 4-31: Correlations between the in vivo ratio of murine milk to plasma ratios in the 
wild-type and Abcg2 knock-out (M/P wild-type/Bcrp-/-) to the in vitro human asymmetry 
efflux ratio (ERα) and ratio of new ABCG2 to empty vector-transfected asymmetry efflux 
ratios (ERα Ratio).  
Panel A. Human ERα.  Nitrofurantoin, cimetidine, and ciprofloxacin are identified by open 
circles as all demonstrated directional flux in the empty vector-transfected cells, 
suggesting endogenous transport processes were present for these drugs. Panel B. 
Human ERα Ratio.  Panels C/D.  The same efflux ratios were calculated for each drug by 
first subtracting PSPC. Ciprofloxacin is not included due to the very large ERα and ERα 
Ratio variability observed following subtraction of PSPC (see Table 4-3).  Panels C. ERα.  
Panel D. ERα Ratio.  The best-fit orthogonal regression lines for all drugs are displayed 
in the ERα Ratio graphs (Panels B and D).  The Pearson correlation coefficient (r) is also 
reported.   
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D. Microarray expression profiling of transporter gene expression in murine 
developmental datasets 
1. Specific Aim 8: To identify xenobiotic transporters highly expressed in mice 
during lactation (in vivo).    
Microarray expression profiling was used to identify murine xenobiotic 
transporters that are differentially expressed during lactation.  Nonlactating and lactating 
mammary gland array data from three independent experiments [174-176] was obtained 
from the published literature and pooled to increase sample size.  Figure 4-32 
demonstrates that no substantial experimental bias was seen from the pooling of these 
datasets as the signal intensities from chips within same group across experiments 
(nonlactating or lactating) were more highly correlated than those in different groups but 
within the same experiment.   
In order to determine transporters of potential importance for xenobiotic transport 
during lactation, the signal intensities of the 32 probesets identified in Table 3-2 (subset 
of transporters genes of interest that are detectable by the Mu74v2A GeneChip®) were 
compared in lactating vs. nonlactating groups.  Of the 32 probesets, 24 were eliminated 
from the analysis as they were Absent in all 15 lactating samples according to the 
probeset detection calls.  Comparisons of the remaining 8 transporter probesets are 
presented in Table 4-4 grouped by the genes that are significantly upregulated, 
downregulated, or with no difference in expression level when comparing lactating vs. 
nonlactating mammary gland samples.  The RNA expression level of Abcg2, Slc22a1, 
Slc15a2, Slc29a1, Slc16a1, and Abcc5 was higher during lactation, resulting in fold 
changes of 20, 10, 4, 2, 2, and 2, respectively over virgin mammary glands.  To further 
emphasize the developmental regulation of Abcg2, Slc22a1, and Slc15a2, specifically 
the higher levels observed during lactation, the array data from all timepoints of one 
experiment (Stein et al) for these genes as well as the β-casein (positive control) is 
presented in Figure 4-33.  Detection call and signal intensity data from each chip is 
provided in Appendix 4. 
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Figure 4-32: Correlations of virgin and lactating murine mammary gland tissue 
microarray chip signal intensities within and between groups in the Stein et al, Clarkson 
et al, and Medrano et al. datasets. 
Signal concordance was evaluated using Pearson’s correlations of the signal values 
generated by the MAS5 algorithm.  The heat map contains all pairwise comparisons 
where the r2 values have been converted into a pseudocolor scale. 
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Table 4-4: Comparison of Affymetrix Mu74v2A array transporter probeset expression 
levels in murine lactating vs. nonlactating mammary gland. 
Genes are grouped based on whether they are increased, decreased or not different 
during lactation.  Probesets for the same gene were then grouped into sections of the 
table sorted by fold change in expression. 
Gene Lactating NonLactating Fold 
Symbol Probeset ID p Value Mean SD Mean SD Change 
Higher during lactation (p < 0.05, fold change >1) 
Abcg2 93626_at 2.02E-07 1735 682 85 27 20.49
Slc22a1 100916_at 6.58E-03 35 38 3 4 10.07
Slc15a2 103918_at 5.10E-05 66 34 16 8 4.06
Slc29a1 95733_at 6.70E-04 445 193 227 58 1.96
Slc16a1 101588_at 1.78E-02 25 13 14 7 1.73
Abcc5 103800_at 1.93E-04 155 38 99 23 1.57
Lower during lactation (p < 0.05, fold change <1) 
Slc23a2 104267_at 2.72E-04 66 15 101 26 0.66
Detectable, but no difference in expression (p > 0.05) 
Slc22a5 98322_at 1.77E-01 55 13 47 17 
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Figure 4-33: Affymetrix Mu74v2A array expression levels of β-casein, Abcg2, Slc22a1, 
and Slc15a2 over the course of murine development. 
Data is from 17 developmental time points in the Stein et al. dataset.  One mouse 
mammary gland was used per chip with 3 chips (biological replicates) analyzed per time 
point.  The positive control, Β-casein (Panel A) and Abcg2 (Panel B), Slc22a1 (Panel C), 
and Slc15a2 (Panel D) were significantly all upregulated during lactation.   
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E. Identification of xenobiotic transporters highly expressed in human LMEC clinical 
samples  
1. Specific Aim 9: To develop a robust methodology to isolate a pure population 
of epithelial cells from human breast milk and reduction mammoplasty clinical samples.   
Previous methods using Dynabeads® resulted in >95% purity of MECs from 
breast milk and breast reduction specimens, but were not robust enough to obtain the 
numbers of cells needed for microarray analysis. Two new approaches, one using 
immunomagnetic nanoparticles and the other using FACS, were evaluated with breast 
milk as it had been difficult to isolate LMECs from this matrix in sufficient numbers 
previously.  The EasySep® immunomagnetic separation system was thoroughly tested 
with different buffers, blocking agents, incubation times, and nanoparticle conjugation 
approaches.  However, the murine anti-MUC1 (clone 214D4) antibody required by the 
system did not appear to have the correct specificity for MECs.  Figure 4-34 is the best 
results of the optimized approach and depicts a higher than expected percentage of 
MUC1 positive (MUC1+) cells prior to selection.  This population was enriched to nearly 
95% by the procedure, but was not associated with a corresponding increase in cells 
stained positive by immunocytostaining for simple epithelial cells (Figure 4-35).     
The FACS-based method utilizing the rat anti-MUC1 (clone MFGM/5/11[ICR.2]) 
antibody generated superior results.  Figure 4-36 shows the percentage of cells that 
were MUC1+ in breast milk prior to isolation.  A clear bimodal distribution that was not 
observed with the murine anti-MUC1 (clone 214D4) antibody was apparent with 
approximately 43% of the initial population MUC1+.  LMECs were enriched in the 
selected population to greater than 99% purity as measure by immunocytostaining 
(Figure 4-37).  The approach was also sufficiently robust with at least 1 x 105 (upwards 
to 3.5 x 106) cells obtained from a single sample. 
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Figure 4-34: Flow cytometric analysis of the purity of LMEC cells separated by 
immunomagnetic separation using the murine anti-MUC1 (clone 214D4) antibody and  
EasySep® nanoparticles. 
Cell-nanoparticle complexes derived breast milk samples were labeled with the FITC-
conjugated anti-dextran antibody (green shaded) or FITC-conjugated isotype control 
(black line).  The percentage of cells in MUC1+ gate (set relative to the isotype control) 
were compared in the before and after isolation. 
Pre-Isolation Not Selected Selected 
 
Figure 4-35: Immunocytostaining of luminal epithelial cell specific cytokeratins in the pre-
isolated and populations selected by a murine EasySep® nanoparticles to verify purity. 
The CK22 simple epithelial cell antibody and Vectastain ABC kit were used to label 
simple epithelial cells (brown) (20x magnification). 
Pre-Isolation Not Selected Selected 
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Figure 4-36: FACS isolation of LMEC from breast milk using the rat anti-MUC1 (clone 
MFGM/5/11[ICR.2] antibody.  
Cells were incubated with an anti-MUC1 (clone MFGM/5/11[ICR.2]) (green shaded) or 
isotype control (black line) antibody and labeled with a FITC-conjugated secondary 
antibody.  The percentage of cells in MUC1+ gate (set at the division of 2 populations in 
the pre-isolation histogram) were compared in the before and after isolation. 
Pre-Isolation 
 
Figure 4-37: Immunocytostaining of luminal epithelial cell specific cytokeratins in the pre-
isolated and populations selected by FACS to verify purity. 
The CK22 simple epithelial cell antibody and Vectastain ABC kit were used to label 
simple epithelial cells (brown).  Purity was assessed by counting (20x magnification). 
Pre-Isolation Not Selected Selected 
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2. Specific Aim 10: To identify xenobiotic transporters highly expressed in human 
lactating mammary epithelial cells relative to nonlactating mammary epithelial cells and 
other secretory tissues 
Seventeen reduction mammoplasty samples were received from UK surgical 
pathology from 2002 – 2006.  Three were consumed during early method optimization, 
three samples were small or too fatty to provide enough organoids, four were ruled out 
due to a pathology reports that were incomplete or indicating significant fibrosis or 
proliferative changes, and three provided too few cells in the final sorted populations.  
The remaining four samples were histologically normal and yielded enough cells to 
generate greater than 2 μg of RNA.  From these, the three yielding the greatest amount 
of high quality RNA were selected for microarray analysis.  Subject demographic 
information that was attainable from the anonymized samples is provided in Table 4-5.  
 Seven breastfeeding volunteers participated in the study from 2005 – 2006, 
providing 45 breast milk samples.  One subject was used for early method development 
and three subjects were excluded as they either did not have enough cells in the breast 
milk or elected to stop participating due to low milk production (weaning).  Demographic 
information from the three subjects who completed the study is provided in Table 4-5.  
Each provided breast milk over a 6-10 week period and ranged from 9-47 weeks post-
partum. 
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Table 4-5: Sample demographics and FACS isolation results 
Number of samples refers to the number of breast milk samples collected from each 
patient over the post-partum time frame indicated.  Number in parenthesis indicates how 
many samples were successfully processed through FACS to generate enough cells for 
subsequent RNA isolation.  For MEC samples, this refers to the number of frozen 
organoid vials (split from the original reduction mammoplasty sample) that were 
processed individually to generate enough cells for subsequent RNA isolation.  Number 
of MEC/LMEC cells isolated is the mean number of MUC1+ cells from each sample 
collected and is expressed as a percentage of the total number of cells put through the 
cytofluorimeter during FACS.     
Sample Age Ethnicity 
Weeks 
post-partum
Number 
of 
samples
MEC/LMEC isolation results 
Number of 
cells isolated
(mean ± SD) 
Percentage of 
total cells 
(mean ± SD) 
Total pooled 
RNA 
(μg) 
MEC #1 25 Caucasian - 2 1.7 x 106 33.7 5.6 μg 
MEC #2 33 Caucasian - 8 7.2 ± 4.6 x105 7.8 ± 2.9 2.2 μg 
MEC #3 33 Caucasian - 4 8.5 ± 5.2 x105 15 ± 2.9 5.0 μg 
LMEC #1 24 Caucasian 39 - 47 7 (6) 1.0 ± 0.7 x 106 29.7 ± 19.2 10.1 μg 
LMEC #2 32 Caucasian 27 - 34 10 (9) 0.5 ± 1.1 x 106 25.0 ± 16.5 4.1 μg 
LMEC #3 21 Caucasian 9-19 12 (11) 3.9 ± 2.2 x 105 9.5 ± 8.6 3.7 μg 
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Figure 4-39: Immunocytostaining of luminal epithelial cell specific cytokeratins in the 
presorted and sorted populations to verify purity. 
The CK22 simple epithelial cell antibody and Vectastain ABC kit was used to label 
simple epithelial cells (brown).  Purity was assessed by counting (20x magnification). 
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Figure 4-40: Bioanalyer 2100 analysis of LMEC and MEC RNA integrity. 
Quality of RNA isolated from LMEC and MEC samples was assessed using the 
Bioanalyzer 2100 at the UK Microarray Core Facility.  Nanogram amounts of RNA were 
fluorescent labeled and separated by microchannel electrophoresis.  RNA integrity was 
evaluated by integrating the peaks associated with the 28s and 18s bands relative to 
degradation products.  Samples are given a RNA Integrity Number (RIN) on a 10 point 
scale. 
 
Representative 
Electropherogram: 
 
RIN values: 
MEC #1 = 9.2 
MEC #2 = 9.3 
MEC #3 = 10 
LMEC #1 = 9.8 
LMEC #2 = 9.5 
LMEC #3 = 9.7 
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The external liver and kidney microarray data that were used to determine the relative 
LMEC expression level when differences between LMEC and MEC samples were not 
significant was obtained from a study by Khaitovich et al. [183].  The sources of the 
human liver tissue samples were four males ages 21, 29, and “adult” and 2 females 
ages 27 and 29.  Human kidney tissue samples were from males ages 24, 24, 26, 46, 
62, and 64.   
Figure 4-41 shows that signal intensities from chips within same group (MEC, 
LMEC, kidney or liver) were more highly correlated than those in different groups.  Also, 
as one would expect from cells from the same tissue, the MEC and LMEC array signal 
intensities were also more correlated with each other than with either the kidney or liver. 
 
Figure 4-41: Correlation of LMEC, MEC, liver, and kidney microarray chip signal 
intensities within and between groups.  
Signal concordance was evaluated using Pearson’s correlations of the signal values 
generated by the MAS5 algorithm.  The heat map contains all pairwise comparisons 
where the r2 values have been converted into a pseudocolor scale. 
Heat Map Key:
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In order to determine transporters of potential importance for xenobiotic transport 
in LMECs, the signal intensities of the 122 probesets identified in Table 3-2 were first 
compared in LMEC vs. MEC arrays.  Those transporter genes whose expression was 
significantly upregulated during lactation were of interest whereas those significantly 
downregulated were not.  The transporter probeset comparisons that did not achieve 
significance were not discarded as similar gene expression in LMEC and MEC cells 
could still be of importance if that expression level were high.  Of the 122 probesets, 85 
were eliminated from the analysis as they were Absent in all three LMEC samples 
according to the probeset detection calls.  Comparisons of the remaining 37 transporter 
probesets are presented in Table 4-6 grouped by the genes that are significantly 
upregulated, downregulated, or with no difference in expression level when comparing 
LMEC vs. MEC.  The RNA expression level of ABCG2, SLCO4C1, SLC15A2, 
SLC22A12, and SLC6A14 was higher in LMECs, resulting in fold changes of 164, 70, 
41, 8 and 2, respectively over MECs.  At least one probeset for ABCB1, ABCB10, 
ABCC4, SLC10A1, SLC16A1, SLC16A7, SLC17A1, SLC22A3, SLC22A4, SLC22A5, 
SLC22A9, SLC23A2, SLC28A1, SLC28A3, SLC29A1, SLC29A2, SLCO2B1, and 
SLC4A1 was detectable, but not different between the groups. 
The expression level relative to liver and kidney for the 37 probesets that were 
not absent on all three LMEC arrays are presented in Table 4-7 and Table 4-8.  Versus 
the liver, SLC6A14, SLC15A, ABCG2, SLCO4C1, SLCO4A1, AND SLC22A4 were 
upregulated 79, 46, 7, 7, 5, and 2 fold respectively.  At least one probeset for ABCB10, 
SLC16A1, SLC22A12, SLC22A5, SLC28A3, SLC29A, SLC29A2, and SLCO4A1 was 
detectable, but not different between the groups.  The similar comparison versus kidney 
demonstrated an increase in the level of expression of SLC6A14, ABCG2, SLC15A2, 
SLC16A1, and SLCO4C1 by 50, 40, 5, 3 and 2 fold.  At least one probeset for ABCC10, 
SLC10A1, SLC16A, SLC22A4, SLC22A9, SLC28A3, SLC29A1, and SCL4A1 was 
detectable, but not different between the groups.  Detection call and signal intensity data 
from each chip is provided in Appendix 5. 
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Table 4-6: Comparison of Affymetrix U133 plus 2.0 array transporter probeset 
expression levels in human LMEC vs. MEC. 
Genes are grouped based on whether they are increased, decreased or not different 
during lactation.  Probesets for the same gene were grouped into sections of the table 
sorted by fold change in expression. 
Gene     LMEC MEC Fold  
 Symbol Probeset ID p-Value Mean SD Mean SD Change 
Higher during lactation (p < 0.05, fold change >1) 
ABCG2 209735_at 3.69E-02 17536 5964 107 75 164.04
SLCO4C1 222071_s_at 2.39E-03 3362 294 48 31 69.70
SLC15A2 205316_at 3.62E-03 3936 421 96 47 40.80
205317_s_at 2.16E-03 868 182 89 62 9.72
240159_at 8.99E-04 243 31 76 10 3.18
SLC22A12 237799_at 2.79E-02 184 80 24 19 7.84
SLC6A14 219795_at 4.13E-02 3988 1193 1773 500 2.25
Lower during lactation (p < 0.05, fold change <1) 
ABCC1 202804_at 8.59E-03 112 21 1400 214 0.08
SLCO3A1 219229_at 8.95E-04 51 63 419 34 0.12
227367_at 1.88E-03 160 67 544 62 0.29
SLC16A7 207057_at 4.24E-02 125 44 442 181 0.28
210807_s_at 7.83E-03 85 14 191 34  0.45
Detectable, but no difference in expression (p > 0.05) 
ABCB1 243951_at 5.29E-01 65 25 52 19   
ABCC10 213485_s_at 1.82E-01 601 169 387 155   
215873_x_at 3.45E-01 301 43 227 112   
ABCC4 1555039_a_at 7.15E-01 42 53 30 12   
SLC10A1 207185_at 6.26E-01 110 122 70 6   
SLC16A1 1557918_s_at 1.53E-01 954 353 526 230   
202236_s_at 1.69E-01 3090 473 1908 1127   
202234_s_at 6.55E-01 736 120 626 375   
202235_at 6.79E-01 267 47 315 181   
209900_s_at 9.11E-01 1005 49 1052 639   
SLC17A1 237049_at 4.23E-01 35 32 16 18   
SLC22A3 242578_x_at 1.78E-01 184 54 784 511   
1570482_at 2.55E-01 29 15 74 56   
SLC22A4 205896_at 2.62E-01 429 82 349 69   
SLC22A5 205074_at 6.34E-01 535 146 477 125   
SLC22A9 241770_x_at 7.26E-01 38 27 47 30   
SLC23A2 211572_s_at 2.95E-01 93 20 109 2   
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Table 4-6 cont. 
Gene     LMEC MEC Fold  
 Symbol Probeset ID p-Value Mean SD Mean SD Change 
Detectable, but no difference in expression (p > 0.05) 
SLC28A1 207560_at 2.91E-01 200 18 135 91   
SLC28A3 220475_at 6.94E-02 191 219 1422 837   
SLC29A1 201802_at 8.38E-02 591 277 220 45   
201801_s_at 1.21E-01 1000 468 306 668   
SLC29A2 204717_s_at 5.07E-02 196 38 123 25   
SLCO2B1 203473_at 3.89E-01 152 86 103 23   
SLCO4A1 1554332_a_at 1.40E-01 1345 598 522 24   
219911_s_at 6.09E-01 907 238 1113 599   
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Table 4-7: Comparison of Affymetrix U133 plus 2.0 array transporter probeset 
expression levels in human LMEC vs. liver. 
Genes are grouped based on whether they are increased, decreased or not different 
during lactation.  Probesets for the same gene were then grouped into sections of the 
table sorted by fold change in expression. 
Gene     LMEC Liver Fold  
 Symbol Probeset ID p Value Mean SD Mean SD Change 
Higher relative to liver (p < 0.05, fold change >1) 
SLC6A14 219795_at 2.92E-02 3988 1193 50 36 79.34
SLC15A2 205316_at 3.72E-03 3936 421 85 54 46.06
205317_s_at 1.89E-02 868 182 184 55 4.72
240159_at 1.67E-02 243 31 144 49 1.69
ABCG2 209735_at 4.51E-02 17536 5964 2582 1542 6.79
SLCO4C1 222071_s_at 3.46E-06 3362 294 505 313 6.65
SLCO4A1 219911_s_at 1.85E-03 907 238 184 198 4.92
SLC22A4 205896_at 6.61E-04 429 82 186 47 2.30
Lower relative to liver (p < 0.05, fold change >1) 
SLC10A1 207185_at 3.73E-06 110 122 16334 1870 0.01
SLCO2B1 203473_at 2.14E-05 152 86 10989 1752 0.01
SLC23A2 211572_s_at 2.02E-02 93 20 2576 1813 0.04
SLC22A9 241770_x_at 1.17E-04 38 27 802 186 0.05
SLC17A1 237049_at 6.34E-04 35 32 359 91 0.10
ABCB1 243951_at 6.03E-04 65 25 482 117 0.13
SLCO3A1 219229_at 1.42E-02 51 63 328 137 0.15
227367_at 5.93E-03 160 67 296 40 0.54
SLC22A3 1570482_at 2.26E-02 29 15 185 118 0.16
242578_x_at 3.65E-03 184 54 837 253 0.22
SLC28A1 207560_at 2.18E-04 200 18 1123 242 0.18
ABCC4 1555039_a_at 9.01E-03 42 53 157 42 0.27
SLC16A7 210807_s_at 2.10E-03 85 14 316 100 0.27
  207057_at 3.23E-02 125 44 378 156 0.33
ABCC1 202804_at 4.10E-03 112 21 371 103 0.30
SLC29A1 201802_at 4.23E-02 591 277 1388 509 0.43
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Table 4-7 cont. 
Gene     LMEC Liver Fold  
 Symbol Probeset ID p Value Mean SD Mean SD Change 
Detectable, but no difference in expression (p > 0.05) 
ABCC10 215873_x_at 1.75E-01 301 43 395 101   
213485_s_at 6.41E-01 601 169 552 129   
SLC16A1 202235_at 1.57E-01 267 47 497 336   
202236_s_at 3.15E-01 3090 473 2314 1161   
202234_s_at 6.68E-01 736 120 867 486   
209900_s_at 8.05E-01 1005 49 947 544   
1557918_s_at 9.65E-01 954 353 943 365   
SLC22A12 237799_at 7.63E-02 184 80 27 10   
SLC22A5 205074_at 9.07E-01 535 146 549 180   
SLC28A3 220475_at 6.50E-01 191 219 240 105   
SLC29A1 201801_s_at 3.13E-01 1000 468 1528 756   
SLC29A2 204717_s_at 6.46E-01 196 38 204 15   
SLCO4A1 1554332_a_at 1.07E-01 1345 598 397 140   
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Table 4-8: Comparison Affymetrix U133 plus 2.0 array transporter probeset expression 
levels in human LMECs vs. kidney. 
Genes are grouped based on whether they are increased, decreased or not different 
during lactation.  Probesets for the same gene were then grouped into sections of the 
table sorted by fold change in expression. 
Gene     LMEC Kidney Fold  
 Symbol Probeset ID p Value Mean SD Mean SD Change 
Higher relative to kidney (p < 0.05, fold change >1) 
SLC6A14 219795_at 2.96E-02 3988 1193 79 42 50.19
ABCG2 209735_at 3.82E-02 17536 5964 437 52 40.12
SLC15A2 205316_at 2.24E-06 3936 421 808 263 4.87
205317_s_at 7.61E-03 868 182 453 148 1.92
SLC16A1 202236_s_at 5.04E-04 3090 473 974 500 3.17
209900_s_at 9.21E-03 1005 49 400 283 2.51
202234_s_at 2.01E-02 736 120 383 182 1.92
202235_at 3.82E-02 267 47 143 76 1.87
SLCO4C1 222071_s_at 5.67E-04 3362 294 1736 417 1.94
Lower relative to Kidney (p < 0.05, fold change >1) 
SLC17A1 237049_at 3.00E-03 35 32 912 404 0.04
SLCO3A1 219229_at 2.79E-04 51 63 637 141 0.08
227367_at 1.83E-03 160 67 584 140 0.27
SLC22A12 237799_at 1.66E-02 184 80 2227 1416 0.08
ABCB1 243951_at 1.94E-04 65 25 671 164 0.10
SLCO2B1 203473_at 5.92E-03 152 86 1380 669 0.11
ABCC4 1555039_a_at 2.93E-03 42 53 336 105 0.13
SLC16A7 210807_s_at 2.26E-02 85 14 655 429 0.13
  207057_at 3.46E-02 125 44 1400 1085 0.09
ABCC1 202804_at 7.62E-05 112 21 814 156 0.14
SLC22A5 205074_at 3.55E-03 535 146 3014 1200 0.18
SLC22A3 1570482_at 1.36E-04 29 15 143 23 0.21
242578_x_at 5.33E-03 184 54 894 378 0.21
SLC28A1 207560_at 1.21E-02 200 18 916 457 0.22
SLC29A2 204717_s_at 2.08E-03 196 38 496 103 0.39
SLC23A2 211572_s_at 0.041286 93 20 231 92 0.40
SLC15A2 240159_at 2.52E-02 243 31 556 184 0.44
ABCC10 215873_x_at 1.44E-03 301 43 604 96 0.50
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Table 4-8 cont. 
Gene     LMEC Kidney Fold  
 Symbol Probeset ID p Value Mean SD Mean SD Change 
Detectable, but no difference in expression (p > 0.05) 
ABCC10 213485_s_at 1.41E-01 601 169 746 99 
SLC10A1 207185_at 7.24E-02 110 122 308 136 
SLC16A1 1557918_s_at 6.35E-02 954 353 194 48 
SLC22A4 205896_at 8.69E-02 429 82 689 212 
SLC22A9 241770_x_at 7.38E-01 38 27 45 24 
SLC28A3 220475_at 9.58E-01 191 219 199 54 
SLC29A1 201801_s_at 3.96E-01 1000 468 710 157 
201802_at 7.59E-01 591 277 550 123 
SLCO4A1 1554332_a_at 7.40E-02 1345 598 158 74 
219911_s_at 8.67E-01 907 238 873 284 
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Using the two step screening paradigm described previously (Figure 3-5), data 
from the three comparisons were merged to generate a single list of transporters of 
interest for potential importance for xenobiotic transport in LMEC (Table 4-9).  ABCG2, 
SLC15A2, SLC22A12, SLC6A14, AND SLCO4C1 are of interest as they were 
significantly upregulated during lactation.  The actual fold change, although certainly the 
most striking with ABCG2, SLOC4C1, and SLC15A2, should be interpreted cautiously as 
the signal intensities reported from the MEC arrays (the denominator of the ratio) were 
often very low with marginal or absent detection calls.  Other transporters, such as 
ABCC10, SLC10A1, SLC16A1, SLC22A4, SLC22A5, SLC22A9, SLC28A3, SLC29A1, 
SLC29A2, and SLCO4A1 may also be of interest as their expression level was similar to 
levels in other secretory tissues. 
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Table 4-9: Results of the microarray analysis screen paradigm for identifying 
transporters potentially responsible for drug accumulation in breast milk.  
Transporter genes upregulated during lactation are shaded.  The direction of the 
differences relative to MEC, liver, and kidney are presented by the arrows.  A dash 
indicates no statistically significant difference was detected.  An asterisk denotes a gene 
detected by other probesets on the chip that were excluded from the analysis (absent on 
all lactating chips). 
LMEC expression vs.: 
MEC Liver Kidney 
ABCC10 MRP7 215873_x_at - -  
  213485_s_at - - - 
ABCG2 BCRP 209735_at    
SLC10A1 NTCP 207185_at -  - 
SLC15A2 PEPT2 240159_at    
  205317_s_at    
  205316_at    
SLC16A1 MCT1 202235_at - -  
  202236_s_at - -  
  202234_s_at - -  
  209900_s_at - -  
  1557918_s_at - - - 
SLC22A12 URAT1 237799_at  -  
SLC22A4* OCTN1 205896_at -  - 
SLC22A5 OCTN2 205074_at - -  
SLC22A9* UST3 241770_x_at -  - 
SLC28A3 CNT3 220475_at - - - 
SLC29A1 ENT1 201801_s_at - - - 
  201802_at -  - 
SLC29A2* ENT2 204717_s_at - -  
SLC6A14 ATB(0+) 219795_at    
SLCO4A1* OATP-E 219911_s_at -  - 
  1554332_a_at - - - 
SLCO4C1 OATP-H 222071_s_at    
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The observation that SLCO4C1 is upregulated in LMECs, the cells forming the 
barrier between serum and breast milk was novel and warranted qPCR validation. 
Quality of the primer pairs used for the quantification of each gene was demonstrated by 
correlation coefficients > 0.99, PCR efficiencies of 95-100%, and single products on the 
melt curve analysis and agarose gel electrophoresis (Figure 4-42 and Figure 4-43).  
Figure 4-44 shows the relative RNA expression levels of SLCO4C1 in each sample and 
in pooled RNA from human liver and kidney external controls.  β-casein RNA expression 
level was measured in parallel as a positive control.  The LMEC expression of SLCO4C1 
was confirmed to be much greater than that of MECs (>1000 fold by qPCR).  Although 
striking, the actual magnitude of this fold change must be interpreted cautiously as all 
three LMEC samples were slightly above the standard curve.  The assay was not 
repeated in order to conserve cDNA for future experiments.  SLCO4C1 expression in 
LMECs was also much higher than that of the kidney and liver samples.  Although not 
the same comparators as were analyzed by microarray analysis, the qPCR shows a 
higher expression of SLCO4C1 in LMEC relative to these tissues by both methods. 
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Figure 4-42: Human β-casein amplification curve, melt curve analysis, standard curve, 
and agarose gel electrophoresis generated from standards over a 5-log10 dilution series. 
  
 
 
←138 bp 
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Figure 4-43: Human SLCO4C1 amplification curve, melt curve analysis, standard curve, 
and agarose gel electrophoresis generated from standards over a 3-log10 dilution series.   
  
 
 
 
←149 bp 
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Figure 4-44: Relative RNA expression of β-casein and SLCO4C1 in human LMEC, MEC, 
and pooled liver and kidney samples as determined by quantitative PCR.  
A. Relative β-casein RNA expression.  Cells isolated from breast milk were used for 
generation of a standard curve (100→10-6).  Samples were prepared in the dilutions 
indicated.  B. Relative SLCO4C1 RNA expression.  cDNA from human kidney tissue 
(100→10-3) served as a positive control and samples were prepared in the dilutions 
indicated.  Bars are the mean ± SD of three replicate measurements of the same 
sample.  BLD = below limit of detection. 
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CHAPTER 5: Discussion 
A. Expression and functional role of Abcg2 in CIT3 cells 
Past efforts have focused on identification of the nitrofurantoin B→A active 
transport system in the CIT3 cell culture model system.  In stimulated CIT3 cells, Gerk et 
al. have previously shown nitrofurantoin active transport to be sodium dependent and 
inhibited by dipyridamole, adenosine, and guanosine [87].  Further, inhibition studies 
measuring radiolabelled nitrofurantoin B→A and A→B flux with and without 250 µM 
unlabelled nitrofurantoin on the basolateral, apical, and both sides suggested a 
basolateral localization of the unidentified transport process [88].  Recent data from the 
lab of Dr. Alfred Schinkel strongly implicate Abcg2 based on several observations:  
substantial upregulation of Abcg2 protein expression in mammary tissue in several 
species during lactation as determined by western blotting and immunohistochemistry 
[124]; nitrofurantoin is an Abcg2 substrate [53]; and perhaps most strikingly, by a study 
in Abcg2-/- mice that demonstrated a 76-fold decrease in the M/S ratio when the Abcg2 
gene was removed [53].  Dipyridamole is known to be an Abcg2 inhibitor [148], but 
Abcg2 is typically expressed on the apical membrane and ABC transporters are not 
sodium dependent.  Although Abcg2 is known to transport zidovudine [185,186], it is not 
known if the purines adenosine or guanosine can function as inhibitors.  The 
inconsistencies of these in vitro observations in CIT3 cells with that of the theory that 
Abcg2 is the unidentified process was the focus of Aims 1-3 of the current work.  The 
hypothesis put forth was that Abcg2 is responsible for the known B→A transport of 
nitrofurantoin in CIT3 cells.  
Abcg2 RNA transcripts and protein were detected in CIT3 cells by qPCR, 
western blotting, and immunofluorescence.  Consistent with the Abcg2 localization in 
other tissues, the Abcg2 expression in stimulated CIT3 cells was apical when visualized 
by confocal microscopy.  Interestingly, a significant upregulation of mRNA was not 
observed following the four days of lactogenic hormone stimulation.  Protein expression 
level was noticeable greater by immunofluorescence but was only marginally elevated 
when quantitated by Western blot.  Functionally, both conditions clearly showed a 
predominant apically-directed nitrofurantoin flux in snapwell assays, but the B→A 
permeability was slightly greater in stimulated vs. unstimulated cells.  This small, but 
significantly different, nitrofurantoin B→A permeability difference between stimulated and 
unstimulated cells was not the result of differences in tight junctions, as the graphs of 
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serial TEER measurements in both conditions were superimposable.  The B→A 
permeabilities achieved (stimulated, 68.0 ± 0.2 µL/h/cm2; unstimulated, 50.7 ± 5.6 
µL/h/cm2) were similar to that reported by Toddywalla et al. (stimulated, 64.5 ± 4 
µL/h/cm2 [86]) and Gerk et al. (stimulated, 70 ± 10.4 µL/h/cm2 or 90.5 ± 4.6 µL/h/cm2 
[87]) in the same cell line tested by similar methods.  A shorter duration of lactogenic 
hormone stimulation was used in the current work (4 days vs. 6-7 days in the literature).  
However, the greatly increased expression of the milk proteins, lactalbumin and β-
casein, suggests the duration of hormone exposure was sufficient for a lactogenic 
response.  Unpublished observations from the lab also indicate that the expression level 
of these two proteins is stable 4-8 days following stimulation of this cell line. 
The role that Abcg2 has in nitrofurantoin transport in CIT3 cells is confirmed by 
the observation that the predominant apically directed flux was ablated by the Abcg2 
inhibitor, FTC.  The B→A and A→B permeabilities of 10 µM nitrofurantoin collapsed to a 
common value in both unstimulated and stimulated cells in transwell flux experiments.  
Similar directionality and inhibition data with 2 µM PhIP further emphasizes the 
functional importance of Abcg2 in this system whether stimulated with lactogenic 
hormones or not.  Data with the Abcg2 substrate cimetidine, however, was not 
supportive.  Although some trends were demonstrated, statistically significant apically-
directed flux and inhibition with FTC was not seen.  The relative magnitude of the 
cimetidine permeability likely contributed to this finding as it is much smaller than that of 
nitrofurantoin and PhIP, nearing that typically achieved by a paracellular marker.  In this 
situation, it may take additional time to move enough mass for true differences in the 
permeabilities to be detectable.  The growth properties of the CIT3 cells likely compound 
this problem as these cells tend to form “domes” or “bumps” when grown for the long 
periods of time typically used in these experiments.  The areas where many cell layers 
exist rather than a simple monolayer function as an additional barrier to transcellular flux.   
Overall, the findings presented support the hypothesis put forth.  The molecular 
mechanisms for the sodium dependence and the greater inhibition of B→A nitrofurantoin 
flux with basolateral placement of 250 µM unlabelled nitrofurantoin previously observed 
by Gerk et al. [87,88], however, remain unclear.  It is possible that there exists a 
basolateral transport process that by itself does not play a substantial role, but together 
with Abcg2 forms a vectorial transport process.  Such interplay has been suggested to 
exist in the placental barrier with ABCG2 and SLCO2B1 [162].  SLCO2B1 is expressed 
in human mammary gland, but it is localized to the myoepithelial cells, not the luminal 
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mammary epithelial cells [112].  It is not known if any of the organic anion transporting 
polypeptides are expressed in CIT3 cells.  Transcripts for Slc22a1 (Oct1) were detected 
in both unstimulated and stimulated CIT3 cells and the localization of this transporter is 
basolateral in other tissues, but this transporter is known to be sodium independent and 
the concentrative transport of its prototypical substrate tetraethylammonium was not 
observed in CIT3 cells [105,187].  Gerk et al. also concluded from a series of purine and 
pyrimidine inhibition experiments that known sodium dependent nucleoside or 
nucleobase transporters were not involved [87].  Although this dissertation work clearly 
demonstrates that Abcg2 has role in the transport of nitrofurantoin in CIT3 cells, more 
work is necessary to elucidate the molecular basis for these observations.     
 
B. Creation of an ABCG2 stably transfected model system  
A large number of xenobiotics known to accumulate significantly in breast milk 
have recently been shown to be ABCG2 substrates [53,93,127].  The objective of this 
series of experiments was to create and validate an ABCG2-transfected cell system that 
could potentially be utilized to predict the extent of drug accumulation in vivo.   
The MDCKII parent cell line was selected after screening several candidates 
based on its extensive use in the published literature, ease of transfection and 
subsequent selection, ability to form a monolayer and tight junctions, and favorable 
background transporter gene expression.  Transcripts for the orthologs of human 
ABCB1, ABCC1, and ABCC2 in particular have been identified in these cells, but 
orthologs of human SLCO1A2, SLCO1B1, and most importantly ABCG2 were not 
detected [160,184].  Despite requiring more than one clonal selection step, ABCG2 was 
successfully stably transfected.  Western blot, flow cytometry, and confocal microscopy 
data together demonstrated good apical expression of the transporter.  Ten clones with 
various expression levels by Western blot of crude membrane fractions were cataloged 
and three, clones 40, 46, and 50, were further evaluated in surface expression and 
functional assays.  MDCKII-ABCG2 clone 40 clearly had the greatest surface expression 
as analyzed by flow cytometry with a MFIABCG2-Isotype of 196.8 versus 125.9 and 1.9 for 
clones 46 and 50 respectively.  The Hoechst 33342 efflux assays demonstrated 
equivalent ABCG2 functionality in clones 40 and 46 whereas clone 50 showed a much 
lower ability to efflux the dye as was expected based on its surface expression data.  
MDCKII-ABCG2 clone 40 was selected based on the belief that its high expression level 
133 
would be ideal to identify ABCG2-attributed transport phenomena.  The new ABCG2 
stably overexpressing model system was then validated with directionality and inhibition 
monolayer flux assays using several established ABCG2 substrates and inhibitors: 
nitrofurantoin, PhIP, cimetidine, methotrexate, and ciprofloxacin.   
The effect of ABCG2 transfection on the flux of 10 µM nitrofurantoin mimicked 
that observed by Merino et al. in their ABCG2 and Abcg2 transfected MDCKII cell lines 
[53].  The predominantly A→B directed flux in the empty vector transfected cells was 
reversed with the addition of ABCG2.  Both 1 µM GF120918 and 10 µM FTC blocked 
this affect, significantly decreasing the B→A flux attributed to ABCG2 by 85.5% and 
96.3%, respectively.   
Experimental estimates of initial flux rates of the ABCG2 substrate, PhIP, were 
more difficult to obtain.  So much of the mass that was initially placed on the donor side 
was transferred over the 4 hour experiment that the flux was only linear for the first 2 
datapoints.  Despite this sparse sampling, a large effect was again observed in the 
ABCG2-transfected cells as the B→A flux significantly increased and the A→B flux 
significantly decreased.  The ABCG2-attributed flux was completely inhibited with 10 µM 
FTC, but unlike with nitrofurantoin, 1 µM GF120918 had little effect.  A similar, but less 
obvious difference between the inhibitors was noted in a PhIP study by van Herwaarden 
et al. [128].  These investigators characterized the flux of a much higher concentration of 
PhIP (100 µM) in murine Abcg2 transfected LLC-PK1 cells and documented complete 
inhibition with the potent FTC derivative, Ko143, at 5 µM but only partial inhibition with 5 
µM GF120918.  Based on Michaelis-Menton enzyme kinetics, if it is assumed that 
ABCG2 has a single binding site, that both substrates (nitrofurantoin and PhIP) are 
tested at concentrations below their apparent Michaelis-Menton constant (Km) and that 
both inhibitors (GF120918 and FTC) are competitive, differences in the inhibitor 
concentration ([I]) divided by Michaelis-Menton inhibitory constant (Ki), ([I]/Ki), may 
explain some of these results.  Concentrations of GF120918 ranging from 0.1-10 µM 
[160,188-192] have been used in the literature to inhibit ABCG2 but the relative ABCG2 
Ki values of the GF1210918 and FTC have not been directly compared.  Allen et al. did 
study the ability of various inhibitors to increase the accumulation of 20 µM mitoxantrone 
in drug-resistant mouse MEF3.8/T6400 cells (which have elevated Abcg2), and found 
that Ko143 was 2- and 10-fold more potent than GF120918 and FTC, respectively [193].  
Extrapolating this data and the relative concentrations of FTC and GF120918 used in 
our experiments suggests that a greater inhibition would be expected with 10 µM FTC 
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than 1 µM GF120918 if studied with the same substrate, but it is less clear why 
GF120918 inhibited nitrofurantoin flux, but not PhIP flux when used at the same 
concentration.  An alternative explanation was put forth by Pozza et al. when they 
observed that 5 µM GF120918 had little effect on the binding of mitoxantrone to purified 
ABCG2; multiple distinct binding sites may exist for this transporter [194].  These 
observations are discussed further in the mathematical modeling section. 
Similar to nitrofurantoin, experiments involving cimetidine were as expected for 
an ABCG2 substrate.  At 5 µM, cimetidine flux was significantly increased in the B→A 
direction and decreased in the A→B direction in the ABCG2 transfectants relative to 
empty vector transfected controls and this directionality was completed ablated by both 
GF120918 and FTC.  These findings are similar to those observed by Pavek et al. with 
the ABCG2 and Abcg2 transfected MDCKII cells created by the lab of Alfred Schinkel, 
but are inconsistent with the cimetidine CIT3 data previously discussed [127]. The 
overall magnitude of the cimetidine flux in the MDCKII-ABCG2 cells was lower than that 
of nitrofurantoin and PhIP as was also noted in the CIT3 experiments.  The very high 
ABCG2 expression level driven by a constitutively active CMV promoter in this 
overexpressing system versus the low endogenous Abcg2 expression in CIT3 cells is a 
likely factor in the conflicting results. 
Methotrexate has been used as an ABCG2 substrate in membrane vesicle or 
cellular accumulation assays performed by many researchers, but monolayer flux data 
was not available in the literature [153,155,188,190,195].  The present work shows why; 
the permeability of this very hydrophilic compound across both the empty vector and 
MDCKII-ABCG2 cells was nearly equal to that of the paracellular marker sucrose.  
Interesting, clinical M/P data is available from a study conducted in 1972 by Johns et al. 
[196].  This study measured the M/P ratios at several timepoints following the oral 
administration of methotrexate to a single patient and found it to achieve a maximum of 
0.08.  The methotrexate n-butanol:water distribution ratios were also measured and 
found to be 0.02:1 at physiological pH.  The conclusion made by the authors that 
methotrexate is > 98% ionized and in a nondiffusable form and therefore not 
contraindicated in breastfeeding, is supported by the current observations in the in vitro 
system.  A significant difference in the B→A and A→B ABCG2-attributed permeability 
was observed, but was small and difficult to interpret as its magnitude in both conditions 
was less than that in the empty vector comparators.   
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The final ABCG2 substrate studied was the fluoroquinolone antibiotic, 
ciprofloxacin at 10 µM.  The addition of ABCG2 again generated directionality data that 
was similar to that of nitrofurantoin, PhIP, and cimetidine and was consistent with 
published data using the ABCG2 and Abcg2 transfected MDCKII cell lines created by 
the lab of Alfred Schinkel [93]. 
Overall, the results with the ABCG2 substrates tested were comparable to that 
observed with ABCG2/Abcg2 transfected cell lines established by other investigators.  
Methotrexate, however, performed poorly in this monolayer flux assay.  A wide range in 
the magnitude of the B→A and A→B permeabilities both in the empty vector and 
ABCG2 transfected cells was noted with the various substrates.  Studies using 
GF120918 and FTC at concentrations comparable to those used for ABCG2 inhibition by 
other investigators produced the expected results with the exception of the 
PhIP/GF120918 observation.  The mathematical modeling presented in the next section 
will explore alternative experimental measurements of ABCG2 functional activity in 
monolayer flux assays in an attempt to explain this observation and to provide guidance 
for future studies.  The successful creation of this ABCG2-transfected cell line will serve 
as a useful experimental tool for future work. 
 
C. Mathematical modeling and derivation of commonly used measurements of efflux 
activity. 
In a recent publication, Kalvass and Pollack, proposed a simple three-
compartment model (apical, cellular, and basolateral) to derive flux equations for the 
initial rate of flux and steady-state mass transfer in the presence or absence of active 
efflux [172].  This dissertation work extends this model to include the permeability-
surface area products for paracellular flux and the basolateral and apical endogenous 
transport processes that may be active in transferring substrates in either direction.  It 
then applies the new concepts derived to drug transfer into breast milk and explores the 
potential utility of the model for estimating the extent of drug accumulation into breast 
milk and its limitations.   
Exploring the model-derived theoretical limitations of the initial B→A and A→B 
rates when PSB,U, PSA,E, PSB,E, and PSA,U were equal to zero and PSPC was negligible 
was a useful exercise.  Eq. 4-1 (graphically depicted in Figure 4-26) and Eq. 4-2 
(graphically depicted in Figure 4-27) show that with increasing PSA,E(ABCG2) the initial 
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B→A and A→B rates achieve a maximum defined by CB 
0 PSD+PSPC  and a minimum 
defined by CA 
0 PSPC , respectively.  It is intuitive that differences in the permeability-
surface area product attributed to paracellular flux (PSPC) and passive diffusion (PSD) 
may produce differences in the measured permeabilities of different substrates.  PhIP 
had a greater MDCKII-ABCG2 B→A permeability than nitrofurantoin in the flux assays 
performed with the new ABCG2-transfected cell line presumably due to a greater PSD.   
The empty vector B→A permeabilities of these drugs followed the same pattern.  The 
A→B rates achieved by substrates such as cimetidine, methotrexate, and ciprofloxacin 
also appeared to achieve a minimum rate that is logically dependent on the leakiness of 
the cell monolayer (measured by the paracellular marker).  However, the observation 
that increases in PSA,E(ABCG2) do not linearly increase (or decrease) these initial rates is 
perhaps less obvious.  As shown by Eq. 3-8 and Eq. 3-11, neither initial rate is directly 
proportional PSA,E(ABCG2).  This has important implications for how data from experiments 
such as those performed with the MDCKII-ABCG2 model system (Aim 5) are analyzed 
and interpretted.  
Next, the theoretical limits of the efflux ratios, ERA and ERα, in a single apical 
efflux transporter system was explored when PSPC was assumed to be negligible.  As 
presented by Kalvass and Pollack, when PSA,E(ABCG2) >> PSD, an ERA upper limit of 2 is 
reached, but ERα remains proportional to PSA,E(ABCG2) [172].  The literature-derived flux 
rates from the cells created by the lab of Alfred Schinkel and permeability data from cell 
line created in Aim 4 supported these findings after substrates that were clearly affected 
by endogenous transport processes (ERα Empty ≠ 1) were removed from the analysis.  
Despite the likely error associated with manually extracting flux data from the published 
MDCKII-ABCG2/Abcg2 graphs in the literature, the maximum achieved apical efflux ratio 
in these cell lines and in the one created in Aim 4 agreed with the model.  The 
asymmetry efflux ratio spanned a much wider range, presumably reflecting the 
proportionality of ERα with PSA,E(ABCG2).  Many drugs had to be excluded from the 
analyses, however, based on an ERα Empty ≠ 1.  These observations served to 
invalidate the model assumption that no other endogenous transporter processes 
existed.  In order to use data from these drugs, the PSB,U, PSA,E, PSB,E, and PSA,U terms 
were allowed to remain in the equations and a new efflux ratio, the ERα Ratio, was 
derived in an attempt to isolate PSA,E(ABCG2) and preserve the proportionality.  In the ERα 
Ratio, the ERα of the ABCG2 transfected cells is normalized to the ERα of the empty 
vector transfected cells, theoretically removing the confounding effect of PSB,U, PSB,E, 
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and PSA,U processes.  Contributions of any potential PSA,E process to the ERα Ratio 
could not be removed.  Eq. 4-10 shows that any variability in the cell line PSA,E(ABCG2) and 
PSA,E (transporter expression levels) or a substrate’s ability to cross the membrane by 
passive diffusion (PSD) or to interact with either transport process (PSA,E(ABCG2) or PSA,E) 
would be expected to affect this ERα Ratio.  The effects of changes in PSD, PSA,E, and 
PSA,E(ABCG2) on ERA and the ERα Ratio were illustrated graphically in Figure 4-28.  ERA 
was included in these graphs despite its lack of direct proportionality with PSA,E(ABCG2) as 
it is commonly measured in the literature.   Increases in PSA,E or a higher relative 
substrate PSD lowers the maximal achievable ERA and blunts the ERα Ratio.  The ERA 
graph in Panel B of this figure is of particular interest as it may explain the lack of 
GF120918 inhibition of PhIP flux observation under Aim 5.  With the same Michaelis-
Menton assumptions made earlier (single binding site, competitive inhibitor, substrate 
concentration below Km), the addition of GF120918 would serve to effectively decrease 
PSA,E(ABCG2).  In the setting of a high expression level (high baseline PSA,E(ABCG2)), as was 
achieved in the MDCKII-ABCG2 clone 40 cells, this decrease may not result in a 
substantial change in ERA due to its nonlinear relationship with PSA,E(ABCG2).  It is 
therefore suggested that any application of Michelis-Menton principles to the transport 
phenomena be made using an experimental measurement that is directly proportional to 
PSA,E(ABCG2).  It is hypothesized that if ERα was measured in the PhIP flux assay, the 
expected GF120918 inhibition would have been observed. 
The initial assumption that PSD >> PSPC or that PSPC→0 was also shown to be 
invalid for the experimental data previously presented, as many of the paracellular 
marker permeabilities approximated that of the substrate studied concurrently.  
Increases in PSPC blunt both the ERA and the ERα Ratio, and of specific concern, cause 
the relationship between PSA,E(ABCG2) and ERα Ratio to become nonlinear as PSPC 
increases relative to PSD (as graphically depicted in Figure 4-29).  Eq. 4-12 and Eq. 4-13 
provide the theoretical basis for a solution, simply subtracting the apparent permeability 
of the paracellular marker from that of the substrate studied prior to calculation of the 
efflux ratio.  Although easy to implement experimentally, it relies on a currently untested 
assumption: that the PSPC of the paracellular marker being measured is equal to the 
PSPC of the drug being studied.  This subtraction increased nitrofurantoin’s ERα and ERα 
Ratio, markedly increased these efflux ratios for ciprofloxacin, and had little effect on 
cimetidine and PhIP.  The analysis of methotrexate could not be performed due to its 
very low permeability.  Large increases in ciprofloxacin efflux ratios were attributed to the 
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very small difference between the ABCG2 A→B and that of mannitol (in the 
denominator) and the relatively larger difference in ABCG2 B→A permeability (in the 
numerator).  The extreme variability in both the ciprofloxacin ERα and the ERα Ratio, 
estimated by calculating all possible combinations of the unmatched permeabilities that 
make up each ratio, decreases confidence in the accuracy of this measurement.   
To determine the potential relevance of this model and the utility of the new 
MDCKII-ABCG2 system for estimations of in vivo accumulation, several correlations 
were attempted.  The in vitro ERα and ERα Ratios were correlated with the ratio of the 
M/P ratios for the same drugs in wild-type versus Abcg2 knock out mice.  As an 
assumption of the ERα is that no endogenous transport processes exist, drugs for which 
ERα Empty ≠ 1 were included on the graphs, but excluded from the correlations.  At the 
outset, these correlations were not expected to perform well for several reasons.  The in 
vivo ratio of wild-type to Abcg2-/- M/P ratios obtained were not ideal, as each was 
calculated by the M/P point ratio method and were only available as the mean 
observations without any descriptor of variability.  The in vitro Schinkel cell line data that 
was extracted from the literature suffered similar problems due to the way it was 
obtained (extracted from graphs) and the lack of replicates.  The in vitro data generated 
in the current work was better in that it involved replicates, but only provided data for a 
handful of drugs.  None of the final correlations were overly impressive, but the ERα 
Ratio did seem to perform well for the drugs where the in vivo ABCG2-attributed effect 
was large (nitrofurantoin and riboflavin).  Ignoring the ciprofloxacin data due to its 
varibability, the final graph of the ERα Ratio incorporating the PSPC subtraction seems 
promising, as the rank order of ABCG2-attributed effect was the same in vivo and in 
vitro.  Much more data is needed to compare more appropriately the utility of the various 
efflux ratios to predict the ABCG2-attributed effect and extent of accumulation in vivo.  
Even if numerical correlations eventually fail to accurately predict the extent of drug 
accumulation in breast milk, these data show that in vitro assessment of a potential 
interaction with ABCG2 holds promise for categorical risk assessment. 
To make general recommendations for future work, several principles should be 
emphasized.  Monolayer flux assays with stably transfected ABCG2 overexpressing cell 
lines are attractive tools as they provide information involving both permeability and 
transporter interaction.  The Kalvass and Pollack publication emphasized the need to 
understand what is truly measured when flux rates, apparent permeabilities, or any one 
of the efflux ratios are reported.  As shown by the model, when performing in vitro and in 
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vivo M/S correlations with flux based assays, one needs to consider several variables in 
the vitro system: potential endogenous transporters (PSB,U, PSA,E, PSB,E, and PSA,U), 
PSPC, PSD, and PSA,E(ABCG2).  Different cell lines or the same cell line under varying 
growth conditions would be expected to have different values for each of these variables 
making comparisions challenging.  If drugs to be compared are studied in the same cell 
line under the same experimental conditions (expression level and experimental 
conditions assumed to be the similar), any variability in ERα or ERα Ratio would be 
expected to be due to differing substrate affinity for ABCG2 or PSD.  Even further, if the 
substrate affinity of two drugs is equivalent, they would still be expected to have different 
efflux ratios if they have different PSD.  PSD is not routinely measured and was not 
measured in the current work.  In a recent review paper, Xia et al. suggests that it should 
be measured from flux measurements conducted at 4°C (a temperature when 
transporters would not function) or in the presence of transporter inhibitors [197].  
Reversing the relationship shown on the right side of Figure 4-28 Panel B for the 
situation of constant PSA,E(ABCG2), Figure 5-1 shows the effect of differing PSD values at 
several different PSA,E(ABCG2) levels.  If PSPC is not neglible or not experimentally 
subtracted, one can see that at both high and low PSD values; it is difficult to see 
ABCG2-attributed effects.  Once PSPC is assumed to be zero or is experimentally 
subtracted, only very high PSD values obscure ABCG2-attributed effects.  This 
relationship suggests that if experiments with low permeability substrates were 
conducted long enough for sufficient mass transfer, a potentially large ABCG2-attributed 
effects could be measured.  Work presented with methotrexate and ciprofloxacin 
underscore the difficulty in accurately measuring flux at minimum permeabilities.  It 
simply may not be possible or practical to conduct experiments for the requisite time 
needed for accurate measurements.  As this relationship shows, it is also difficult to 
distinguish the contribution of PSA,E(ABCG2) for drugs with high flux rates; selecting clones 
with lower expression levels may actually improve the ability to measure the ABCG2-
attributed effect as the PSA,E(ABCG2)/PSD ratio would decrease and improve the dynamic 
range of the possible efflux ratios.  Lower expressing MDCKII-ABCG2 clones were 
identified during development of the model system and are available for future work to 
explore these relationships.   
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Figure 5-1: Effect of variable PSA,E(ABCG2) values on the relationship between PSD and the 
ERα Ratio with and without PSPC. 
Effect of different PSA,E(ABCG2) values ranging from 0 to 20 on the relationship between 
PSD and the ERα Ratio.  Left. PSPC was set to 0.1.  Right. PSPC was set to 0.  Arrows 
depict the changes in ERα Ratio with increasing PSD.  PSA,E was set at 0 in both cases.   
 
 For in vitro data to truly be able to estimate the extent of in vivo accumulation, the 
ratio of the permeability-surface area product terms (eg. PSA,E(ABCG2) to PSD) and 
clearance terms (eg. ClA,E(ABCG2) to ClD) should be roughly equivalent.  It is typically 
assumed that the in vitro and in vivo transporter substrate affinities are similar, but the 
other factor making up PSA,E(ABCG2) is transporter expression level.  In the course of 
validating in vitro methods for prediction, transporter expression levels should be 
quantified and any potential day to day variability in expression level be controlled or 
corrected.  Finally, when applying this kinetic model to experimental observations, 
investigators must be particularly mindful of several of its assumptions; that no unstirred 
water layers exist, that no intercellular metabolism or binding occur, and that all 
permeability-surface area products remain constant.  Violations of any of these 
assumptions could yield unexpected results. 
  
D. Microarray expression profiling of transporter gene expression in murine 
developmental datasets 
Knowledge of which xenobiotic transporters are of importance during lactation is 
incomplete.  The literature includes studies focused on individual transporters or 
organism-wide screens of gene expression in multiple tissues that happens to include 
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the mammary gland.  As discussed previously, these data are either too limited in scope 
to provide a complete picture or are of questionable usefulness as the data often comes 
from nonlactating tissue that may not be representative of the lactating condition.  The 
identification of xenobiotic transporters that are highly expressed during lactation 
specifically may identify those of functional relevance for xenobiotic exposure.  
Fortunately, three existing datasets (Stein et al., Clarkson et al., and Medrano et al.) 
were available in public repositories [174-176].  The objective of this first experiment was 
to mine these data to identify murine xenobiotic transporters that were differentially 
expressed (upregulated) during lactation using microarray analysis.  The pooling of the 
Affymetrix Mu74v2A GeneChip® Array data from the 3 independent experiments into a 
lactating and nonlactating group increased power without introducing significant bias 
between the datasets as shown by the signal intensity correlations.  Unfortunately, only 
a small fraction of the genes of interest were actually detectable by this older chip (Table 
3-2).  A conservative method of analysis was chosen, only eliminating probesets from 
the analysis if the detections calls of all 15 samples in the lactating group were labeled 
“Absent”.  Despite this approach, only 8 xenobiotic transporter genes were detected in 
the mouse mammary gland homogenates during lactation.  Abcg2, Slc22a1, Slc15a2, 
Slc29a1, Slc16a1, and Abcc5 were upregulated, Slc23a2 was present but not 
differentially regulated, and Slc22a5 was downregulated during lactation.  Abcg2, 
Scl22a1, and Slc15a2 were the most substantially upregulated with 20-, 10-, and 4-fold 
higher expression during lactation in the pooled data, respectively.  These overall results 
were remarkably consistent with existing literature [49,110,116].  The Stein et al. [176] 
dataset showed the most visually striking patterns of apparent lactation-specific 
developmental regulation of these transporters as shown in Figure 4-33.  Although 
certainly useful information, the small number of genes detectable by this chip and the 
fact that the tissue samples were from whole gland homogenates rather than LMECs are 
limitations of these data. 
 
E. Identification of xenobiotic transporters highly expressed in human LMEC clinical 
samples  
The identification of all xenobiotic transporters in LMECs is necessary to improve 
M/S predictive models and to determine the drugs for which an active transport 
mechanism governs transfer into breast milk.  The comparison of the RNA transcript 
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levels of 30 transporter genes in human LMECs and MECs produced in our lab by 
Alcorn et al. in 2002 remains the most robust investigation of mammary gland xenobiotic 
transporter gene expression [49].  The immunomagnetic separation procedure used 
produced highly purified populations of luminal mammary epithelial cells using 
Dynabeads®, but unfortunately required the pooling of the several breast milk or 
reduction mammoplasty specimens to assure adequate RNA for the single (n=1 in each 
group) qPCR comparison.  Although the methodology did not allow for biological 
replicates, each sample was normalized to the β-actin expression in the pool to control 
for potential processing variability.   The small amount of RNA collected also limited the 
number of genes that could be analyzed and together with the time-consuming nature of 
qPCR, precluded a complete investigation of the expression level of all known xenobiotic 
transporters.  The omission of ABCG2 provides a good example of potential 
consequences having to limit the numbers of transporters studied with this methodology. 
The current work aimed to expand this work through the development of a more 
robust method to isolate pure populations of luminal mammary epithelial cells from 
breast milk or reduction mammoplasty tissue.   The goal was to isolate a large enough 
pure population of cells to provide sufficient RNA for the microarray analysis of biological 
replicates, as the new arrays allowed for quantification of all known human xenobiotic 
transporters on a single chip.  Initially, the EasySep® immunomagnetic nanoparticle 
system was tried with a novel murine anti-MUC1 (clone 214D4) antibody as the system 
was incompatible with the rat antibody used previously.  The nanoparticles provided a 
theoretical benefit, as poor affinity to luminal cells and steric hindrance have been 
suggested in the literature as the cause of low yields with the Dynabead® method [182].  
The end result of rigorously testing this new immunomagnetic nanoparticle system was 
that the new antibody did not have the correct specificity for luminal mammary epithelial 
cells.  Purification of LMECs through macrophage depletion by glass adherence has 
been reported in the literature, but this technique only moderately enriched LMEC 
populations (average 65% pure) so this method was not attempted [198].  Flow 
cytometry had produced highly purified populations as early as 1991, but low yields (less 
than 1 x 105 per sample) were commonly reported in these early studies [181,199].  A 
more recent study by Clayton et al. had greater success, so this method was tested 
[180].  The optimized FACS-based method eventually developed (using solely the 
original EMA/MUC1-selective (MFGM/5/11[ICR.2]) antibody to positively sort cells) 
enriched LMECs and MECs to greater than 99% purity as measured by 
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immunocytostaining.  The approach was also sufficiently robust as at least 1 x 105 
(upwards to 3.5 x 106) cells were typically obtained from a single sample. 
 Successful development of this method allowed for the clinical study to 
commence.  The number of subjects and number of samples required from each subject 
to obtain the requisite RNA for microarray was greater than expected, but the 
methodology was successful as greater than 2 µg of high quality RNA was obtained from 
each patient.  The percentage of total cells in each sample that were sorted as luminal 
mammary epithelial cells ranged from 7.8 – 29.7%.  These percentages are slightly 
lower than the 20 – 40% reported in the literature; likely due to the high stringency of the 
sort parameters used in this study [180-182]. 
Microarray signal intensity correlations showed that signal concordance of chips 
within the same group was greater than those in different groups and that the MEC and 
LMEC chips were more highly correlated with one another than with chips from a 
different tissue.  Probesets for all 52 genes of transporter genes of interest were present 
on the Affymetrix U133 plus 2.0 GeneChip® Array, but only 25 genes were detectable in 
at least one of the LMEC samples.  The final results of screening paradigm (Figure 3-5) 
are presented in Table 4-9.  ABCG2, SLC15A2, SLC22A12, SLC6A14, AND SLCO4C1 
are of particular interest as they were significantly upregulated during lactation.  Other 
transporters, such as ABCC10, SLC10A1, SLC16A1, SLC22A4, SLC22A5, SLC22A9, 
SLC28A3, SLC29A1, SLC29A2, and SLCO4A1 were also identified by the screening 
paradigm as their expression level was similar to levels in other secretory tissues.  The 
individual findings are put in the context of current knowledge below. 
The substantially higher (164-fold) ABCG2 expression in LMECs during lactation 
mirrors that observed in the murine developmental dataset (20-fold) and underscores the 
major role ABCG2 plays in drug transfer into breast milk.  An appreciation of potential 
substrate interactions with this transporter is of vital importance for estimating the extent 
of drug accumulation in breast milk.  In CIT3 cells, the current work showed that 
lactogenic hormones only slightly increased Abcg2 protein expression (Aim 1), but a 
basal transport function was still observed (Aim 2).  Jonker et al. reported, however, that 
in vivo, ABCG2 expression substantially increased in murine whole tissue homogenates 
during lactation [124].  It was therefore unclear as to whether ABCG2 is upregulated 
within individual LMECs during lactation or if expression is constant and mammogenesis 
causes the expansion of this cell type relative to others within the mammary gland 
resulting in a higher level in the whole tissue homogenate.  This microarray expression 
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data proves Hypothesis 3b, that it is the expression level within individual LMECs that 
significantly increases during lactation.  
The discovery that SLCO4C1 is expressed in human LMECs and that it is 
upregulated substantially during lactation (70-fold by microarray) are novel findings of 
this work.  Very little is currently known about this transporter.  Mikkaichi et al. originally 
identified it in 2004 using a human kidney cDNA library and also found it expressed in 
the rat kidney [200].  OATP4C1 is the first member of the organic anion transporting 
polypeptide family found expressed in human kidney and has been localized to the 
basolateral membrane of the proximal tubule.  Substrates include the cardiac glycosides 
(digoxin and ouabain), thyroid hormones (T3 and T4), cAMP, methotrexate, and 
sitagliptin [200,201].  The physiological role of SLCO4C1 is unknown, but it has been 
suggested that it may work in a concerted effort with P-glycoprotein to eliminate 
xenobiotics like digoxin in the nephron.  The ABCG2 apical and potential SLCO4C1 
basolateral localization and significant upregulation of both transporters in the same cells 
during lactation leads to the interesting possibility that they also may function in concert 
to create a vectorial transport system in the mammary gland.  More work is necessary to 
confirm SLCO4C1 localization in the mammary gland and to determine if drugs that are 
known to significantly accumulate in breast milk, such as nitrofurantoin, are substrates.   
 The higher SLC15A2 expression in LMECs is consistent with data from the 
murine developmental data and the literature.  Alcorn et al. detected this transporter in 
their pooled human LMEC sample but not in the MEC comparator [49].  Groneberg et al. 
also detected it in human LMECs and localized SLC15A2 to the ductal epithelium of rat 
mammary tissue [116].  These investigators proposed a role of SLC15A2 in the high-
affinity low-capacity apical uptake of peptides from breast milk.  The localization and 
directionality of this transport system suggests it is involved in scavenging peptides from 
milk and that it may function to limit infant exposure to substrates such as 
aminopenicillins and angiotensin converting enzyme inhibitors. 
 The neutral and cationic amino acid transporter SLC6A14 was also expressed in 
LMECs at a higher level than in MECs.  Similar to ABCG2 and SLCO4C1, its expression 
in LMECs was also higher than that in liver and kidney compactors.  Kwok et al. 
detected SLC6A14 at the RNA level in human mammary tissue and through uptake 
studies with MCF-12A cells, proposed that it may have a role in carnitine transport  [81].  
The localization of SLC6A14 is unknown in the mammary gland; however, Hatanka et al. 
have determined it is expressed apically in the mouse colon, lung, and eye [202].  
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Transport appears to bidirectional and is dependent on sodium and chloride gradients 
[113]. 
 SLC22A12 is the final transporter that had a significantly higher expression level 
in LMECs vs. MECs in the microarray analysis.  No mammary gland expression data 
currently exists in the literature.  Its known physiological function involves the renal 
reabsorption of urate at the proximal tubule cell apical membrane in exchange for the 
secretion of anions [105].  
In reviewing the transporters identified by the screening paradigm for having an 
expression level equivalent to or greater than liver or kidney and comparing the results 
to Alcorn et al. and the murine developmental dataset (Aim 8), some other findings are 
worth noting.  Although SLC22A1 was upregulated over 7-fold in the Alcorn et al. study 
and over 10-fold in the developmental dataset, its detection call was labeled “Absent” in 
all three LMEC samples in the current study.  SLC22A4, SLC22A5, SLC29A1, and 
SLCO4A1 were present in LMECs in both human investigations.  Despite a much higher 
expression of SLC28A3 in the previous work from our lab, no differences were detected 
between LMEC and MEC sample means in the current work.  SLC16A1 expression 
increased during lactation in the mouse, but no changes were evident in this new human 
data.  The datasets were in agreement regarding P-glycoprotein (ABCB1) and the 
organic anion transporters (SLC22A6-8) as they were either not present or expressed at 
a very low level during lactation.   
Overall, the results were in good agreement with the literature and the screening 
paradigm did identify transporters currently known to be responsible for drug 
accumulation in breast milk, thereby supporting Hypothesis 3a.  To summarize this large 
amount of microarray data, a diagram of xenobiotic transporter gene expression in 
LMECs that incorporates localization and directionality data where available and 
emphasizes those transporters upregulated during lactation was created (Figure 5-2).  
As depicted, many combinations of basolateral and apical transporters may work in 
concert to move xenobiotics across the LMEC barrier towards either breast milk or the 
maternal circulation to drive exposure risk.  The SLCO4C1 observation is the most 
interesting finding, as it hints at an existence of an undiscovered vectorial pathway with 
ABCG2 for substrate movement into milk.  Other such pathways have been proposed to 
exist in other tissues such as the placental trophoblast, intestine, kidney, liver, and 
blood-brain barrier and are the current focus of intensive  research and a recent review 
by Ito et al. [203]. 
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Limitations to this clinical study include the small sample size and variability in 
lactation stage (postpartum week) of the breastfeeding subjects.  Intrapatient (eg. 
transporter expression level changing with lactation stage) or interpatient differences 
(eg. due to previous breastfeeding, ethnicity, or age) may exist and affect xenobiotic 
exposure risk but were not well captured or compared in this small study.  Perhaps even 
more importantly, it is not currently known if these observations at the RNA level 
translate into similar expression level differences and functional consequences.  Future 
studies should tackle these issues as well as explore the role and significance of 
SLCO4C1 in LMEC cells.  The FACS-based LMEC isolation technique developed and 
validated in Aim 9 could measure transporter protein surface expression level with 
relatively small cell numbers if appropriate antibodies were available.  The single ABCG2 
transfection system created in Aim 4 could be also particularly useful as it may lay the 
groundwork for the creation of a SLCO4C1/ABCG2 double transfection system.  Such a 
system would be invaluable to study the postulated vectorial process and its functional 
consequences for xenobiotic accumulation in breast milk.  
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Figure 5-2: Proposed model of xenobiotic transport in LMEC based on microarray 
expression data with localization and directionality derived from the published literature. 
Panel A. Xenobiotic transporters that were upregulated during lactation with fold change 
from the microarray analysis.  Panel B. Xenobiotic transporters that were expressed at a 
level equivalent to, or greater than, that in the liver or kidney.  Localization and 
directionality was speculated based on information from other tissues.  If data was 
inconclusive, the transporter is labeled with an asterisk. 
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CHAPTER 6: Conclusions 
This dissertation work focused on three unresolved issues regarding drug 
transport into breast milk during lactation: (1) determining if Abcg2, recently identified as 
having a major role in drug accumulation in breast milk, is the molecular cause of the 
apically-directed nitrofurantoin flux in CIT3 cells, a commonly used in vitro cell culture 
model of lactation; (2) developing a mathematical model to aid in understanding of the 
individual processes that determine xenobiotic flux rates across the mammary barrier, 
steady-state concentrations, and calculated M/S ratios in order to improve the utility of 
experimental flux assays; and (3) identifying the subset of all known xenobiotic 
transporters that are highly expressed, and therefore potentially clinically relevant, during 
lactation in mice and humans. 
Breastfeeding is widely advocated as the best nutritional choice for infants, their 
mothers, and society [1-3].  Medication use, however, is highly prevalent in the post-
partum period and puts patients and health care professions in the difficult position of 
weighing maternal benefit and potential exposure risks to the suckling infant [41].  The 
majority of xenobiotics enter breast milk by passive diffusion and mathematical models 
based on this concept perform well for most drugs, but fail to predict the M/S ratio of 
xenobiotics that accumulate via active transport [49-53].  Apically-directed nitrofurantoin 
transport was observed in the CIT3 cell culture model of lactation and clinically this drug 
was found to concentrate in breast milk.  In CIT3 cells, the transport process was 
sodium-dependent, inhibited by dipyridamole, and believed to be localized to the 
basolateral membrane, but remained unidentified [88].  Recent literature clearly 
demonstrates that ABCG2, is responsible for the accumulation of nitrofurantoin and 
many other drugs in murine breast milk [53,91-93].  The current work was designed to 
determine if Abcg2 is responsible for CIT3 cell observations. Abcg2 RNA transcripts 
were detected and the protein was found apically expressed in CIT3 cells.  Abcg2 was 
further demonstrated to be responsible for the directional flux of nitrofurantoin and other 
Abcg2 substrates such as PhIP, cimetidine, and ciprofloxacin through inhibition studies 
with the Abcg2-specific inhibitor FTC.  Interestingly, the transport was observed both 
with and without the lactogenic hormone stimulation that was presumed necessary in the 
cell culture model of lactation.  Some inconsistencies with past observations remain 
(sodium dependence and enhanced inhibition when inhibitors are placed on the 
basolateral side) and suggest other transport processes may also be present. 
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Knowledge of a xenobiotic’s potential interaction with ABCG2 may help improve 
in vitro M/S predictions.  With this goal in mind, the stable transfection of ABCG2 into a 
cell line that would be suitable for monolayer flux assays was performed.  A MDCKII-
ABCG2 clone with high expression was chosen and validated with a series of ABCG2 
substrates and the inhibitors GF120918 and FTC.  Data was as expected with 
nitrofurantoin, cimetidine, and ciprofloxacin with the ABCG2-attributed effect significantly 
altering both the B→A and A→B permeabilities, but results with PhIP and methotrexate 
were more difficult to explain.  PhIP flux was predominantly apically directed and was 
ablated with 10 µM FTC, but was not affected by the addition of 1 µM GF120918.  
Methotrexate monolayer flux assays failed due to passive permeability issues.  To help 
explain these results and to provide a greater understanding of the rate processes, a 
new mathematical model was put forth.  A simple three compartment model 
incorporating several permeability surface area products: PSB,U, PSA,E, PSB,E, and PSA,U, 
PSPC, PSD, and PSA,E(ABCG2) was developed as an extension of the work of Kalvass and 
Pollack [172].  Derivations demonstrated that ERA was not proportional to PSA,E(ABCG2) 
and had a maximal value of 2.  ERα remained proportional to PSA,E(ABCG2) if PSPC was 
assumed to be negligible.  If endogenous transport process existed in the model, it was 
theoretically shown that the ERα Ratio is useful as it better preserves the proportionality 
to PSA,E(ABCG2).  Overall increases in PSA,E or a higher relative substrate PSD lowers the 
maximal achievable ERA and blunted the ERα Ratio.  A nonzero PSPC was also shown to 
blunt these ratios and cause nonlinearity in the relationships.  Data extracted from the 
literature and from the validation of the MDCKII-ABCG2 cell line supported the 
mathematically derived principles.  Correlations with the in vitro efflux ratios from these 
datasets and the ratio of the milk to plasma ratios in the wild-type and Bcrp1-/- mice 
were performed.  Although most were not significant due to the quality and amount of 
the data available, ERα Ratio showed some promise as the in vitro and in vivo rank order 
of the tested substrates was similar.  Much more work is required to demonstrate the 
utility and understand the limitations of this new model and the model-derived efflux 
ratios.   
In addition to ABCG2, the expression of other members of the SLC and ABC 
transporter superfamilies has been documented in mammary tissue from a variety of 
species but interpretation is complicated as expression data is often from nonlactating 
tissues and/or whole tissue homogenates rather than LMECs.  The qPCR analysis of the 
expression of 30 transporters generated by Alcorn et al. in our lab remains the most 
150 
robust investigation of mammary xenobiotic transporter gene expression [49].  The utility 
of this study is limited however by its lack of biological replicates and the incomplete list 
of transporters chosen for analysis (ABCG2 was not investigated).  To address evaluate 
the hypotheses that microarray analysis could identify transporters known to accumulate 
in milk, xenobiotic transporters that were upregulated during lactation were first identified 
in three murine mammary gland developmental datasets obtained from the literature.  
The transporters identified as upregulated during lactation was remarkably consistent 
with the literature and included Abcg2, Slc22a1, Slc15a2, Slc29a1, Slc16a1, and Abcc5.  
Next, this experimental paradigm was translated to humans and the work of Alcorn et al. 
was extended through the development of a new robust method to pure populations of 
luminal mammary epithelial cells from breast milk or breast reduction mammoplasty 
samples.  Microarray expression profiling on the biological replicates (n=3 LMEC and 
n=3 MEC samples) was then performed to measure the expression level of all known 
human xenobiotic transporters.  The first step of the two step screening paradigm 
identified ABCG2, SLC15A2, SLC22A12, SLC6A14, AND SLCO4C1 as xenobiotic 
transporters of potential importance as they were significantly upregulated during 
lactation.  This ABCG2 data addresses an unanswered question in literature by 
documenting that it is the expression level within individual LMECs that significantly 
increases during lactation not that the ABCG2 expression is constant in LMECs and that 
mammogenesis causes the expansion of this cell type relative to others within the 
mammary gland.  The second step identified ABCC10, SLC10A1, SLC16A1, SLC22A4, 
SLC22A5, SLC22A9, SLC28A3, SLC29A1, SLC29A2, and SLCO4A1 as also of potential 
interest as their expression level was similar to, or greater than, levels in the kidney or 
liver.  Overall, the significant upregulation of SLCO4C1 (increased 70-fold) is the most 
interesting finding in this study, as this novel observation suggests that a vectorial 
pathway with ABCG2 (increased 164-fold) for substrate movement into milk may exist.  
Future studies will explore the role and significance of SLCO4C1 in LMEC cells. 
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APPENDICES  
Appendix 1: List of Abbreviations  
A membrane surface area 
ABC ATP-binding cassette transporter superfamily 
AUC area under the concentration-time curve 
C0 initial concentration 
CA concentration in the apical (milk) compartment 
CB concentration in the basolateral (serum) compartment) 
CC concentration in the cellular (LMEC) compartment 
Cinfant,serum infant serum concentration 
Clinfant infant systemic clearance  
Cmaternal maternal serum concentration 
Cmilk, unbound unbound concentration in the milk 
Cserum, unbound unbound concentration in the serum 
DAPI 4',6-diamidino-2-phenylindole 
DMSO dimethyl sulfoxide 
ERA apical efflux ratio; the ratio of the initial rate of B→A flux when all active 
transport processes are not inhibited divided by the initial rate of B→A 
flux when all active transport processes are inhibited completely 
ERα asymmetry efflux ratio; ratio of the initial rate of B→A flux divided by the 
initial rate of A→B flux 
ERα Ratio ratio of asymmetry efflux ratio; ratio of the ERα in ABCG2-tranfected cells 
to the ERα of the empty vector transfectants 
FACS fluorescence-activated cell sorting 
Finfant infant bioavailability  
FITC fluorescein isothiocyanate 
fm fraction protein bound in the milk  
fs fraction protein bound in the serum  
FTC fumitremorgin C 
fm
un fraction of the drug unionized in the milk  
fs
un fraction of the drug unionized in the serum  
HBSS Hanks balanced salt solution 
IRB institutional review board 
J flux 
LMEC lactating luminal mammary epithelial cell 
Km Michaelis-Menton constant 
Ki Michaelis-Menton inhibitory constant 
M/P milk to plasma ratio 
M/S milk to serum ratio 
M/Spoint milk to serum point ratio  
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MEC nonlactating luminal mammary epithelial cell 
MFI mean fluorescence intensity 
MUC1 epithelial basement membrane antigen 
Papp apparent permeability  
PBS phosphate-buffered saline 
PDR Physicians Desk Reference 
PE phycoerythrin 
PI propidium iodide 
PSA,E permeability-surface area product attributed to passive apical efflux 
PSA,E(ABCG2) permeability-surface area product attributed to passive the transfected 
transporter ABCG2 
PSA,U permeability-surface area product attributed to passive apical uptake 
PSB,E permeability-surface area product attributed to passive basolateral efflux 
PSB,U permeability-surface area product attributed to passive basolateral uptake
PSD permeability-surface area product attributed to passive diffusion across 
the LMEC basolateral and apical membranes 
PSPC permeability-surface area product attributed to passive paracellular flux 
between the cells 
qPCR quantitative PCR 
RIN RNA integrity number 
Sk fat partitioning into skim milk 
SLC solute carrier transporter superfamily 
TEER transepithelial electrical resistance  
Vmilk/τ milk consumption rate 
W fat partitioning into whole milk 
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Appendix 2: Chemical Structures  
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Appendix 3: Mathematical model derivation – Drug transfer from serum into milk with 
active uptake and efflux in the basolateral and apical membranes. 
The following is the expanded derivation of the mathematical model for active 
flux from serum into milk with active uptake and efflux in the basolateral and apical 
membranes of LMECs presented in the Methods and Results.  Equations are numbered 
sequentially with any cross-reference to the aforementioned sections noted in 
parenthesis.  
 
Simple kinetic model for flux across a LMEC monolayer (Figure 3-2). 
 
The model incorporates the permeability-surface area products attributed to: 
- PSPC: passive paracellular flux between cells 
- PSD: passive diffusion across the LMEC basolateral and apical membranes 
- PSB,U: basolateral uptake 
- PSB,E: basolateral efflux 
- PSA,U: apical uptake 
- PSA,E: apical efflux 
Assumptions: 
- 3 compartments, all well-stirred. 
- passive diffusion across the basolateral and apical membranes is equal. 
- no protein binding, ionization, or fat partioning phenomena exist. 
- unstirred water layers are negligible. 
- permeabilities are constant. 
Basolateral Cellular Apical 
PSD 
PSB,U 
PSD
PSA,E 
PSA,UPSB,E 
PSPC
Serum LMEC Milk 
B C A 
Tight 
Junction
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Substrate flux into and out of the basolateral (serum) compartment: 
 dXB
dt
 = CC PSD+PSB,E - CB PSD+PSB,U + CA-CB PSPC 
Eq. A-1 
(Eq. 3-3)
Substrate flux into and out of the cellular (LMEC) compartment: 
 dXC
dt
 = CA PSD+PSA,U  + CB PSD+PSB,U - CC 2PSD+PSA,E+PSB,E  
Eq. A-2 
(Eq. 3-4)
Substrate flux into and out of the apical (milk) compartment: 
 dXA
dt
 = CC PSD+PSA,E - CA PSD+PSA,U + CB-CA PSPC 
Eq. A-3 
(Eq. 3-5)
 
Initial rate: B→A 
With initial unidirectional flux into the apical compartment (CA = 0), Eq. A-3 becomes: 
 dXA,B→A
dt
=CC PSD+PSA,E +CBPSPC Eq. A-4 
and assuming rapid equilibration between the B and C compartments (dXC/dt = 0) Eq. A-
2 can be rearranged to yield:  
 CC=
CB PSD+PSB,U
2PSD+PSA,E+PSB,E
 Eq. A-5 
Substitution of Eq. A-5 into Eq. A-4 yields: 
 
dXA,B→A
dt
 = CB 
0 PSD+PSB,U PSD+PSA,E
2PSD+PSA,E+PSB,E
+PSPC  Eq. A-6 (Eq. 3-6)
In the absence of both active uptake into and efflux out of the cell (PSB,U, PSA,E, PSB,E, 
and PSA,U = 0), (eg. parent cell line with no endogenous transporter expression): 
 
dXA,B→A
dt parent
 = CB 
0 PSD
2
+PSPC  
Eq. A-7 
(Eq. 3-7)
In a single apical efflux transporter transfected cell line (like the MDCKII-ABCG2 cells 
created in Section C), the addition of PSA,E(ABCG2)  into a parent cell line with no 
endogenous transporter expression yields: 
 
dXA,B→A
dt ABCG2
 = CB 
0 PSD PSD+PSA,E(ABCG2)
2PSD+PSA,E(ABCG2)
+PSPC  
Eq. A-8 
(Eq. 3-8)
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Initial rate: A→B  
With initial unidirectional flux into the apical compartment (CB = 0), Eq. A-1 becomes: 
 dXB, A→B
dt
=CC PSD+PSB,E +CAPSPC Eq. A-9 
and assuming rapid equilibration between the A and C compartments (dXC/dt = 0), Eq. 
A-2 can be rearranged to yield:  
 CC=
CA PSD+PSA,U
2PSD+PSA,E+PSB,E
 Eq. A-10
Substitution of Eq. A-10 into Eq. A-9 yields: 
 
dXB, A→B
dt
 = CA
0 PSD+PSA,U PSD+PSB,E
2PSD+PSA,E+PSB,E
+PSPC  
Eq. A-11
(Eq. 3-9)
In the absence of both active uptake into and efflux out of the cell (PSB,U, PSA,E, PSB,E, 
and PSA,U = 0), (eg. parent cell line with no endogenous transporter expression): 
 
dXB, A→B
dt parent
 = CA 
0 PSD
2
+PSPC  
Eq. A-12
(Eq. 3-10)
In a single apical efflux transporter transfected cell line (like the MDCKII-ABCG2 cells 
created in Section C), the addition of PSA,E(ABCG2)  into a parent cell line with no 
endogenous transporter expression yields: 
 
dXB, A→B
dt ABCG2
 = CA 
0 PSD 2
2PSD+PSA,E(ABCG2)
+PSPC  
Eq. A-13
(Eq. 3-11)
 
Apical efflux ratio: ERA 
The apical efflux ratio, ERA, is defined as the ratio of the initial rate of B→A flux when all 
active transport processes are not inhibited (Eq. A-6) divided by the initial rate of B→A 
flux when all active transport processes are inhibited completely (Eq. A-7): 
 ERA=
dXA,B→A
dt
dXA,B→A
dt inhibited
 = 
CB 
0 PSD+PSB,U PSD+PSA,E
2PSD+PSA,E+PSB,E
+PSPC
CB 
0 PSD
2 +PSPC
 
Eq. A-14
(Eq. 3-12)
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If we assume PSD >> PSPC or that PSPC→0, ERA reduces to: 
 ERA=
dXA,B→A
dt
dXA,B→A
dt inhibited
 = 
2 PSD+PSB,U PSD+PSA,E
PSD 2PSD+PSA,E+PSB,E
 Eq. A-15(Eq. 3-13)
The ERA for the transfection of the single apical efflux transporter ABCG2 into the parent 
cell line with no background endogenous transporter expression (Eq. A-8 divided by Eq. 
A-7), is: 
 ERA=
dXA,B→A
dt ABCG2
dXA,B→A
dt parent
 = 
CB 
0 PSD PSD+PSA,E(ABCG2)
2PSD+PSA,E(ABCG2)
+PSPC
CB 
0 PSD
2 +PSPC
 Eq. A-16
If the same assumption regarding PSPC is made, relationship reduces to: 
 ERA= 
2 PSD+PSA,E(ABCG2)
2PSD+PSA,E(ABCG2)
 Eq. A-17(Eq. 3-14)
If PSA,E(ABCG2) >> PSD) an ERA upper limit of 2 is reached as shown by Kalvass et al. 
[172]. 
 lim
PSA,E ∞
ERA,ABCG2
parent
 =  2 Eq. A-18Eq. 4-3 
 
Asymmetry efflux ratio: ERα 
The asymmetry efflux ratio, ERα, is defined as the ratio of the initial rate of B→A flux (Eq. 
A-6) divided by the initial rate of A→B (Eq. A-11): 
 ERα
dXA,B→A
dt
dXB,A→B
dt
CB 
0 PSD+PSB,U PSD+PSA,E
2PSD+PSA,E+PSB,E
+PSPC
CA 
0 PSD+PSA,U PSD+PSB,E
2PSD+PSA,E+PSB,E
+PSPC
 Eq. A-19(Eq. 3-15)
If we assume the initial donor concentrations in the basolateral and apical compartments 
are equal experimentally (CB 
0 CA
0 ), and that PSPC is negligible (PSPC→0), the equation 
can be simplified to: 
 ERα=
PSD+PSA,E PSD+PSB,U
PSD+PSA,U PSD+PSB,E
 Eq. A-20(Eq. 3-16)
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The ERα for the transfection of the single apical efflux transporter ABCG2 into the parent 
cell line with no background endogenous transporter expression (Eq. A-8 divided by Eq. 
A-13), is: 
 ERα
dXA,B→A
dt ABCG2
dXB,A→B
dt ABCG2
CB 
0 PSD PSD+PSA,E(ABCG2)
2PSD+PSA,E(ABCG2)
+PSPC
CA 
0 PSD 2
2PSD+PSA,E(ABCG2)
+PSPC
 Eq. A-21
If the same assumption regarding PSPC and the initial concentrations (CB 
0 CA
0 ) is 
made, relationship reduces to: 
 ERα=
PSD+PSA,E(ABCG2)
PSD
 Eq. A-22(Eq. 3-17)
 
Steady-state concentrations in compartments A, B, and C 
The steady-state substrate concentrations in compartments A, B, and C (dXA/dt, dXB/dt, 
and dXC/dt = 0) can be determined by rearranging the differential equations: 
 
Substrate flux into and out of the basolateral (serum) compartment: 
 CB,SS=
CA,SSPSPC+CC,SS PSD+PSB,E
PSD+PSB,U+PSPC
 Eq. A-23
(Eq. 3-18)
Substrate flux into and out of the cellular (LMEC) compartment: 
 CC,SS=
CA,SS PSD+PSA,U +CB,SS PSD+PSB,U
2PSD+PSA,E+PSB,E
 Eq. A-24
(Eq. 3-19)
Substrate flux into and out of the apical (milk) compartment: 
 CA,SS=
CB,SSPSPC+CC,SS PSD+PSA,E
PSD+PSA,U+PSPC
 Eq. A-25
(Eq. 3-20)
If we assume PSPC→0, Eq. A-23 and Eq. A-25 can be reduced to:: 
 CB,SS=
CC,SS PSD+PSB,E
PSD+PSB,U
 Eq. A-26(Eq. 3-21)
 CA,SS=
CC,SS PSD+PSA,E
PSD+PSA,U
 Eq. A-27
(Eq. 3-22)
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Recalling that concentrations in this model are unbound drug, the steady-state ratio of a 
drug in the apical vs. the basolateral compartment can be determined by dividing CA,SS 
by CB,SS (Eq. A-27 by Eq. A-26).  This results in the same asymmetry efflux ratio (ERα) 
presented earlier:  
 
CA,SS,unbound
CB,SS,unbound
=
PSD+PSA,E PSD+PSB,U
PSD+PSA,U PSD+PSB,E
ERα 
Eq. A-28
(Eq. 3-23)
 
Relationships to M/S ratio 
The in vivo clearance terms that define the unbound ratio of the drug at steady state in 
the milk and serum are comparable to the in vitro permeability-surface area product 
terms that define the similar ratio in the model (Eq. A-28), such that: 
 
Cmilk,unbound
Cserum,unbound
=
ClD+ClA,E ClD+ClB,U
ClD+ClA,U ClD+ClB,E
 Eq. A-29(Eq. 3-24)
The Passive Diffusion model for drug transfer into breast milk is based on total drug 
concentrations and provides the following prediction for the M/S ratio [68]: 
 
M
Sin vivo
M
Sdiffusion
=
fs
un fs W
fm
un fm Sk
 Eq. A-30(Eq. 3-25)
It assumes Cmilk,unbound = Cserum,unbound and suggests that the M/S ratio observed in vivo 
is governed by protein binding and ionization in the milk, and serum and partitioning into 
milk fat.  But, if active processes exist this assumption is not valid (Cmilk,unbound ≠ 
Cserum,unbound), so these concentrations need to be added to the prediction:  
 
M
Sin vivo
=
Cmilk,unbound
Cserum,unbound
fs
un fs W
fm
un fm Sk
 Eq. A-31(Eq. 3-26)
Replacing Cmilk,unbound/Cserum,unbound with the clearance in Eq. A-29 allows for the 
incorporation of active processes to put forth a new in vivo conceptual model and 
suggests that it may be possible to approximate the in vivo M/S using in vitro ERα 
determinations and simple in vitro measurements of protein binding, ionization potential, 
and skim to whole milk partitioning: 
 
M
Sin vivo
=
ClD+ClA,E ClD+ClB,U
ClD+ClA,U ClD+ClB,E
fs
un fs W
fm
un fm Sk
 Eq. A-32(Eq. 3-27)
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ClD+ClA,E ClD+ClB,U
ClD+ClA,U ClD+ClB,E
≈
PSD+PSA,E PSD+PSB,U
PSD+PSA,U PSD+PSB,E
 Eq. A-33(Eq. 3-28)
 
M
Sin vivo
=
PSD+PSA,E PSD+PSB,U
PSD+PSA,U PSD+PSB,E
fs
un fs W
fm
un fm Sk
 Eq. A-34(Eq. 3-29)
 
M
Sin vivo
=ERα
fs
un fs W
fm
un fm Sk
Eq. A-35
(Eq. 3-30)
This relationship assumes: 
- PSD  ClD 
- No differences in substrate interaction with individual transport processes and 
that expression level is comparable such that for a series of drugs PSB,U  
ClB,U, PSB,E  ClB,E, PSA,U  ClA,U, and PSA,E  ClA,E. 
 
Experimental Considerations: Maximum and minimum experimentally achievable initial 
rates. 
The theoretical limits of the initial rates with increasing PSA,E(ABCG2) are explored.  
Recall the initial B→A rate for a single transfected system with an apical efflux 
transporter (eg. ABCG2) is described by Eq. A-8: 
 
dXA,B→A
dt ABCG2
 = CB 
0 PSD PSD+PSA,E(ABCG2)
2PSD+PSA,E(ABCG2)
+PSPC  
Eq. A-8 
(Eq. 3-8)
If PSA,E(ABCG2) >> PSD, dXA/dt increases until it achieves a maximal flux for a given initial 
basolateral concentration: 
 lim
PSA,E
dXA,B→A
dt ABCG2
= CB 
0 PSD+PSPC  
Eq. A-36
(Eq. 4-1)
Recall the initial A→B rate for a single transfected system with an apical efflux 
transporter (eg. ABCG2) is described by Eq. A-13: 
 
dXB, A→B
dt ABCG2
 = CA 
0 PSD 2
2PSD+PSA,E(ABCG2)
+PSPC  
Eq. A-13
(Eq. 3-11)
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If PSA,E(ABCG2) >> PSD, dXB/dt decreases until it achieves a minimum flux for a given initial 
basolateral concentration: 
 lim
PSA,E
dXB, A→B
dt ABCG2
 = CA 
0 PSPC  
Eq. A-37
(Eq. 4-2)
 
Experimental Considerations: Proportionality of PSA,E(ABCG2) to ERA and ERα. 
Assuming no other transporter processes exist, PSD can also be measured from Papp,B->A 
or Papp,A->B in the empty vector transfected cells such that PSD = 2 PSB->A.  However, an 
experimental measurement that correlates with the transport phenomena of interest (ie. 
PSA,E(ABCG2)) is less obvious.  
 
Recall, as presented in Eq. A-17, in a single transfected system with an apical efflux 
transporter (ie. ABCG2) where PSD >> PSPC or that PSPC→0, ERA is: 
  ERA= 
2 PSD+PSA,E(ABCG2)
2PSD+PSA,E(ABCG2)
 Eq. A-17(Eq. 3-14)
Solving for PSA,E(ABCG2) in this equation results in a complex relationship where no direct 
proportionality to ERA exists:   
 PSA,E(ABCG2)= 
2PSD (ERA,ABCG2
parent
-1)
2-ERA,ABCG2
parent
 Eq. A-38(Eq. 4-5)
Recall, as presented in Eq. A-22, in a single transfected system with an apical efflux 
transporter (ie. ABCG2) where PSD >> PSPC or that PSPC→0, ERα is: 
 ERα=
PSD+PSA,E(ABCG2)
PSD
 Eq. A-22(Eq. 3-17)
 
Solving for PSA,E(ABCG2) in this equation, however, shows that this efflux ratio is expected 
to remain proportional to ERα as previously shown by Kalvass and Pollack [172]. 
 PSA,E(ABCG2)=PSD ERα-1  
Eq. A-39
(Eq. 4-4)
Therefore, the experimental calculation of ERα,ABCG2 from Papp,B->A/Papp,A->B is useful as for 
a given substrate, it would be expected to be proportional to PSA,E(ABCG2). 
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Experimental Considerations: Relationship of PSA,E(ABCG2) to ERA and ERα when 
endogenous transporters are present. 
Rejecting the assumption that endogenous transporters are absent complicates the 
relationships between PSA,E(ABCG2) and the efflux ratios.  If PSA,E is the endogenous apical 
efflux transporter and PSA,E(ABCG2)  is added to Eq. A-6 and Eq. A-11, the following rate 
relationships result:  
 
dXA,B→A
dt
 = CB 
0 PSD+PSB,U PSD+PSA,E+PSA,E(ABCG2
2PSD+PSA,E+PSB,E+PSA,E(ABCG2
+PSPC  
Eq. A-40
(Eq. 4-6)
 
dXB, A→B
dt
 = CA 
0 PSD+PSA,U PSD+PSB,E
2PSD+PSA,E+PSB,E+PSA,E(ABCG2
+PSPC  
Eq. A-41
(Eq. 4-7)
If ERA and ERα are redefined using these new rate equations and we again assume 
CB 
0 CA 
0 experimentally and PSPC→0: 
 ERA= 
PSD+PSA,E+PSA,E(ABCG2)
2PSD+PSA,E+PSB,E+PSA,E(ABCG2)
2PSD+PSA,E
PSD+PSA,E
 Eq. A-42(Eq. 4-8)
 ERα=
PSD+PSA,E+PSA,E(ABCG2)
PSD+PSA,U
PSD+PSB,U
PSD+PSB,E
 Eq. A-43(Eq. 4-9)
In an attempt to isolate PSA,E(ABCG2), the ERα was further divided by ERα of the empty 
vector-transfected cells (PSB,U, PSA,E, PSB,E, and PSA,U are present, but PSA,E(ABCG2) is 
not) to produce the ERα Ratio (ERα(ABCG2)/ERα(Empty) :  
 
ERα(ABCG2)
ERα(Empty)
=
PSD+PSA,E+PSA,E(ABCG2)
PSD+PSA,E
Eq. A-44
(Eq. 4-10)
Rearrangement of Eq. A-44 to Eq. A-45 shows PSB,U, PSB,E, and PSA,U can be removed 
from the relationship, but it is not possible to isolate PSA,E(ABCG2) from PSA,E.  However, A 
proportionality between PSA,E(ABCG2) and this ERα Ratio still does exist: 
 PSA,E(ABCG2)= PSD+PSA,E
ERα(ABCG2)
ERα(Empty)
1  Eq. A-45(Eq. 4-11)
Experimentally, any variability in PSA,E(ABCG2) and  PSA,E (eg. transporter expression 
levels), a substrate’s ability to cross the membrane by passive diffusion (PSD), or to 
interact with either transport process (PSA,E(ABCG2) or PSA,E) would be expected to affect 
the ratio. 
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Experimental Considerations: Controlling for Variable PSPC 
Flux of paracellular markers sucrose and mannitol are somewhat variable between 
different cell lines (empty vs. transfected) and inter-day.  PSPC is therefore not negligible 
relative to the PSB->A for drugs that either have poor PSD or relative to PSA->B for drugs 
that are good substrates for ABCG2.  To control for the potential consequences 
associated with this variable PSPC in the experimental data, the permeability of the 
paracellular marker can theoretically be subtracted from that of the drug being studied.  
The rearrangement of Eq. A-40 and Eq. A-41 to Eq. 4-12 and Eq. 4-13, respectively 
illustrates this solution:    
 
dXA,B→A
dt
CB 
0  - PSPC = 
PSD+PSB,U PSD+PSA,E+PSA,E(ABCG2)
2PSD+PSA,E+PSB,E+PSA,E(ABCG2)
 
Eq. A-46
(Eq. 4-12)
 
dXB, A→B
dt
CA 
0  - PSPC = 
PSD+PSA,U PSD+PSB,E
2PSD+PSA,E+PSB,E+PSA,E(ABCG2)
 
Eq. A-47
(Eq. 4-13)
It is very important to note that this approach is dependent on one major assumption; 
that the PSPC of the paracellular marker being measured is equal to the PSPC of the drug 
being studied.  
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Appendix 4: Raw data – murine microarray transporter expression levels from each chip. 
Mu74v2A Chip detection calls. A=”Absent”; M=”Marginal”; P=”Present”, shading 
indicates probeset that was “Absent” on all chips in the lactating group. 
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103800_at Abcc5 A A A A A A A A A A A A A A M A A A P A A A A A M A
93407_at Abcc6 A A A A A A A A A A A A A A A A A A A A A A A A A A
93626_at Abcg2 P P P P P P P P P P P P P P P P P P P P P P P P P P
160978_at Osta A A A A A A A A A A A A A A A A A A A A A A M A A A
100339_at Slc10a1 A A A A A A A A A A A A A A A A A A A A A A A A A A
100340_at Slc10a1 A A A A A A A A A A A A A A A A A A A A A A A A A A
100341_g_at Slc10a1 A A A A A A A A A A A A A A A A A A A A A A A A A A
97150_at Slc10a2 A A A A A A A A A A A A A A A A A A A A A A A A A A
103918_at Slc15a2 A A A A A A A A M A A A A A A A P P P P P A A A P P
101588_at Slc16a1 A A A A A P A A A A A A A A A A A A M P P P A A A A
95060_at Slc16a7 P P A A A A A A A A A A A A A A A A A A A A P P A A
96077_at Slc17a1 A A A A A A A A A A A A A A A A A A A A A A A A A A
96078_g_at Slc17a1 A A A A P A A A A A A A A A A A A A A A A A A A A A
100916_at Slc22a1 A A A A A A A A A A A A A A A A A A M A A A A A A M
102429_at Slc22a12 A A A A A A A A A A A A A A A A A A A A A A A A A A
102947_at Slc22a2 A A A A A A A A A A A A A A A A A A A A A A A A A A
92497_at Slc22a4 A A A A A A A A A A A A A A A A A A A A A A A A A A
98322_at Slc22a5 P M P A P P P P P P P P A P P A M P A M P P P P P P
97431_at Slc22a6 A A A A A A A A A A A A A A A A A A A A A A A A A A
104387_at Slc23a1 A A A A A A A A A A A A A A A A A A A A A A A A A A
104267_at Slc23a2 P P P P P P P A A P M A A A A M P A A A A P P P A M
161687_r_at Slc29a1 A A A A A A A A A A A A A A A A A A A A A A A A A A
95733_at Slc29a1 P P P P P P P P P P P P M P P P P P A M P P P A A A
92950_at Slc29a2 A A A A A A A A A A A A A A A A A A A A A A A A A A
161006_at Slco3a1 A A A A A A A A A A A A A A A A P A A A A M A A A A
94663_at Slco5a1 A A A A A A A A A A A A A A A A P A A A A P P P A A
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Mu74v2A chip signal intensities. “Absent” probesets were excluded.  
    Stein Clarkson Medrano 
Probe Set ID 
Gene 
Symbol S
_V
10
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-s
ig
na
l 
S
_V
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l 
S
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l 
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93626_at Abcg2 10
4 
10
5 
69
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1 
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64
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2 
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5 
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10
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13
59
 
20
45
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18
 
64
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9 
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84
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59
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31
79
 
26
66
 
98322_at Slc22a5 26
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46
 
56
 
61
 
43
 
61
 
57
 
30
 
53
 
73
 
45
 
61
 
76
 
19
 
49
 
58
 
65
 
45
 
41
 
56
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47
 
62
 
95733_at Slc29a1 19
3 
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1 
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3 
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1 
27
5 
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1 
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5 
64
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5 
89
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103918_at Slc15a2 14
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9 12
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104267_at Slc23a2 96
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103800_at Abcc5 70
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6 
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5 
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6 
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5 
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3 
19
4 
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0 
19
5 
11
5 
75
 
11
7 
11
6 
10
3 
18
3 
89
 
12
0 
11
4 
14
3 
13
1 
101588_at Slc16a1 14
 
16
 
2 19
 
9 23
 
20
 
24
 
15
 
21
 
20
 
11
 
21
 
3 16
 
19
 
12
 
48
 
47
 
32
 
45
 
22
 
15
 
4 28
 
19
 
100916_at Slc22a1 3 1 2 3 6 2 3 4 5 3 7 10
 
10
 
11
 
18
 
15
 
3 40
 
46
 
89
 
70
 
3 1 1 11
0 
94
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Appendix 5: Raw data – human microarray transporter expression levels from each chip. 
U133 plus 2.0 chip detection calls. A=”Absent”; M=”Marginal”; P=”Present”, shading 
indicates probeset that was “Absent” on all chips in the lactating group. 
Probe Set ID Gene Symbol LM
E
C
 1
m
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n 
LM
E
C
 2
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D
et
ec
tio
n 
K
 3
m
as
5-
D
et
ec
tio
n 
K
 4
m
as
5-
D
et
ec
tio
n 
K
 5
m
as
5-
D
et
ec
tio
n 
K
 6
m
as
5-
D
et
ec
tio
n 
L 
1m
as
5-
D
et
ec
tio
n 
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L 
6m
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5-
D
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tio
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210099_at ABCA2 A A A A A A A A A A A A A A A A A A 
210100_s_at ABCA2 A A A A A A A A A A A A A A A A A A 
212772_s_at ABCA2 A A A A A P P P P P P P P P P P P P 
204343_at ABCA3 A A A A A A P P P A A A A A A A A A 
209993_at ABCB1 A A A A A A P P P P P P P P P P P P 
243951_at ABCB1 A P P A A A P P P P P P P P P P P P 
209994_s_at ABCB1 /// ABCB4 A A A A A A P P P P P P P P P P P P 
208288_at ABCB11 A A A A A A A A A A A A P P P P P P 
211224_s_at ABCB11 A A A A A A A A A A A A P P A P A P 
1570505_at ABCB4 A A A A A A A A A A A A P P M P P A 
207819_s_at ABCB4 A A A A A A A A A A A A P P P P P P 
237138_at ABCB4 A A A A A A A A A A A A A A A A P A 
202805_s_at ABCC1 A A A P P P A P A A A A A A A A A A 
202804_at ABCC1 P P P P P P P P P P P P P P P P P P 
215873_x_at ABCC10 A A P A A A P P P A P P A A A A P A 
213485_s_at ABCC10 P P P P P P P P P P P P P P P P P M 
1554911_at ABCC11 A A A A A A A A A A A A A A A A A A 
224146_s_at ABCC11 A A A A P P A A A A A A A A A A A A 
1552590_a_at ABCC12 A A A A A A A A A A A A A A A A A A 
1553410_a_at ABCC12 A A A A A A A A A A A A A A A A A A 
206155_at ABCC2 A A A A A A A A P A A A P P P P P P 
208161_s_at ABCC3 A A A P P P A P A A A A P P P P P P 
209641_s_at ABCC3 A A A A A A A A A A A A A A A A A A 
214979_at ABCC3 A A A A A A A A A A A A P A A A A A 
230682_x_at ABCC3 A A A P A A A A A A A A P A M A P P 
239217_x_at ABCC3 A A A P A P A A A A A A A A A A A P 
242553_at ABCC3 A A A A A A A A A A A A A A A A A A 
1554918_a_at ABCC4 A A A A A A P P P P P A A A A A A A 
203196_at ABCC4 A A A A A A P P P P P P A A A A A A 
243928_s_at ABCC4 A A A A A A A A M A A A A A A A A A 
244053_at ABCC4 A A A A A A A A A A A A A A A A A A 
1555039_a_at ABCC4 P A A A A A P P P P P P A A A A A P 
1558460_at ABCC5 A A A A A A P P P A A A P M P A P P 
209380_s_at ABCC5 A A A A A A P P P P P P P M P A A P 
226363_at ABCC5 A A A A A A P P P P P P A A A A A A 
208480_s_at ABCC6 A A A A A A A A A A A A A A A P A P 
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U133 plus 2.0 chip detection calls. A=”Absent”; M=”Marginal”; P=”Present”, shading 
indicates probeset that was “Absent” on all chips in the lactating group (cont.). 
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K
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K
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K
 5
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K
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L 
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as
5-
D
et
ec
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215559_at ABCC6 A A A A A A P P P P P P P P P P P P 
209735_at ABCG2 P P P A P P P A A P A M P P P P P P 
229230_at OSTalpha A A A P A P A A A A A A P P P P P P 
207185_at SLC10A1 P A A P A M A A A A A A P P P P P P 
207095_at SLC10A2 A A A A A M P P P P P P P A A A A A 
207254_at SLC15A1 A A A A A A A A A P P A P P P P P P 
211349_at SLC15A1 A A A A A A P A P P P P A P P A A P 
205316_at SLC15A2 P P P A A P P P P P P P A A A A A A 
205317_s_at SLC15A2 P P P A P P P P P P P P A A A A A A 
240159_at SLC15A2 P P P P A M P P P P P P M A A A A A 
202235_at SLC16A1 P M A P P P A A P A A A P P P P P A 
1557918_s_at SLC16A1 P P P A P P A A A A A A P P P P A P 
202234_s_at SLC16A1 P P P P P P M P P P P A P P P P P P 
202236_s_at SLC16A1 P P P P P P P P P P P P P P P P P P 
209900_s_at SLC16A1 P P P P P P A A P A P A P P P P P P 
241866_at SLC16A7 A A A P A A P P P P P P P P P P P P 
210807_s_at SLC16A7 A A P P P P P P P P P P P P P P P P 
207057_at SLC16A7 P P P P P P P P P P P P P P P A P P 
1560884_at SLC17A1 A A A A A A P P P P P P A P P A P A 
1560885_x_at SLC17A1 A A A A A A P P P A P P A A A A A A 
206872_at SLC17A1 A A A A A A P P P P P P P P P M A P 
242536_at SLC17A1 A A A A A A P P P P P P P P P A A P 
237049_at SLC17A1 A A M A A A P P P P P P P P P P P P 
207201_s_at SLC22A1 A A A A A A A A A A A A P P P P P P 
220100_at SLC22A11 A A A A A A P P P P P P A A A A A A 
237799_at SLC22A12 M A A A A A P P P P P P A A A A A A 
207429_at SLC22A2 A A A A A A P P P P P P A A A A A A 
205421_at SLC22A3 A A A A A A A A A A A A P P P P P P 
1570482_at SLC22A3 A A P A A P A A A A A A A P A A P P 
242578_x_at SLC22A3 M P M P P P P P P P P P P P P P P P 
233900_at SLC22A4 A A A A A A A A A A A A A A A A A A 
205896_at SLC22A4 P P P P P P A P P P A A A A A A A A 
205074_at SLC22A5 A P P P P P P P P P P P P A M P A P 
210343_s_at SLC22A6 A A A A A A P P P P P P A A A A A A 
216599_x_at SLC22A6 A A A A A A P P P P P P A A A A A A 
244890_at SLC22A6 A A A A A A P A A M P P A A A A A A 
1555553_a_at SLC22A7 A A A A A A A M A P P A P P P P P P 
220554_at SLC22A7 A A A A A A P P P P P P P P P P P P 
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U133 plus 2.0 chip detection calls. A=”Absent”; M=”Marginal”; P=”Present”, shading 
indicates probeset that was “Absent” on all chips in the lactating group (cont.). 
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K
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K
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K
 5
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D
et
ec
tio
n 
K
 6
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D
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L 
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D
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n 
L 
2m
as
5-
D
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tio
n 
L 
3m
as
5-
D
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n 
L 
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5-
D
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tio
n 
L 
5m
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5-
D
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n 
L 
6m
as
5-
D
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tio
n 
221661_at SLC22A7 A A A A A A P P P P P P P P P P P P 
221662_s_at SLC22A7 A A A A A A A P P P P A P P P P P P 
231398_at SLC22A7 A A A A A A P P P P P P P P P P P P 
221298_s_at SLC22A8 A A A A A A P P P P P P A A A A A A 
231352_at SLC22A8 A A A A A A P P P P P P A A A A A A 
231625_at SLC22A9 A A A A A A A A A A A A P P P P P P 
241770_x_at SLC22A9 A A P A A P P A P A P A P P P P P P 
223732_at SLC23A1 A A A A A A P P P P P P P P P P P P 
1554692_at SLC23A2 A A A M P P P A A A A A P A M M P A 
209236_at SLC23A2 A A A P A A P A M A A A P P P P P P 
209237_s_at SLC23A2 A A A P A A A A A A A A P A P P A A 
211572_s_at SLC23A2 P A A P A P A A A A A A P P P P P P 
216425_at SLC28A1 A A A A A A A A A A A A A A A A A A 
216790_at SLC28A1 A A A A A A A A A A A A A A A A A A 
231187_at SLC28A1 A A A A A A P P P P P P P P P P P P 
207560_at SLC28A1 M P P A P A P P P P P P P P P P P P 
207249_s_at SLC28A2 A A A A A A A A A A A A A A A A A A 
216432_at SLC28A2 A A A A A A A A A A A A A A A A A A 
220475_at SLC28A3 A A P P P P A A A A A A A A A A A A 
201802_at SLC29A1 A P P P A P P A A P A M P P P P P P 
201801_s_at SLC29A1 P P P P P P P P P P P P P P P P P P 
1553540_a_at SLC29A2 A A A A A A A A A A A A A A A A A A 
1560062_at SLC29A2 A A A A A A A A A A A A A A A A A A 
1560149_at SLC29A2 A A A A A A A A A A A A A A A A A A 
1560151_x_at SLC29A2 A A A A A A A A A A A A A A A A A A 
204717_s_at SLC29A2 P P P P A P P P P P A P A A A A A A 
219344_at SLC29A3 A A A A A A A A A A A P A A M A P P 
227281_at SLC29A4 A A A A A A A A A A A A A A A A A A 
219795_at SLC6A14 P P P P P P A A A A P P A A A A A P 
207308_at SLCO1A2 A A A A P A P A A A A P P P A A M P 
211480_s_at SLCO1A2 A A A A A A A A A A A A A P A A A A 
211481_at SLCO1A2 A A A A A A A A A A A A M P P A P A 
210366_at SLCO1B1 A A A A A A A A A A P P P P P P P P 
206354_at SLCO1B3 A A A A A P A A A A A A P P P P P P 
220460_at SLCO1C1 A A A A A P A A A A A A A A A A A A 
204368_at SLCO2A1 A A A A A A P P P P P P A A A A A A 
203472_s_at SLCO2B1 A A A A A A A A A A P A P P P P P P 
211557_x_at SLCO2B1 A A A A A A A P A M P A P P P P P P 
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U133 plus 2.0 chip detection calls. A=”Absent”; M=”Marginal”; P=”Present”, shading 
indicates probeset that was “Absent” on all chips in the lactating group (cont.). 
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203473_at SLCO2B1 A P P P A A P P M P P M P P P P P P 
210542_s_at SLCO3A1 A A A P P P A A A A A A A A A A A A 
219229_at SLCO3A1 P A A P P P P P P P P P A P P P P P 
227367_at SLCO3A1 P A A P P P P P P P P P P P P P P A 
229239_x_at SLCO4A1 A A A A A A A A A A A A A A A A A A 
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1552745_at SLCO6A1 A A A A A A A A A A M A A A A A A A 
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U133 plus 2.0 chip signal intensities. Genes “Absent” were excluded. 
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U133 plus 2.0 chip signal intensities. Genes “Absent” were excluded. (cont.) 
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